US20060235220A1 - Dipeptide nitriles - Google Patents
Dipeptide nitriles Download PDFInfo
- Publication number
- US20060235220A1 US20060235220A1 US11/374,995 US37499506A US2006235220A1 US 20060235220 A1 US20060235220 A1 US 20060235220A1 US 37499506 A US37499506 A US 37499506A US 2006235220 A1 US2006235220 A1 US 2006235220A1
- Authority
- US
- United States
- Prior art keywords
- mmol
- methyl
- lower alkyl
- solution
- cathepsin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010016626 Dipeptides Proteins 0.000 title abstract description 16
- 150000002825 nitriles Chemical class 0.000 title abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 126
- 102000005600 Cathepsins Human genes 0.000 claims abstract description 42
- 108010084457 Cathepsins Proteins 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 11
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 9
- 230000001419 dependent effect Effects 0.000 claims abstract description 8
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 89
- -1 4-(piperidinyl)-phenyl Chemical group 0.000 claims description 87
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 54
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- 125000002947 alkylene group Chemical group 0.000 claims description 24
- 229910052717 sulfur Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 21
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 150000001721 carbon Chemical group 0.000 claims description 14
- 108090000625 Cathepsin K Proteins 0.000 claims description 12
- 102000004171 Cathepsin K Human genes 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000006413 ring segment Chemical group 0.000 claims description 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 25
- 238000011282 treatment Methods 0.000 abstract description 14
- 150000002148 esters Chemical class 0.000 abstract description 13
- 235000018417 cysteine Nutrition 0.000 abstract description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 10
- 229910052700 potassium Inorganic materials 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 abstract description 3
- 206010064390 Tumour invasion Diseases 0.000 abstract description 3
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 230000001687 destabilization Effects 0.000 abstract description 3
- 230000009401 metastasis Effects 0.000 abstract description 3
- 230000009400 cancer invasion Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 479
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 255
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 225
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 196
- 235000019439 ethyl acetate Nutrition 0.000 description 184
- 239000000243 solution Substances 0.000 description 163
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 130
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 110
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 101
- 229940093499 ethyl acetate Drugs 0.000 description 94
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 81
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- 239000000203 mixture Substances 0.000 description 69
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 65
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 55
- 239000012267 brine Substances 0.000 description 54
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 54
- 239000007787 solid Substances 0.000 description 54
- 239000002904 solvent Substances 0.000 description 54
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 47
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 47
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 45
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 239000000047 product Substances 0.000 description 45
- 239000011541 reaction mixture Substances 0.000 description 39
- IIEWJVIFRVWJOD-UHFFFAOYSA-N CCC1CCCCC1 Chemical compound CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 35
- 238000004587 chromatography analysis Methods 0.000 description 32
- 238000001704 evaporation Methods 0.000 description 32
- 230000008020 evaporation Effects 0.000 description 32
- 235000019341 magnesium sulphate Nutrition 0.000 description 31
- 239000000377 silicon dioxide Substances 0.000 description 30
- 239000003921 oil Substances 0.000 description 28
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- QWTDNUCVQCZILF-UHFFFAOYSA-N CCC(C)C Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 27
- 229960004132 diethyl ether Drugs 0.000 description 27
- 125000000623 heterocyclic group Chemical group 0.000 description 26
- 125000003118 aryl group Chemical group 0.000 description 25
- LAGWZWJDSQHXQZ-UHFFFAOYSA-N CCC1=CC(Cl)=C(Cl)C=C1 Chemical compound CCC1=CC(Cl)=C(Cl)C=C1 LAGWZWJDSQHXQZ-UHFFFAOYSA-N 0.000 description 24
- ZLCSFXXPPANWQY-UHFFFAOYSA-N CCC1=CC=CC(C)=C1 Chemical compound CCC1=CC=CC(C)=C1 ZLCSFXXPPANWQY-UHFFFAOYSA-N 0.000 description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 239000012043 crude product Substances 0.000 description 24
- 239000000284 extract Substances 0.000 description 24
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 20
- 239000012044 organic layer Substances 0.000 description 20
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
- DNTNLUHRNVEKSZ-UHFFFAOYSA-N CC1=CC(C(C)(C)C)=NN1C Chemical compound CC1=CC(C(C)(C)C)=NN1C DNTNLUHRNVEKSZ-UHFFFAOYSA-N 0.000 description 19
- LOXUEGMPESDGBQ-UHFFFAOYSA-N CCC1=CC=CC(Cl)=C1 Chemical compound CCC1=CC=CC(Cl)=C1 LOXUEGMPESDGBQ-UHFFFAOYSA-N 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- GOVXKUCVZUROAN-UHFFFAOYSA-N CCC1=CNC2=C1C=CC=C2 Chemical compound CCC1=CNC2=C1C=CC=C2 GOVXKUCVZUROAN-UHFFFAOYSA-N 0.000 description 16
- 125000002837 carbocyclic group Chemical group 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 229910052736 halogen Inorganic materials 0.000 description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 16
- 0 **CNC([2*])([3*])C(=[Y])NC([4*])([5*])C#N.C.C Chemical compound **CNC([2*])([3*])C(=[Y])NC([4*])([5*])C#N.C.C 0.000 description 15
- 108090000624 Cathepsin L Proteins 0.000 description 15
- 102000004172 Cathepsin L Human genes 0.000 description 15
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 125000003545 alkoxy group Chemical group 0.000 description 15
- 150000002367 halogens Chemical class 0.000 description 15
- 125000001424 substituent group Chemical group 0.000 description 15
- 229940086542 triethylamine Drugs 0.000 description 15
- 108090000613 Cathepsin S Proteins 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 14
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 229920006395 saturated elastomer Polymers 0.000 description 14
- 102100035654 Cathepsin S Human genes 0.000 description 13
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N C1CC1 Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 12
- OSOUNOBYRMOXQQ-UHFFFAOYSA-N CC1=CC=CC(Cl)=C1 Chemical compound CC1=CC=CC(Cl)=C1 OSOUNOBYRMOXQQ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 125000002252 acyl group Chemical group 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 229960005190 phenylalanine Drugs 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- BSZXAFXFTLXUFV-UHFFFAOYSA-N CC(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(C1=CC=CC=C1)C1=CC=CC=C1 BSZXAFXFTLXUFV-UHFFFAOYSA-N 0.000 description 11
- JCCCMAAJYSNBPR-UHFFFAOYSA-N CCC1=CC=CS1 Chemical compound CCC1=CC=CS1 JCCCMAAJYSNBPR-UHFFFAOYSA-N 0.000 description 11
- 108090000712 Cathepsin B Proteins 0.000 description 11
- 102000004225 Cathepsin B Human genes 0.000 description 11
- 125000001589 carboacyl group Chemical group 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- BUZYGTVTZYSBCU-UHFFFAOYSA-N CC(=O)C1=CC=C(Cl)C=C1 Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 9
- HDNRAPAFJLXKBV-UHFFFAOYSA-N CCC1=CC=C(OC)C=C1 Chemical compound CCC1=CC=C(OC)C=C1 HDNRAPAFJLXKBV-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940124639 Selective inhibitor Drugs 0.000 description 9
- BHNHHSOHWZKFOX-UHFFFAOYSA-N [H]N1C(C)=CC2=CC=CC=C21 Chemical compound [H]N1C(C)=CC2=CC=CC=C21 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical class [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 8
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 8
- GNKZMNRKLCTJAY-UHFFFAOYSA-N CC(=O)C1=CC=C(C)C=C1 Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 8
- BJMUOUXGBFNLSN-UHFFFAOYSA-N CC1=CC2=C(C=CC=C2)N1C Chemical compound CC1=CC2=C(C=CC=C2)N1C BJMUOUXGBFNLSN-UHFFFAOYSA-N 0.000 description 8
- WYUIWKFIFOJVKW-UHFFFAOYSA-N CC1=CC=C(Cl)C(Cl)=C1 Chemical compound CC1=CC=C(Cl)C(Cl)=C1 WYUIWKFIFOJVKW-UHFFFAOYSA-N 0.000 description 8
- OSIGJGFTADMDOB-UHFFFAOYSA-N COC1=CC(C)=CC=C1 Chemical compound COC1=CC(C)=CC=C1 OSIGJGFTADMDOB-UHFFFAOYSA-N 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 239000012131 assay buffer Substances 0.000 description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 8
- 125000004093 cyano group Chemical group *C#N 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- XLNGOOZEHFHHME-UHFFFAOYSA-N CC1=CC(C(C)(C)C)=NN1CC1=CC=CC=C1 Chemical compound CC1=CC(C(C)(C)C)=NN1CC1=CC=CC=C1 XLNGOOZEHFHHME-UHFFFAOYSA-N 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 150000001602 bicycloalkyls Chemical group 0.000 description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
- WBPAOUHWPONFEQ-UHFFFAOYSA-N CC(=O)C1=CC=C(Cl)C(Cl)=C1 Chemical compound CC(=O)C1=CC=C(Cl)C(Cl)=C1 WBPAOUHWPONFEQ-UHFFFAOYSA-N 0.000 description 6
- RYMMNSVHOKXTNN-UHFFFAOYSA-N CC1=CC(Cl)=CC(Cl)=C1 Chemical compound CC1=CC(Cl)=CC(Cl)=C1 RYMMNSVHOKXTNN-UHFFFAOYSA-N 0.000 description 6
- URLKBWYHVLBVBO-UHFFFAOYSA-N CC1=CC=C(C)C=C1 Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 6
- VJYXZJGDFJJDGF-UHFFFAOYSA-N CC1=CC=CC(C(F)(F)F)=C1 Chemical compound CC1=CC=CC(C(F)(F)F)=C1 VJYXZJGDFJJDGF-UHFFFAOYSA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 125000004423 acyloxy group Chemical group 0.000 description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 125000004076 pyridyl group Chemical group 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- SGSGCQGCVKWRNM-UHFFFAOYSA-N CC(=O)C1=CC2=C(C=CC=C2)S1 Chemical compound CC(=O)C1=CC2=C(C=CC=C2)S1 SGSGCQGCVKWRNM-UHFFFAOYSA-N 0.000 description 5
- KWBQKUZVJVKXHI-UHFFFAOYSA-N CC(=O)C1CCCO1 Chemical compound CC(=O)C1CCCO1 KWBQKUZVJVKXHI-UHFFFAOYSA-N 0.000 description 5
- QIMMUPPBPVKWKM-UHFFFAOYSA-N CC1=CC2=C(C=CC=C2)C=C1 Chemical compound CC1=CC2=C(C=CC=C2)C=C1 QIMMUPPBPVKWKM-UHFFFAOYSA-N 0.000 description 5
- BOHCMQZJWOGWTA-UHFFFAOYSA-N CC1=CC=CC(C#N)=C1 Chemical compound CC1=CC=CC(C#N)=C1 BOHCMQZJWOGWTA-UHFFFAOYSA-N 0.000 description 5
- IVSZLXZYQVIEFR-UHFFFAOYSA-N CC1=CC=CC(C)=C1 Chemical compound CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 5
- BTQZKHUEUDPRST-UHFFFAOYSA-N CC1=CC=CC(F)=C1 Chemical compound CC1=CC=CC(F)=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 description 5
- HNRMPXKDFBEGFZ-UHFFFAOYSA-N CCC(C)(C)C Chemical compound CCC(C)(C)C HNRMPXKDFBEGFZ-UHFFFAOYSA-N 0.000 description 5
- ZEWGMOQWTWMZMZ-UHFFFAOYSA-N CCC1=CC(F)=CC=C1 Chemical compound CCC1=CC(F)=CC=C1 ZEWGMOQWTWMZMZ-UHFFFAOYSA-N 0.000 description 5
- ZBODWGAANATFAV-UHFFFAOYSA-N CCN1CCN(C2=CC=C(F)C=C2)CC1 Chemical compound CCN1CCN(C2=CC=C(F)C=C2)CC1 ZBODWGAANATFAV-UHFFFAOYSA-N 0.000 description 5
- AXPZDYVDTMMLNB-UHFFFAOYSA-N CCOCC1=CC=CC=C1 Chemical compound CCOCC1=CC=CC=C1 AXPZDYVDTMMLNB-UHFFFAOYSA-N 0.000 description 5
- GMWZORPRRIRCIE-UHFFFAOYSA-N COCCNCC1=CC=C(C)C=C1 Chemical compound COCCNCC1=CC=C(C)C=C1 GMWZORPRRIRCIE-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 239000005864 Sulphur Substances 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 125000003226 pyrazolyl group Chemical group 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 125000001544 thienyl group Chemical group 0.000 description 5
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 5
- OUFRSVLEPMEAJD-HNNXBMFYSA-N (2s)-4-methyl-2-(naphthalene-2-carbonylamino)pentanoic acid Chemical compound C1=CC=CC2=CC(C(=O)N[C@@H](CC(C)C)C(O)=O)=CC=C21 OUFRSVLEPMEAJD-HNNXBMFYSA-N 0.000 description 4
- KLUBHUSIIXNIQR-NHYWBVRUSA-N (2s,3s)-3-methyl-2-(naphthalene-2-carbonylamino)pentanoic acid Chemical compound C1=CC=CC2=CC(C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)=CC=C21 KLUBHUSIIXNIQR-NHYWBVRUSA-N 0.000 description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- URBHKVWOYIMKNO-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexane-1-carboxylic acid Chemical compound CC(C)(C)OC(=O)NC1(C(O)=O)CCCCC1 URBHKVWOYIMKNO-UHFFFAOYSA-N 0.000 description 4
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 4
- JQULXIOYDDCNGR-UHFFFAOYSA-N 2-amino-2-methylpropanenitrile Chemical compound CC(C)(N)C#N JQULXIOYDDCNGR-UHFFFAOYSA-N 0.000 description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 4
- HPUPCEKBLMDOGY-UHFFFAOYSA-N CC1=C(C)OC(C(C)(C)C)=C1 Chemical compound CC1=C(C)OC(C(C)(C)C)=C1 HPUPCEKBLMDOGY-UHFFFAOYSA-N 0.000 description 4
- GWHJZXXIDMPWGX-UHFFFAOYSA-N CC1=CC=C(C)C(C)=C1 Chemical compound CC1=CC=C(C)C(C)=C1 GWHJZXXIDMPWGX-UHFFFAOYSA-N 0.000 description 4
- ZZLCFHIKESPLTH-UHFFFAOYSA-N CC1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=CC=C2)C=C1 ZZLCFHIKESPLTH-UHFFFAOYSA-N 0.000 description 4
- VYUNLDVEMSMJNP-UHFFFAOYSA-N CC1=CC=C(N2C=CC=C2)C=C1 Chemical compound CC1=CC=C(N2C=CC=C2)C=C1 VYUNLDVEMSMJNP-UHFFFAOYSA-N 0.000 description 4
- FETIWDPIODONQB-UHFFFAOYSA-N CC1=CC=C(OC(C)(C)C)C=C1 Chemical compound CC1=CC=C(OC(C)(C)C)C=C1 FETIWDPIODONQB-UHFFFAOYSA-N 0.000 description 4
- XQQBUAPQHNYYRS-UHFFFAOYSA-N CC1=CC=CS1 Chemical compound CC1=CC=CS1 XQQBUAPQHNYYRS-UHFFFAOYSA-N 0.000 description 4
- JTQKFJWXQHKANB-UHFFFAOYSA-N CCC1=CC(F)=C(F)C=C1 Chemical compound CCC1=CC(F)=C(F)C=C1 JTQKFJWXQHKANB-UHFFFAOYSA-N 0.000 description 4
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N CCC1=CC=CC=C1 Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
- XCKCTTHTLKTLNJ-UHFFFAOYSA-N CCNC1=CC=CC2=C1CCCC2 Chemical compound CCNC1=CC=CC2=C1CCCC2 XCKCTTHTLKTLNJ-UHFFFAOYSA-N 0.000 description 4
- CHLICZRVGGXEOD-UHFFFAOYSA-N COC1=CC=C(C)C=C1 Chemical compound COC1=CC=C(C)C=C1 CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- CCRUOINWQMXIDD-UHFFFAOYSA-N [1-(2-cyanopropan-2-ylamino)-4-methyl-1-oxopentan-2-yl]carbamic acid Chemical compound CC(C)CC(NC(O)=O)C(=O)NC(C)(C)C#N CCRUOINWQMXIDD-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003435 aroyl group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000000335 thiazolyl group Chemical group 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 229920002554 vinyl polymer Chemical group 0.000 description 4
- YVUKGDFKUFKFNH-FJXQXJEOSA-N (2s)-2-amino-5-(3-methoxycarbonylpyrazol-1-yl)pentanoic acid;hydrochloride Chemical compound Cl.COC(=O)C=1C=CN(CCC[C@H](N)C(O)=O)N=1 YVUKGDFKUFKFNH-FJXQXJEOSA-N 0.000 description 3
- HBBXWMALJNZDOM-LBPRGKRZSA-N (2s)-3-(3-methylphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC1=CC=CC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=C1 HBBXWMALJNZDOM-LBPRGKRZSA-N 0.000 description 3
- RXKOCVHVAUFAQY-UHFFFAOYSA-N 1-(naphthalene-2-carbonylamino)cyclohexane-1-carboxylic acid Chemical compound C=1C=C2C=CC=CC2=CC=1C(=O)NC1(C(=O)O)CCCCC1 RXKOCVHVAUFAQY-UHFFFAOYSA-N 0.000 description 3
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 3
- YNCPXBIZAPNQIJ-UHFFFAOYSA-N 1h-imidazole;sodium Chemical compound [Na].C1=CNC=N1 YNCPXBIZAPNQIJ-UHFFFAOYSA-N 0.000 description 3
- XFKYKTBPRBZDFG-UHFFFAOYSA-N 2-aminoacetonitrile;hydrochloride Chemical compound Cl.NCC#N XFKYKTBPRBZDFG-UHFFFAOYSA-N 0.000 description 3
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 3
- AUUIARVPJHGTSA-UHFFFAOYSA-N 3-(aminomethyl)chromen-2-one Chemical compound C1=CC=C2OC(=O)C(CN)=CC2=C1 AUUIARVPJHGTSA-UHFFFAOYSA-N 0.000 description 3
- QVBAUIHBJJDVHR-UHFFFAOYSA-N 4-(2-chloroethylsulfanyl)benzoic acid Chemical compound OC(=O)C1=CC=C(SCCCl)C=C1 QVBAUIHBJJDVHR-UHFFFAOYSA-N 0.000 description 3
- CQQSQBRPAJSTFB-UHFFFAOYSA-N 4-(bromomethyl)benzoic acid Chemical compound OC(=O)C1=CC=C(CBr)C=C1 CQQSQBRPAJSTFB-UHFFFAOYSA-N 0.000 description 3
- WEGYGNROSJDEIW-UHFFFAOYSA-N CC(=O)C1=CN=CC=C1 Chemical compound CC(=O)C1=CN=CC=C1 WEGYGNROSJDEIW-UHFFFAOYSA-N 0.000 description 3
- SWGILLQQUULMJB-UHFFFAOYSA-N CC(=O)C1=NC2=C(C=CC=C2)N=C1 Chemical compound CC(=O)C1=NC2=C(C=CC=C2)N=C1 SWGILLQQUULMJB-UHFFFAOYSA-N 0.000 description 3
- QUKGYYKBILRGFE-UHFFFAOYSA-N CC(=O)OCC1=CC=CC=C1 Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 3
- UWBNDZJSKMKSOD-UHFFFAOYSA-N CC1=CC(F)=CC(C(F)(F)F)=C1 Chemical compound CC1=CC(F)=CC(C(F)(F)F)=C1 UWBNDZJSKMKSOD-UHFFFAOYSA-N 0.000 description 3
- GHPODDMCSOYWNE-UHFFFAOYSA-N CC1=CC2=C(C=C1)OCO2 Chemical compound CC1=CC2=C(C=C1)OCO2 GHPODDMCSOYWNE-UHFFFAOYSA-N 0.000 description 3
- GBGPVUAOTCNZPT-UHFFFAOYSA-N CC1=CC2=C(C=CC=C2)O1 Chemical compound CC1=CC2=C(C=CC=C2)O1 GBGPVUAOTCNZPT-UHFFFAOYSA-N 0.000 description 3
- NSNHEJLADTWTFE-UHFFFAOYSA-N CC1=CC=C(CN2CCCC2)C=C1 Chemical compound CC1=CC=C(CN2CCCC2)C=C1 NSNHEJLADTWTFE-UHFFFAOYSA-N 0.000 description 3
- GSDPDUAEOGGTQE-UHFFFAOYSA-N CC1=CC=C(CN2CCN(C)CC2)C=C1 Chemical compound CC1=CC=C(CN2CCN(C)CC2)C=C1 GSDPDUAEOGGTQE-UHFFFAOYSA-N 0.000 description 3
- ALHUXMDEZNLFTA-UHFFFAOYSA-N CC1=NC2=C(C=CC=C2)N=C1 Chemical compound CC1=NC2=C(C=CC=C2)N=C1 ALHUXMDEZNLFTA-UHFFFAOYSA-N 0.000 description 3
- UZXMIJNWMMWMBV-UHFFFAOYSA-N CC1=NN(C2=CC=CC=C2)N=C1C Chemical compound CC1=NN(C2=CC=CC=C2)N=C1C UZXMIJNWMMWMBV-UHFFFAOYSA-N 0.000 description 3
- RJTJVVYSTUQWNI-UHFFFAOYSA-N CCC1=CC2=C(C=CC=C2)C=C1 Chemical compound CCC1=CC2=C(C=CC=C2)C=C1 RJTJVVYSTUQWNI-UHFFFAOYSA-N 0.000 description 3
- IHHXYTIKYUHTQU-UHFFFAOYSA-N CCC1=CC=C(C(F)(F)F)C=C1 Chemical compound CCC1=CC=C(C(F)(F)F)C=C1 IHHXYTIKYUHTQU-UHFFFAOYSA-N 0.000 description 3
- JRLPEMVDPFPYPJ-UHFFFAOYSA-N CCC1=CC=C(C)C=C1 Chemical compound CCC1=CC=C(C)C=C1 JRLPEMVDPFPYPJ-UHFFFAOYSA-N 0.000 description 3
- NBXLPPVOZWYADY-UHFFFAOYSA-N CCC1=CC=C(C)O1 Chemical compound CCC1=CC=C(C)O1 NBXLPPVOZWYADY-UHFFFAOYSA-N 0.000 description 3
- SRQOBNUBCLPPPH-UHFFFAOYSA-N CCC1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound CCC1=CC=C(C2=CC=CC=C2)C=C1 SRQOBNUBCLPPPH-UHFFFAOYSA-N 0.000 description 3
- HETCYASWPLGPGT-UHFFFAOYSA-N CCC1=CC=C(SC)C=C1 Chemical compound CCC1=CC=C(SC)C=C1 HETCYASWPLGPGT-UHFFFAOYSA-N 0.000 description 3
- HLUNIRWBGNBJOO-UHFFFAOYSA-N CCC1=CSC2=C1C=CC=C2 Chemical compound CCC1=CSC2=C1C=CC=C2 HLUNIRWBGNBJOO-UHFFFAOYSA-N 0.000 description 3
- ODLMAHJVESYWTB-UHFFFAOYSA-N CCCC1=CC=CC=C1 Chemical compound CCCC1=CC=CC=C1 ODLMAHJVESYWTB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 150000005347 biaryls Chemical group 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- CGGLKWTURIUCMN-UHFFFAOYSA-N methyl 3-(2-bromoethoxy)benzoate Chemical compound COC(=O)C1=CC=CC(OCCBr)=C1 CGGLKWTURIUCMN-UHFFFAOYSA-N 0.000 description 3
- NYECALBCMWCKJN-UHFFFAOYSA-N methyl 3-(2-iodoethoxy)benzoate Chemical compound COC(=O)C1=CC=CC(OCCI)=C1 NYECALBCMWCKJN-UHFFFAOYSA-N 0.000 description 3
- KOXFGWQBGWCIIA-UHFFFAOYSA-N methyl 3-(3-amino-3-cyanopropoxy)benzoate Chemical compound COC(=O)C1=CC=CC(OCCC(N)C#N)=C1 KOXFGWQBGWCIIA-UHFFFAOYSA-N 0.000 description 3
- SZDTVDKXNMQIHH-AWEZNQCLSA-N methyl 3-[(4s)-5-amino-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopent-1-ynyl]benzoate Chemical compound COC(=O)C1=CC=CC(C#CC[C@H](NC(=O)OC(C)(C)C)C(N)=O)=C1 SZDTVDKXNMQIHH-AWEZNQCLSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- BMOBLEZARNPCGX-UHFFFAOYSA-N n-[1-[(1-cyano-3-methylbutyl)amino]-4-methyl-1-oxopentan-2-yl]naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C#N)=CC=C21 BMOBLEZARNPCGX-UHFFFAOYSA-N 0.000 description 3
- XNLBCXGRQWUJLU-UHFFFAOYSA-N naphthalene-2-carbonyl chloride Chemical compound C1=CC=CC2=CC(C(=O)Cl)=CC=C21 XNLBCXGRQWUJLU-UHFFFAOYSA-N 0.000 description 3
- 150000002826 nitrites Chemical class 0.000 description 3
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- FTVPHMFKKFOZSK-JTQLQIEISA-N tert-butyl (2s)-5-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CCCO)C(=O)OC(C)(C)C FTVPHMFKKFOZSK-JTQLQIEISA-N 0.000 description 3
- QPPOILFAPMMPJG-JTQLQIEISA-N tert-butyl (2s)-5-iodo-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate Chemical compound CC(C)(C)OC(=O)N[C@@H](CCCI)C(=O)OC(C)(C)C QPPOILFAPMMPJG-JTQLQIEISA-N 0.000 description 3
- NOFHGLNTDFJGCM-UHFFFAOYSA-N tert-butyl 3,4-diamino-3-methyl-4-oxobutanoate Chemical compound CC(C)(C)OC(=O)CC(C)(N)C(N)=O NOFHGLNTDFJGCM-UHFFFAOYSA-N 0.000 description 3
- GIGXCVOTKUOLHM-UHFFFAOYSA-N tert-butyl n-(2-cyanopropan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)C#N GIGXCVOTKUOLHM-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- ROAHGHLLRAUFEQ-LURJTMIESA-N (2s)-2-amino-4-methylpentanenitrile Chemical compound CC(C)C[C@H](N)C#N ROAHGHLLRAUFEQ-LURJTMIESA-N 0.000 description 2
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- IKTDBEVNXJFZKC-UHFFFAOYSA-N 1-amino-n-(2-cyanopropan-2-yl)cyclohexane-1-carboxamide Chemical compound N#CC(C)(C)NC(=O)C1(N)CCCCC1 IKTDBEVNXJFZKC-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- CJZFPFHGMQLPSV-UHFFFAOYSA-N 2-[[4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-phenylmethoxypropanoic acid Chemical compound C=1C=CC=CC=1COCC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 CJZFPFHGMQLPSV-UHFFFAOYSA-N 0.000 description 2
- ZIOBGZDFMKCKGZ-UHFFFAOYSA-N 2-amino-2-methylpropanamide Chemical compound CC(C)(N)C(N)=O ZIOBGZDFMKCKGZ-UHFFFAOYSA-N 0.000 description 2
- RWPZHHGTDNTPFY-UHFFFAOYSA-N 2-amino-2-methylpropanenitrile;hydrochloride Chemical compound Cl.CC(C)(N)C#N RWPZHHGTDNTPFY-UHFFFAOYSA-N 0.000 description 2
- MLEXPCFGRWPRBR-UHFFFAOYSA-N 2-amino-n-(cyanomethyl)-3-methylpentanamide;hydrochloride Chemical compound Cl.CCC(C)C(N)C(=O)NCC#N MLEXPCFGRWPRBR-UHFFFAOYSA-N 0.000 description 2
- HDBMIDJFXOYCGK-UHFFFAOYSA-N 2-aminobutanamide;hydrochloride Chemical compound Cl.CCC(N)C(N)=O HDBMIDJFXOYCGK-UHFFFAOYSA-N 0.000 description 2
- 125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- JZRBSTONIYRNRI-VIFPVBQESA-N 3-methylphenylalanine Chemical compound CC1=CC=CC(C[C@H](N)C(O)=O)=C1 JZRBSTONIYRNRI-VIFPVBQESA-N 0.000 description 2
- RJYLWBRPROPHTD-UHFFFAOYSA-N 4-(2-chloroethylsulfonyl)benzoic acid Chemical compound OC(=O)C1=CC=C(S(=O)(=O)CCCl)C=C1 RJYLWBRPROPHTD-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- FQWQTRUPSBZIRZ-UHFFFAOYSA-N 4-(bromomethyl)-n-[1-(2-cyanopropan-2-ylamino)-4-methyl-1-oxopentan-2-yl]benzamide Chemical compound N#CC(C)(C)NC(=O)C(CC(C)C)NC(=O)C1=CC=C(CBr)C=C1 FQWQTRUPSBZIRZ-UHFFFAOYSA-N 0.000 description 2
- ZSFDFIAXHSZLPV-UHFFFAOYSA-N 4-(bromomethyl)-n-[1-(cyanomethylcarbamoyl)cyclohexyl]benzamide Chemical compound C1=CC(CBr)=CC=C1C(=O)NC1(C(=O)NCC#N)CCCCC1 ZSFDFIAXHSZLPV-UHFFFAOYSA-N 0.000 description 2
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 2
- MPNJQHXLTFOYKD-UHFFFAOYSA-N CC(=O)C(C1=CC=CC=C1)C1=CC=CN=C1 Chemical compound CC(=O)C(C1=CC=CC=C1)C1=CC=CN=C1 MPNJQHXLTFOYKD-UHFFFAOYSA-N 0.000 description 2
- WPRAXAOJIODQJR-UHFFFAOYSA-N CC(=O)C1=CC=C(C)C(C)=C1 Chemical compound CC(=O)C1=CC=C(C)C(C)=C1 WPRAXAOJIODQJR-UHFFFAOYSA-N 0.000 description 2
- QEWHNJPLPZOEKU-UHFFFAOYSA-N CC(=O)C1=CC=C(F)C=C1F Chemical compound CC(=O)C1=CC=C(F)C=C1F QEWHNJPLPZOEKU-UHFFFAOYSA-N 0.000 description 2
- BMHMKWXYXFBWMI-UHFFFAOYSA-N CC(=O)C1=CC=C2OCOC2=C1 Chemical compound CC(=O)C1=CC=C2OCOC2=C1 BMHMKWXYXFBWMI-UHFFFAOYSA-N 0.000 description 2
- UUWJBXKHMMQDED-UHFFFAOYSA-N CC(=O)C1=CC=CC(Cl)=C1 Chemical compound CC(=O)C1=CC=CC(Cl)=C1 UUWJBXKHMMQDED-UHFFFAOYSA-N 0.000 description 2
- ARKIFHPFTHVKDT-UHFFFAOYSA-N CC(=O)C1=CC=CC([N+](=O)[O-])=C1 Chemical compound CC(=O)C1=CC=CC([N+](=O)[O-])=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 description 2
- GKUBGXGRJNAABQ-UHFFFAOYSA-N CC(=O)C1=CC=NO1 Chemical compound CC(=O)C1=CC=NO1 GKUBGXGRJNAABQ-UHFFFAOYSA-N 0.000 description 2
- JFHISDYXSZPOMZ-LBPRGKRZSA-N CC(C)(C)OC(=O)N[C@@H](CCC1=CC=CC=C1)C(N)=O Chemical compound CC(C)(C)OC(=O)N[C@@H](CCC1=CC=CC=C1)C(N)=O JFHISDYXSZPOMZ-LBPRGKRZSA-N 0.000 description 2
- NEJWTQIEQDHWTR-UHFFFAOYSA-N CC(C)(C)OC1=CC=C(Cl)C=C1 Chemical compound CC(C)(C)OC1=CC=C(Cl)C=C1 NEJWTQIEQDHWTR-UHFFFAOYSA-N 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N CC(C)C Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- QVLVXKKHSCUSCZ-UHFFFAOYSA-N CC(C1=CC=CC=C1)C1=CC=CS1 Chemical compound CC(C1=CC=CC=C1)C1=CC=CS1 QVLVXKKHSCUSCZ-UHFFFAOYSA-N 0.000 description 2
- NJWGQARXZDRHCD-UHFFFAOYSA-N CC1=CC2=C(C=C1)C(=O)C1=C(C=CC=C1)C2=O Chemical compound CC1=CC2=C(C=C1)C(=O)C1=C(C=CC=C1)C2=O NJWGQARXZDRHCD-UHFFFAOYSA-N 0.000 description 2
- BLZKSRBAQDZAIX-UHFFFAOYSA-N CC1=CC2=CC=CC=C2S1 Chemical compound CC1=CC2=CC=CC=C2S1 BLZKSRBAQDZAIX-UHFFFAOYSA-N 0.000 description 2
- NPDACUSDTOMAMK-UHFFFAOYSA-N CC1=CC=C(Cl)C=C1 Chemical compound CC1=CC=C(Cl)C=C1 NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 2
- YYDNBUBMBZRNQQ-UHFFFAOYSA-N CC1=CC=C(S(C)(=O)=O)C=C1 Chemical compound CC1=CC=C(S(C)(=O)=O)C=C1 YYDNBUBMBZRNQQ-UHFFFAOYSA-N 0.000 description 2
- QAHKQESOBNRNSZ-UHFFFAOYSA-N CC1=CC=CC(CN2C=CN=C2)=C1 Chemical compound CC1=CC=CC(CN2C=CN=C2)=C1 QAHKQESOBNRNSZ-UHFFFAOYSA-N 0.000 description 2
- VQKFNUFAXTZWDK-UHFFFAOYSA-N CC1=CC=CO1 Chemical compound CC1=CC=CO1 VQKFNUFAXTZWDK-UHFFFAOYSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N CC1=CC=NC=C1 Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- ITQTTZVARXURQS-UHFFFAOYSA-N CC1=CN=CC=C1 Chemical compound CC1=CN=CC=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 2
- MWGYLUXMIMSOTM-UHFFFAOYSA-N CC1CC2=C(C=CC=C2)C1 Chemical compound CC1CC2=C(C=CC=C2)C1 MWGYLUXMIMSOTM-UHFFFAOYSA-N 0.000 description 2
- JYYQLEBULAPBGS-UHFFFAOYSA-N CCCC1=CC=C(S(C)(=O)=O)C=C1 Chemical compound CCCC1=CC=C(S(C)(=O)=O)C=C1 JYYQLEBULAPBGS-UHFFFAOYSA-N 0.000 description 2
- JYMZRBDMDIWMSE-UHFFFAOYSA-N CCN1CCC(C2=CC=CC=C2)CC1 Chemical compound CCN1CCC(C2=CC=CC=C2)CC1 JYMZRBDMDIWMSE-UHFFFAOYSA-N 0.000 description 2
- RPPGCNGCGZNPPL-UHFFFAOYSA-N CCN1CCN(C2=CC=C(OC)C=C2)CC1 Chemical compound CCN1CCN(C2=CC=C(OC)C=C2)CC1 RPPGCNGCGZNPPL-UHFFFAOYSA-N 0.000 description 2
- WFGYSQDPURFIFL-UHFFFAOYSA-N CNC1=CC(Cl)=CC=C1 Chemical compound CNC1=CC(Cl)=CC=C1 WFGYSQDPURFIFL-UHFFFAOYSA-N 0.000 description 2
- JBZKUMYCNPNIJF-UHFFFAOYSA-N COC(C(C)=O)C1=CC=CC=C1 Chemical compound COC(C(C)=O)C1=CC=CC=C1 JBZKUMYCNPNIJF-UHFFFAOYSA-N 0.000 description 2
- ASKBXZKXIBPNRA-UHFFFAOYSA-N COC1=CC=C(C2=CC=C(C)C=C2)C=C1 Chemical compound COC1=CC=C(C2=CC=C(C)C=C2)C=C1 ASKBXZKXIBPNRA-UHFFFAOYSA-N 0.000 description 2
- GQKZBCPTCWJTAS-UHFFFAOYSA-N COCC1=CC=CC=C1 Chemical compound COCC1=CC=CC=C1 GQKZBCPTCWJTAS-UHFFFAOYSA-N 0.000 description 2
- JCDWETOKTFWTHA-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC=C1 Chemical compound CS(=O)(=O)C1=CC=CC=C1 JCDWETOKTFWTHA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101000761509 Homo sapiens Cathepsin K Proteins 0.000 description 2
- 101000983583 Homo sapiens Procathepsin L Proteins 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 241000534944 Thia Species 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- OAPQFRZGLKERCS-WDSKDSINSA-N [H]N(C(=O)[C@H](C)N([H])C(C)=O)[C@@H](C)C#N Chemical compound [H]N(C(=O)[C@H](C)N([H])C(C)=O)[C@@H](C)C#N OAPQFRZGLKERCS-WDSKDSINSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- KUIWZMNRCAEXNG-UHFFFAOYSA-N benzyl n-[1-[(1-amino-1-oxo-3-phenylmethoxypropan-2-yl)amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound C=1C=CC=CC=1COCC(C(N)=O)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 KUIWZMNRCAEXNG-UHFFFAOYSA-N 0.000 description 2
- BMFYRFFIWZYPGT-UHFFFAOYSA-N benzyl n-[1-[(1-cyano-2-phenylmethoxyethyl)amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound C=1C=CC=CC=1COCC(C#N)NC(=O)C(CC(C)C)NC(=O)OCC1=CC=CC=C1 BMFYRFFIWZYPGT-UHFFFAOYSA-N 0.000 description 2
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000049698 human CTSK Human genes 0.000 description 2
- 102000050937 human CTSL Human genes 0.000 description 2
- IENZCGNHSIMFJE-UHFFFAOYSA-N indole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2NC=CC2=C1 IENZCGNHSIMFJE-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- HSZCZNFXUDYRKD-UHFFFAOYSA-M lithium iodide Chemical compound [Li+].[I-] HSZCZNFXUDYRKD-UHFFFAOYSA-M 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QCMFLUCBYOQVOZ-LRDDRELGSA-N methyl (2s,3s)-3-methyl-2-(naphthalene-2-carbonylamino)pentanoate Chemical compound C1=CC=CC2=CC(C(=O)N[C@@H]([C@@H](C)CC)C(=O)OC)=CC=C21 QCMFLUCBYOQVOZ-LRDDRELGSA-N 0.000 description 2
- NEBQPYRZIGDSJO-ZDUSSCGKSA-N methyl 1-[(4s)-5-[(2-methylpropan-2-yl)oxy]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentyl]pyrazole-3-carboxylate Chemical compound COC(=O)C=1C=CN(CCC[C@H](NC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)N=1 NEBQPYRZIGDSJO-ZDUSSCGKSA-N 0.000 description 2
- YUHSMQQNPRLEEJ-UHFFFAOYSA-N methyl 3-(bromomethyl)benzoate Chemical compound COC(=O)C1=CC=CC(CBr)=C1 YUHSMQQNPRLEEJ-UHFFFAOYSA-N 0.000 description 2
- CDXSNHAQEFUTJZ-CVRLYYSRSA-N methyl 3-[(4s)-5-amino-4-(butoxycarbonylamino)-5-oxopentan-2-yl]benzoate Chemical compound CCCCOC(=O)N[C@H](C(N)=O)CC(C)C1=CC=CC(C(=O)OC)=C1 CDXSNHAQEFUTJZ-CVRLYYSRSA-N 0.000 description 2
- YKUCHDXIBAQWSF-UHFFFAOYSA-N methyl 3-hydroxybenzoate Chemical compound COC(=O)C1=CC=CC(O)=C1 YKUCHDXIBAQWSF-UHFFFAOYSA-N 0.000 description 2
- WHBQNMWZLZKDSD-UHFFFAOYSA-N methyl 5-(bromomethyl)furan-2-carboxylate Chemical compound COC(=O)C1=CC=C(CBr)O1 WHBQNMWZLZKDSD-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- BOFKWLMYQAUHND-UHFFFAOYSA-N n-[1-(2-cyanopropan-2-ylamino)-4-methyl-1-oxopentan-2-yl]-4-(imidazol-1-ylmethyl)benzamide Chemical compound C1=CC(C(=O)NC(CC(C)C)C(=O)NC(C)(C)C#N)=CC=C1CN1C=NC=C1 BOFKWLMYQAUHND-UHFFFAOYSA-N 0.000 description 2
- DEWILIAMQYFWKE-UHFFFAOYSA-N n-[1-(2-cyanopropan-2-ylcarbamoyl)cyclohexyl]-1h-indole-2-carboxamide Chemical compound C=1C2=CC=CC=C2NC=1C(=O)NC1(C(=O)NC(C)(C)C#N)CCCCC1 DEWILIAMQYFWKE-UHFFFAOYSA-N 0.000 description 2
- FYSXODMXPITAJI-UHFFFAOYSA-N n-[1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]-4-(2-pyrrolidin-1-ylethylsulfonyl)benzamide Chemical compound C1=CC(C(=O)NC(CC(C)C)C(=O)NCC#N)=CC=C1S(=O)(=O)CCN1CCCC1 FYSXODMXPITAJI-UHFFFAOYSA-N 0.000 description 2
- USQYDMLPDUTMBP-UHFFFAOYSA-N n-[1-(cyanomethylcarbamoyl)cyclohexyl]-4-(imidazol-1-ylmethyl)benzamide Chemical compound C=1C=C(CN2C=NC=C2)C=CC=1C(=O)NC1(C(=O)NCC#N)CCCCC1 USQYDMLPDUTMBP-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003140 primary amides Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- AGBCKTRPDKOAAU-ZETCQYMHSA-N tert-butyl N-[(2S)-2-aminopent-4-ynoyl]carbamate Chemical compound C(C)(C)(C)OC(=O)NC([C@@H](N)CC#C)=O AGBCKTRPDKOAAU-ZETCQYMHSA-N 0.000 description 2
- HNTBSHVGXMFKKB-UHFFFAOYSA-N tert-butyl n-[1-(cyanomethylamino)-3-methyl-1-oxopentan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C(C)CC)C(=O)NCC#N HNTBSHVGXMFKKB-UHFFFAOYSA-N 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OHWBGKONMFYEKL-FQEVSTJZSA-N (2r)-2-amino-3-tritylsulfanylpropanamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(SC[C@H](N)C(N)=O)C1=CC=CC=C1 OHWBGKONMFYEKL-FQEVSTJZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- MCODLPJUFHPVQP-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC1=CC=CC=C1 MCODLPJUFHPVQP-LBPRGKRZSA-N 0.000 description 1
- AMKHAJIFPHJYMH-ZETCQYMHSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-4-ynoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC#C AMKHAJIFPHJYMH-ZETCQYMHSA-N 0.000 description 1
- AEYTXGCLZAJPCX-RGMNGODLSA-N (2s)-2-amino-4-methylpentanenitrile;hydrochloride Chemical compound Cl.CC(C)C[C@H](N)C#N AEYTXGCLZAJPCX-RGMNGODLSA-N 0.000 description 1
- PBTNVAYSJPRTLQ-STQMWFEESA-N (2s)-4-methyl-2-[[(2s)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]pentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C PBTNVAYSJPRTLQ-STQMWFEESA-N 0.000 description 1
- QJCNLJWUIOIMMF-YUMQZZPRSA-N (2s,3s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C QJCNLJWUIOIMMF-YUMQZZPRSA-N 0.000 description 1
- YMOYURYWGUWMFM-VIFPVBQESA-N (4s)-5-[(2-methylpropan-2-yl)oxy]-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CCC(O)=O)C(=O)OC(C)(C)C YMOYURYWGUWMFM-VIFPVBQESA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- RUWBBBUXZRUXBG-UHFFFAOYSA-N 1-amino-n-(cyanomethyl)cyclohexane-1-carboxamide Chemical compound N#CCNC(=O)C1(N)CCCCC1 RUWBBBUXZRUXBG-UHFFFAOYSA-N 0.000 description 1
- IINRZEIPFQHEAP-UHFFFAOYSA-N 1-aminocycloheptane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCCCC1 IINRZEIPFQHEAP-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- MSYLETHDEIJMAF-UHFFFAOYSA-N 2,2-diphenylacetyl chloride Chemical compound C=1C=CC=CC=1C(C(=O)Cl)C1=CC=CC=C1 MSYLETHDEIJMAF-UHFFFAOYSA-N 0.000 description 1
- FWALJUXKWWBNEO-UHFFFAOYSA-N 2-(4-chloroanilino)acetic acid Chemical compound OC(=O)CNC1=CC=C(Cl)C=C1 FWALJUXKWWBNEO-UHFFFAOYSA-N 0.000 description 1
- VRLJFRODHVSTIK-UHFFFAOYSA-N 2-(benzhydrylideneamino)acetonitrile Chemical compound C=1C=CC=CC=1C(=NCC#N)C1=CC=CC=C1 VRLJFRODHVSTIK-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- PNFVIPIQXAIUAY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CCC(C(O)=O)NC(=O)OC(C)(C)C PNFVIPIQXAIUAY-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- YHYXYSHMKVFQIR-UHFFFAOYSA-N 2-amino-2-methylpropanamide;hydrochloride Chemical compound Cl.CC(C)(N)C(N)=O YHYXYSHMKVFQIR-UHFFFAOYSA-N 0.000 description 1
- XCSYDLQKFBIDLO-UHFFFAOYSA-N 2-amino-3-(1h-indol-3-yl)propanenitrile Chemical compound C1=CC=C2C(CC(N)C#N)=CNC2=C1 XCSYDLQKFBIDLO-UHFFFAOYSA-N 0.000 description 1
- COOMAYNPLIMRGM-UHFFFAOYSA-N 2-amino-4-phenylbutanenitrile;hydrochloride Chemical compound Cl.N#CC(N)CCC1=CC=CC=C1 COOMAYNPLIMRGM-UHFFFAOYSA-N 0.000 description 1
- HXIMQRUHNCQGTO-UHFFFAOYSA-N 2-amino-n-(2-cyanopropan-2-yl)-4-methylpentanamide Chemical compound CC(C)CC(N)C(=O)NC(C)(C)C#N HXIMQRUHNCQGTO-UHFFFAOYSA-N 0.000 description 1
- GQHJCLXWRQHKPT-UHFFFAOYSA-N 2-amino-n-(cyanomethyl)-4-methylpentanamide Chemical compound CC(C)CC(N)C(=O)NCC#N GQHJCLXWRQHKPT-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- UKAMWVYNAVUZEA-UHFFFAOYSA-N 2-butylnaphthalene Chemical compound C1=CC=CC2=CC(CCCC)=CC=C21 UKAMWVYNAVUZEA-UHFFFAOYSA-N 0.000 description 1
- LLWADFLAOKUBDR-UHFFFAOYSA-N 2-methyl-4-chlorophenoxybutyric acid Chemical compound CC1=CC(Cl)=CC=C1OCCCC(O)=O LLWADFLAOKUBDR-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- PBSUMBYSVFTMNG-UHFFFAOYSA-N 3-(chloromethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(CCl)=C1 PBSUMBYSVFTMNG-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LMJXSOYPAOSIPZ-UHFFFAOYSA-N 4-sulfanylbenzoic acid Chemical compound OC(=O)C1=CC=C(S)C=C1 LMJXSOYPAOSIPZ-UHFFFAOYSA-N 0.000 description 1
- ILMIPFYXCSUIQR-UHFFFAOYSA-N 5-(bromomethyl)furan-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(CBr)O1 ILMIPFYXCSUIQR-UHFFFAOYSA-N 0.000 description 1
- APQGIAYQAYOKSU-UHFFFAOYSA-N 5-aminoquinoline-2-carboxylic acid Chemical compound OC(=O)C1=CC=C2C(N)=CC=CC2=N1 APQGIAYQAYOKSU-UHFFFAOYSA-N 0.000 description 1
- OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- ZFKDTOLBRBCFIC-UHFFFAOYSA-N C(=O)(OC(C)(C)C)C(C(=O)N)(CCC1=CC=CC=C1)N Chemical compound C(=O)(OC(C)(C)C)C(C(=O)N)(CCC1=CC=CC=C1)N ZFKDTOLBRBCFIC-UHFFFAOYSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- GFXCSEZRSZLPPD-GORDUTHDSA-N C/C=C/C1=CNC2C=CC=CC12 Chemical compound C/C=C/C1=CNC2C=CC=CC12 GFXCSEZRSZLPPD-GORDUTHDSA-N 0.000 description 1
- VVGSHJCERNMTNI-UHFFFAOYSA-N C1=CC=CC2=CC(C(=O)NC(C(C)CC)C(=O)NCC#N)=CC=C21 Chemical compound C1=CC=CC2=CC(C(=O)NC(C(C)CC)C(=O)NCC#N)=CC=C21 VVGSHJCERNMTNI-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N CC#CC Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- CVWMNAWLNRRPOL-UHFFFAOYSA-N CC(=O)C(C)C1=CC=CC=C1 Chemical compound CC(=O)C(C)C1=CC=CC=C1 CVWMNAWLNRRPOL-UHFFFAOYSA-N 0.000 description 1
- DBNWBEGCONIRGQ-UHFFFAOYSA-N CC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(=O)C(C1=CC=CC=C1)C1=CC=CC=C1 DBNWBEGCONIRGQ-UHFFFAOYSA-N 0.000 description 1
- ADVYFMPKEHQQFT-UHFFFAOYSA-N CC(=O)C(C1=CC=CN=C1)C1=CN=CC=C1 Chemical compound CC(=O)C(C1=CC=CN=C1)C1=CN=CC=C1 ADVYFMPKEHQQFT-UHFFFAOYSA-N 0.000 description 1
- VZOPIMRGXPQUOI-UHFFFAOYSA-N CC(=O)C(C=O)C1=CC=CC=C1 Chemical compound CC(=O)C(C=O)C1=CC=CC=C1 VZOPIMRGXPQUOI-UHFFFAOYSA-N 0.000 description 1
- YXWWHNCQZBVZPV-UHFFFAOYSA-N CC(=O)C1=C(C)C=CC=C1 Chemical compound CC(=O)C1=C(C)C=CC=C1 YXWWHNCQZBVZPV-UHFFFAOYSA-N 0.000 description 1
- MCYCSIKSZLARBD-UHFFFAOYSA-N CC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound CC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 MCYCSIKSZLARBD-UHFFFAOYSA-N 0.000 description 1
- WYECURVXVYPVAT-UHFFFAOYSA-N CC(=O)C1=CC=C(Br)C=C1 Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- ZDPAWHACYDRYIW-UHFFFAOYSA-N CC(=O)C1=CC=C(F)C=C1 Chemical compound CC(=O)C1=CC=C(F)C=C1 ZDPAWHACYDRYIW-UHFFFAOYSA-N 0.000 description 1
- HUDYANRNMZDQGA-UHFFFAOYSA-N CC(=O)C1=CC=C(N(C)C)C=C1 Chemical compound CC(=O)C1=CC=C(N(C)C)C=C1 HUDYANRNMZDQGA-UHFFFAOYSA-N 0.000 description 1
- ORQQKSZUXNAWAX-UHFFFAOYSA-N CC(=O)C1=CC=C([N+](=O)[O-])O1 Chemical compound CC(=O)C1=CC=C([N+](=O)[O-])O1 ORQQKSZUXNAWAX-UHFFFAOYSA-N 0.000 description 1
- KWOLFJPFCHCOCG-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1 Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 1
- ZDOYHCIRUPHUHN-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1Cl Chemical compound CC(=O)C1=CC=CC=C1Cl ZDOYHCIRUPHUHN-UHFFFAOYSA-N 0.000 description 1
- QMATYTFXDIWACW-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1F Chemical compound CC(=O)C1=CC=CC=C1F QMATYTFXDIWACW-UHFFFAOYSA-N 0.000 description 1
- IEMMBWWQXVXBEU-UHFFFAOYSA-N CC(=O)C1=CC=CO1 Chemical compound CC(=O)C1=CC=CO1 IEMMBWWQXVXBEU-UHFFFAOYSA-N 0.000 description 1
- RIFKADJTWUGDOV-UHFFFAOYSA-N CC(=O)C1CCCCC1 Chemical compound CC(=O)C1CCCCC1 RIFKADJTWUGDOV-UHFFFAOYSA-N 0.000 description 1
- QCCDLTOVEPVEJK-UHFFFAOYSA-N CC(=O)CC1=CC=CC=C1 Chemical compound CC(=O)CC1=CC=CC=C1 QCCDLTOVEPVEJK-UHFFFAOYSA-N 0.000 description 1
- FOWXQMONAFWJAD-UHFFFAOYSA-N CC(=O)CC1=CC=CS1 Chemical compound CC(=O)CC1=CC=CS1 FOWXQMONAFWJAD-UHFFFAOYSA-N 0.000 description 1
- QWAVNXZAQASOML-UHFFFAOYSA-N CC(=O)COC1=CC=CC=C1 Chemical compound CC(=O)COC1=CC=CC=C1 QWAVNXZAQASOML-UHFFFAOYSA-N 0.000 description 1
- SJDLQTSMJPEHGA-UHFFFAOYSA-N CC(=O)NC(CC(C)C)C(=O)NC(C)(C)C#N Chemical compound CC(=O)NC(CC(C)C)C(=O)NC(C)(C)C#N SJDLQTSMJPEHGA-UHFFFAOYSA-N 0.000 description 1
- HIEMCBFEHHJBDV-VIFPVBQESA-N CC(=O)NC1(C(=O)N[C@@H](C)C#N)CCCCC1 Chemical compound CC(=O)NC1(C(=O)N[C@@H](C)C#N)CCCCC1 HIEMCBFEHHJBDV-VIFPVBQESA-N 0.000 description 1
- JEZSJOWAVIBTRO-STQMWFEESA-N CC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C#N)CC(C)C Chemical compound CC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C#N)CC(C)C JEZSJOWAVIBTRO-STQMWFEESA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N CC(=O)OC1=CC=CC=C1 Chemical compound CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- SGPFUCRQUZMQCP-UHFFFAOYSA-N CC(C)C1=CC(S(C)(=O)=O)=CC=C1 Chemical compound CC(C)C1=CC(S(C)(=O)=O)=CC=C1 SGPFUCRQUZMQCP-UHFFFAOYSA-N 0.000 description 1
- PHHUDJQYUVMKFT-SFHVURJKSA-N CC(C)C[C@H](NC(=O)C1=CC2=CC=CC=C2C=C1)C(=O)NC(C)(C)C#N Chemical compound CC(C)C[C@H](NC(=O)C1=CC2=CC=CC=C2C=C1)C(=O)NC(C)(C)C#N PHHUDJQYUVMKFT-SFHVURJKSA-N 0.000 description 1
- GFXCQATURMOFPK-DQEYMECFSA-N CC(C)C[C@H](NC(=O)C1=CC2=CC=CC=C2C=C1)C(=O)N[C@H](C#N)CCC1=CC=CC=C1 Chemical compound CC(C)C[C@H](NC(=O)C1=CC2=CC=CC=C2C=C1)C(=O)N[C@H](C#N)CCC1=CC=CC=C1 GFXCQATURMOFPK-DQEYMECFSA-N 0.000 description 1
- QSWLESBOZBYNRI-UHFFFAOYSA-N CC(C1=CC=CC=C1)C1=CN=CC=C1 Chemical compound CC(C1=CC=CC=C1)C1=CN=CC=C1 QSWLESBOZBYNRI-UHFFFAOYSA-N 0.000 description 1
- RAEHXSVBNPRYDM-UHFFFAOYSA-N CC(C1=CC=CC=C1)C1=CSC=C1 Chemical compound CC(C1=CC=CC=C1)C1=CSC=C1 RAEHXSVBNPRYDM-UHFFFAOYSA-N 0.000 description 1
- XLWCIHPMASUXPI-UHFFFAOYSA-N CC(CC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(CC1=CC=CC=C1)C1=CC=CC=C1 XLWCIHPMASUXPI-UHFFFAOYSA-N 0.000 description 1
- QUTPKZJGTMSMJI-UHFFFAOYSA-N CC(CC1=CC=CC=C1)C1=CC=CC=N1 Chemical compound CC(CC1=CC=CC=C1)C1=CC=CC=N1 QUTPKZJGTMSMJI-UHFFFAOYSA-N 0.000 description 1
- RMYALFZYPYPKCW-UHFFFAOYSA-N CC1=C(C)C(C(C)(C)C)=CO1 Chemical compound CC1=C(C)C(C(C)(C)C)=CO1 RMYALFZYPYPKCW-UHFFFAOYSA-N 0.000 description 1
- CUJNZTKYZLLKBY-UHFFFAOYSA-N CC1=CC(C(C)(C)C)=NN1 Chemical compound CC1=CC(C(C)(C)C)=NN1 CUJNZTKYZLLKBY-UHFFFAOYSA-N 0.000 description 1
- WGUXTQDCAZNJIF-UHFFFAOYSA-N CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 Chemical compound CC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 WGUXTQDCAZNJIF-UHFFFAOYSA-N 0.000 description 1
- AAIJEURQKZASKQ-UHFFFAOYSA-N CC1=CC(C)=C(F)C=C1 Chemical compound CC1=CC(C)=C(F)C=C1 AAIJEURQKZASKQ-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N CC1=CC(C)=CC(C)=C1 Chemical compound CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- WYVKQPSDGDWDEF-UHFFFAOYSA-N CC1=CC(C)=NN1C(C)(C)C Chemical compound CC1=CC(C)=NN1C(C)(C)C WYVKQPSDGDWDEF-UHFFFAOYSA-N 0.000 description 1
- COVGXNSRDOYAJD-UHFFFAOYSA-N CC1=CC(Cl)=NC(C)=C1 Chemical compound CC1=CC(Cl)=NC(C)=C1 COVGXNSRDOYAJD-UHFFFAOYSA-N 0.000 description 1
- YISYUYYETHYYMD-UHFFFAOYSA-N CC1=CC(F)=CC(F)=C1 Chemical compound CC1=CC(F)=CC(F)=C1 YISYUYYETHYYMD-UHFFFAOYSA-N 0.000 description 1
- HWCMIABYHBVAJW-UHFFFAOYSA-N CC1=CC(S(C)(=O)=O)=CC=C1 Chemical compound CC1=CC(S(C)(=O)=O)=CC=C1 HWCMIABYHBVAJW-UHFFFAOYSA-N 0.000 description 1
- QZYHIOPPLUPUJF-UHFFFAOYSA-N CC1=CC([N+](=O)[O-])=CC=C1 Chemical compound CC1=CC([N+](=O)[O-])=CC=C1 QZYHIOPPLUPUJF-UHFFFAOYSA-N 0.000 description 1
- YPKBCLZFIYBSHK-UHFFFAOYSA-N CC1=CC2=C(C=C1)NC=C2 Chemical compound CC1=CC2=C(C=C1)NC=C2 YPKBCLZFIYBSHK-UHFFFAOYSA-N 0.000 description 1
- ONYNOPPOVKYGRS-UHFFFAOYSA-N CC1=CC2=C(C=CN2)C=C1 Chemical compound CC1=CC2=C(C=CN2)C=C1 ONYNOPPOVKYGRS-UHFFFAOYSA-N 0.000 description 1
- GYMFBYTZOGMSQJ-UHFFFAOYSA-N CC1=CC2=CC3=C(C=CC=C3)C=C2C=C1 Chemical compound CC1=CC2=CC3=C(C=CC=C3)C=C2C=C1 GYMFBYTZOGMSQJ-UHFFFAOYSA-N 0.000 description 1
- LRLRAYMYEXQKID-UHFFFAOYSA-N CC1=CC=C(C(F)(F)F)C=C1 Chemical compound CC1=CC=C(C(F)(F)F)C=C1 LRLRAYMYEXQKID-UHFFFAOYSA-N 0.000 description 1
- GSNUFIFRDBKVIE-UHFFFAOYSA-N CC1=CC=C(C)O1 Chemical compound CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- JSBJQQZPQJIGFJ-UHFFFAOYSA-N CC1=CC=C(C2=CC=C(F)C=C2)C=C1 Chemical compound CC1=CC=C(C2=CC=C(F)C=C2)C=C1 JSBJQQZPQJIGFJ-UHFFFAOYSA-N 0.000 description 1
- DKFPQCUHILRPNN-UHFFFAOYSA-N CC1=CC=C(C2=CC=CS2)C=C1 Chemical compound CC1=CC=C(C2=CC=CS2)C=C1 DKFPQCUHILRPNN-UHFFFAOYSA-N 0.000 description 1
- HNCPAJPMBWXHEH-UHFFFAOYSA-N CC1=CC=C(C2=CSC=C2)C=C1 Chemical compound CC1=CC=C(C2=CSC=C2)C=C1 HNCPAJPMBWXHEH-UHFFFAOYSA-N 0.000 description 1
- HMTSWYPNXFHGEP-UHFFFAOYSA-N CC1=CC=C(CN)C=C1 Chemical compound CC1=CC=C(CN)C=C1 HMTSWYPNXFHGEP-UHFFFAOYSA-N 0.000 description 1
- DQXGQHAFADWCKG-UHFFFAOYSA-N CC1=CC=C(CN2C=CN=C2)C=C1 Chemical compound CC1=CC=C(CN2C=CN=C2)C=C1 DQXGQHAFADWCKG-UHFFFAOYSA-N 0.000 description 1
- JBZFWJJJLREXJO-UHFFFAOYSA-N CC1=CC=C(CN2CCOCC2)C=C1 Chemical compound CC1=CC=C(CN2CCOCC2)C=C1 JBZFWJJJLREXJO-UHFFFAOYSA-N 0.000 description 1
- UJPXOHXMJDQRLY-UHFFFAOYSA-N CC1=CC=C(CNCCO)C=C1 Chemical compound CC1=CC=C(CNCCO)C=C1 UJPXOHXMJDQRLY-UHFFFAOYSA-N 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N CC1=CC=C(N)C=C1 Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- RGXUCUWVGKLACF-UHFFFAOYSA-N CC1=CC=CC(CN)=C1 Chemical compound CC1=CC=CC(CN)=C1 RGXUCUWVGKLACF-UHFFFAOYSA-N 0.000 description 1
- QFFYIFNIIRBVLI-UHFFFAOYSA-N CC1=CC=CC(CN2CCCC2)=C1 Chemical compound CC1=CC=CC(CN2CCCC2)=C1 QFFYIFNIIRBVLI-UHFFFAOYSA-N 0.000 description 1
- KKPCPGWGLHHNSW-UHFFFAOYSA-N CC1=CC=CC(CN2CCOCC2)=C1 Chemical compound CC1=CC=CC(CN2CCOCC2)=C1 KKPCPGWGLHHNSW-UHFFFAOYSA-N 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N CC1=CC=CC(N)=C1 Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- RNVCVTLRINQCPJ-UHFFFAOYSA-N CC1=CC=CC=C1N Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 1
- KZBQJUIDAWPMJQ-UHFFFAOYSA-N CC1=CC=CC=C1S(C)(=O)=O Chemical compound CC1=CC=CC=C1S(C)(=O)=O KZBQJUIDAWPMJQ-UHFFFAOYSA-N 0.000 description 1
- GNFLFHZJXXFDRA-UHFFFAOYSA-N CC1=CC=CN1C Chemical compound CC1=CC=CN1C GNFLFHZJXXFDRA-UHFFFAOYSA-N 0.000 description 1
- IPOHWQDCODUHTD-UHFFFAOYSA-N CC1=CSC(C2=CC=CC=C2)=N1 Chemical compound CC1=CSC(C2=CC=CC=C2)=N1 IPOHWQDCODUHTD-UHFFFAOYSA-N 0.000 description 1
- SEBRPHZZSLCDRQ-UHFFFAOYSA-N CC1=CSC2=C1C=CC=C2 Chemical compound CC1=CSC2=C1C=CC=C2 SEBRPHZZSLCDRQ-UHFFFAOYSA-N 0.000 description 1
- SMUQFGGVLNAIOZ-UHFFFAOYSA-N CC1=NC2=C(C=CC=C2)C=C1 Chemical compound CC1=NC2=C(C=CC=C2)C=C1 SMUQFGGVLNAIOZ-UHFFFAOYSA-N 0.000 description 1
- NODLZCJDRXTSJO-UHFFFAOYSA-N CC1=NN(C)C=C1 Chemical compound CC1=NN(C)C=C1 NODLZCJDRXTSJO-UHFFFAOYSA-N 0.000 description 1
- HHIJYJOINWQPIG-UHFFFAOYSA-N CC1C=CN2=C1C=CN=C2C1=CC=CC=C1 Chemical compound CC1C=CN2=C1C=CN=C2C1=CC=CC=C1 HHIJYJOINWQPIG-UHFFFAOYSA-N 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N CCC Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- VHOMAPWVLKRQAZ-UHFFFAOYSA-N CCC(=O)OCC1=CC=CC=C1 Chemical compound CCC(=O)OCC1=CC=CC=C1 VHOMAPWVLKRQAZ-UHFFFAOYSA-N 0.000 description 1
- ZJMWRROPUADPEA-UHFFFAOYSA-N CCC(C)C1=CC=CC=C1 Chemical compound CCC(C)C1=CC=CC=C1 ZJMWRROPUADPEA-UHFFFAOYSA-N 0.000 description 1
- NEBQMYHKOREVAL-UHFFFAOYSA-N CCC1=CC(OC)=C(OC)C=C1 Chemical compound CCC1=CC(OC)=C(OC)C=C1 NEBQMYHKOREVAL-UHFFFAOYSA-N 0.000 description 1
- ZMXIYERNXPIYFR-UHFFFAOYSA-N CCC1=CC=CC2=C1C=CC=C2 Chemical compound CCC1=CC=CC2=C1C=CC=C2 ZMXIYERNXPIYFR-UHFFFAOYSA-N 0.000 description 1
- MFEIKQPHQINPRI-UHFFFAOYSA-N CCC1=CC=CN=C1 Chemical compound CCC1=CC=CN=C1 MFEIKQPHQINPRI-UHFFFAOYSA-N 0.000 description 1
- BAJDLXDMWFRTNT-UHFFFAOYSA-N CCC1=CN(C)C2=C1C=CC=C2 Chemical compound CCC1=CN(C)C2=C1C=CC=C2 BAJDLXDMWFRTNT-UHFFFAOYSA-N 0.000 description 1
- QEFLNYXPYKZGEX-UHFFFAOYSA-N CCC1=CN(C)C=N1 Chemical compound CCC1=CN(C)C=N1 QEFLNYXPYKZGEX-UHFFFAOYSA-N 0.000 description 1
- CGOVTZGCKPMLMN-UHFFFAOYSA-N CCC1=CSC=N1 Chemical compound CCC1=CSC=N1 CGOVTZGCKPMLMN-UHFFFAOYSA-N 0.000 description 1
- XJJVJKLSFMUBAR-UHFFFAOYSA-N CCC1=NSC=C1 Chemical compound CCC1=NSC=C1 XJJVJKLSFMUBAR-UHFFFAOYSA-N 0.000 description 1
- AYIYBBZENMJOER-UHFFFAOYSA-N CCC1CNC2=C1C=CC=C2 Chemical compound CCC1CNC2=C1C=CC=C2 AYIYBBZENMJOER-UHFFFAOYSA-N 0.000 description 1
- MQESVSITPLILCO-UHFFFAOYSA-N CCCCC1=CC=C(C(C)=O)C=C1 Chemical compound CCCCC1=CC=C(C(C)=O)C=C1 MQESVSITPLILCO-UHFFFAOYSA-N 0.000 description 1
- QRXUXNUNFHPWLQ-UHFFFAOYSA-N CCCCS(C)(=O)=O Chemical compound CCCCS(C)(=O)=O QRXUXNUNFHPWLQ-UHFFFAOYSA-N 0.000 description 1
- CDWDEDNPRYWFNM-UHFFFAOYSA-N CCN1CCN(C2=CC(C)=CC=C2)CC1 Chemical compound CCN1CCN(C2=CC(C)=CC=C2)CC1 CDWDEDNPRYWFNM-UHFFFAOYSA-N 0.000 description 1
- FBVWQXPEPQGWJN-UHFFFAOYSA-N CCN1CCN(C2=CC(OC)=CC=C2)CC1 Chemical compound CCN1CCN(C2=CC(OC)=CC=C2)CC1 FBVWQXPEPQGWJN-UHFFFAOYSA-N 0.000 description 1
- KDFFXYVOTKKBDI-UHFFFAOYSA-N CCNC1=CC=CC2=C1C=CC=C2 Chemical compound CCNC1=CC=CC2=C1C=CC=C2 KDFFXYVOTKKBDI-UHFFFAOYSA-N 0.000 description 1
- BQBROHBMIBOPFU-UHFFFAOYSA-N CCOC1=CC=C(CC)C=C1 Chemical compound CCOC1=CC=C(CC)C=C1 BQBROHBMIBOPFU-UHFFFAOYSA-N 0.000 description 1
- KUUODIRQTBFPQJ-UHFFFAOYSA-N CCOCC1=CC(C(N)=O)=CC=C1 Chemical compound CCOCC1=CC(C(N)=O)=CC=C1 KUUODIRQTBFPQJ-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N CN(C)C1=CC=C(C=O)C=C1 Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- AKEYUWUEAXIBTF-UHFFFAOYSA-N CNC1=C2C=CC=CC2=CC=C1 Chemical compound CNC1=C2C=CC=CC2=CC=C1 AKEYUWUEAXIBTF-UHFFFAOYSA-N 0.000 description 1
- DUSNCFKVMGTTFK-UHFFFAOYSA-N CNC1=CC(Cl)=C(Cl)C=C1 Chemical compound CNC1=CC(Cl)=C(Cl)C=C1 DUSNCFKVMGTTFK-UHFFFAOYSA-N 0.000 description 1
- IJNQJQRKLLCLMC-UHFFFAOYSA-N CNC1=CC2=CC=CC=C2C=C1 Chemical compound CNC1=CC2=CC=CC=C2C=C1 IJNQJQRKLLCLMC-UHFFFAOYSA-N 0.000 description 1
- QCIFLGSATTWUQJ-UHFFFAOYSA-N CNC1=CC=C(C)C=C1 Chemical compound CNC1=CC=C(C)C=C1 QCIFLGSATTWUQJ-UHFFFAOYSA-N 0.000 description 1
- JFXDIXYFXDOZIT-UHFFFAOYSA-N CNC1=CC=C(OC)C=C1 Chemical compound CNC1=CC=C(OC)C=C1 JFXDIXYFXDOZIT-UHFFFAOYSA-N 0.000 description 1
- HHHOFIZZTGKWKP-UHFFFAOYSA-N COC(=O)C1(NC(=O)C2=CC3=CC=CC=C3C=C2)CCCCC1 Chemical compound COC(=O)C1(NC(=O)C2=CC3=CC=CC=C3C=C2)CCCCC1 HHHOFIZZTGKWKP-UHFFFAOYSA-N 0.000 description 1
- LXZIWFHPXKJKGS-ZWXJPIIXSA-N COC(=O)C1=CC=CC(COC[C@@H](C#N)NC(=O)[C@H](CC2=CC(C)=CC=C2)NC(=O)C(C2=CC=CC=C2)C2=CC=CC=C2)=C1 Chemical compound COC(=O)C1=CC=CC(COC[C@@H](C#N)NC(=O)[C@H](CC2=CC(C)=CC=C2)NC(=O)C(C2=CC=CC=C2)C2=CC=CC=C2)=C1 LXZIWFHPXKJKGS-ZWXJPIIXSA-N 0.000 description 1
- IQZLUWLMQNGTIW-UHFFFAOYSA-N COC1=C(OC)C=C(C(C)=O)C=C1 Chemical compound COC1=C(OC)C=C(C(C)=O)C=C1 IQZLUWLMQNGTIW-UHFFFAOYSA-N 0.000 description 1
- NQMUGNMMFTYOHK-UHFFFAOYSA-N COC1=C2C=CC=CC2=CC=C1 Chemical compound COC1=C2C=CC=CC2=CC=C1 NQMUGNMMFTYOHK-UHFFFAOYSA-N 0.000 description 1
- BAYUSCHCCGXLAY-UHFFFAOYSA-N COC1=CC(C(C)=O)=CC=C1 Chemical compound COC1=CC(C(C)=O)=CC=C1 BAYUSCHCCGXLAY-UHFFFAOYSA-N 0.000 description 1
- VISJRVXHPNMYRH-UHFFFAOYSA-N COC1=CC(Cl)=C(Cl)C=C1 Chemical compound COC1=CC(Cl)=C(Cl)C=C1 VISJRVXHPNMYRH-UHFFFAOYSA-N 0.000 description 1
- YUKILTJWFRTXGB-UHFFFAOYSA-N COC1=CC(Cl)=CC=C1 Chemical compound COC1=CC(Cl)=CC=C1 YUKILTJWFRTXGB-UHFFFAOYSA-N 0.000 description 1
- VSWGLJOQFUMFOQ-UHFFFAOYSA-N COC1=CC2=C(C=C1)NC(C)=C2 Chemical compound COC1=CC2=C(C=C1)NC(C)=C2 VSWGLJOQFUMFOQ-UHFFFAOYSA-N 0.000 description 1
- LUZDYPLAQQGJEA-UHFFFAOYSA-N COC1=CC2=CC=CC=C2C=C1 Chemical compound COC1=CC2=CC=CC=C2C=C1 LUZDYPLAQQGJEA-UHFFFAOYSA-N 0.000 description 1
- NTPLXRHDUXRPNE-UHFFFAOYSA-N COC1=CC=C(C(C)=O)C=C1 Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 1
- RHDYQUZYHZWTCI-UHFFFAOYSA-N COC1=CC=C(C2=CC=CC=C2)C=C1 Chemical compound COC1=CC=C(C2=CC=CC=C2)C=C1 RHDYQUZYHZWTCI-UHFFFAOYSA-N 0.000 description 1
- YRGAYAGBVIXNAQ-UHFFFAOYSA-N COC1=CC=C(Cl)C=C1 Chemical compound COC1=CC=C(Cl)C=C1 YRGAYAGBVIXNAQ-UHFFFAOYSA-N 0.000 description 1
- OHBQPCCCRFSCAX-UHFFFAOYSA-N COC1=CC=C(OC)C=C1 Chemical compound COC1=CC=C(OC)C=C1 OHBQPCCCRFSCAX-UHFFFAOYSA-N 0.000 description 1
- RDOXTESZEPMUJZ-UHFFFAOYSA-N COC1=CC=CC=C1 Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 1
- GMBFNZCPZFVKAT-UHFFFAOYSA-N COC1=CC=CC=C1CC(C)=O Chemical compound COC1=CC=CC=C1CC(C)=O GMBFNZCPZFVKAT-UHFFFAOYSA-N 0.000 description 1
- WCPNLLXEOITEPG-UHFFFAOYSA-N COCCN(C)CC1=CC=C(C)C=C1 Chemical compound COCCN(C)CC1=CC=C(C)C=C1 WCPNLLXEOITEPG-UHFFFAOYSA-N 0.000 description 1
- LNDYNJLEODYPLS-UHFFFAOYSA-N COO(=O)C1=CC=C(S(C)(=O)=O)S1 Chemical compound COO(=O)C1=CC=C(S(C)(=O)=O)S1 LNDYNJLEODYPLS-UHFFFAOYSA-N 0.000 description 1
- DRQGZMZPKOYPKW-UHFFFAOYSA-N CS(=O)(=O)C1=C(F)C=CC=C1 Chemical compound CS(=O)(=O)C1=C(F)C=CC=C1 DRQGZMZPKOYPKW-UHFFFAOYSA-N 0.000 description 1
- VAUDOALZTARJIW-UHFFFAOYSA-N CS(=O)(=O)C1=C([N+](=O)[O-])C=CC=C1 Chemical compound CS(=O)(=O)C1=C([N+](=O)[O-])C=CC=C1 VAUDOALZTARJIW-UHFFFAOYSA-N 0.000 description 1
- BWPZAUWSFKCBNG-UHFFFAOYSA-N CS(=O)(=O)C1=CC(Cl)=CC=C1 Chemical compound CS(=O)(=O)C1=CC(Cl)=CC=C1 BWPZAUWSFKCBNG-UHFFFAOYSA-N 0.000 description 1
- JTKXOVHBLURUOP-UHFFFAOYSA-N CS(=O)(=O)C1=CC(F)=CC=C1 Chemical compound CS(=O)(=O)C1=CC(F)=CC=C1 JTKXOVHBLURUOP-UHFFFAOYSA-N 0.000 description 1
- BNRKPIUZQHYIAL-UHFFFAOYSA-N CS(=O)(=O)C1=CC2=C(C=CC=C2)C=C1 Chemical compound CS(=O)(=O)C1=CC2=C(C=CC=C2)C=C1 BNRKPIUZQHYIAL-UHFFFAOYSA-N 0.000 description 1
- FJLFSYRGFJDJMQ-UHFFFAOYSA-N CS(=O)(=O)C1=CC=C(Br)C=C1 Chemical compound CS(=O)(=O)C1=CC=C(Br)C=C1 FJLFSYRGFJDJMQ-UHFFFAOYSA-N 0.000 description 1
- JKBCENKBTQPCCH-UHFFFAOYSA-N CS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 Chemical compound CS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 JKBCENKBTQPCCH-UHFFFAOYSA-N 0.000 description 1
- DNWUINQASFDJJS-UHFFFAOYSA-N CS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 Chemical compound CS(=O)(=O)C1=CC=C(Cl)C(Cl)=C1 DNWUINQASFDJJS-UHFFFAOYSA-N 0.000 description 1
- RJDVUMLFYFNKEW-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC2=C1C=CC=C2 Chemical compound CS(=O)(=O)C1=CC=CC2=C1C=CC=C2 RJDVUMLFYFNKEW-UHFFFAOYSA-N 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N CS(C)(=O)=O Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- SSKUUDUKJMIOKQ-UHFFFAOYSA-N CSC1=CC2=CC=CC=C2C=C1 Chemical compound CSC1=CC2=CC=CC=C2C=C1 SSKUUDUKJMIOKQ-UHFFFAOYSA-N 0.000 description 1
- RYMMPFNGZYBZRR-UHFFFAOYSA-N C[NH+](C1CCCCC1)[O-] Chemical compound C[NH+](C1CCCCC1)[O-] RYMMPFNGZYBZRR-UHFFFAOYSA-N 0.000 description 1
- KKZPDGTYKVSIMR-UHFFFAOYSA-N C[NH+]([O-])Oc1ccccc1 Chemical compound C[NH+]([O-])Oc1ccccc1 KKZPDGTYKVSIMR-UHFFFAOYSA-N 0.000 description 1
- QAJLUBIKEIVWEM-UHFFFAOYSA-N C[NH+](c(cc1)cc(N)c1N)[O-] Chemical compound C[NH+](c(cc1)cc(N)c1N)[O-] QAJLUBIKEIVWEM-UHFFFAOYSA-N 0.000 description 1
- GWIDQKWZSRPDQO-UHFFFAOYSA-N C[NH+](c1ccccc1)[O-] Chemical compound C[NH+](c1ccccc1)[O-] GWIDQKWZSRPDQO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000222716 Crithidia Species 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- PYLWMHQQBFSUBP-UHFFFAOYSA-N FC1=CC=CC=C1 Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000898449 Homo sapiens Cathepsin B Proteins 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- DNUSCNCBQLTUAG-VWLOTQADSA-N N#C[C@H](CCC1=CC=CC=C1)NC(=O)C1(NC(=O)C2=CC3=CC=CC=C3C=C2)CCCCC1 Chemical compound N#C[C@H](CCC1=CC=CC=C1)NC(=O)C1(NC(=O)C2=CC3=CC=CC=C3C=C2)CCCCC1 DNUSCNCBQLTUAG-VWLOTQADSA-N 0.000 description 1
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- IDGQXGPQOGUGIX-UHFFFAOYSA-N O-Benzyl-DL-serine Chemical compound OC(=O)C(N)COCC1=CC=CC=C1 IDGQXGPQOGUGIX-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N O=CC1=CC=NC=C1 Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- LCEDQNDDFOCWGG-UHFFFAOYSA-N O=CN1CCOCC1 Chemical compound O=CN1CCOCC1 LCEDQNDDFOCWGG-UHFFFAOYSA-N 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DLELKZFCVLJXKZ-GOTSBHOMSA-N Z-Arg-Arg-NHMec Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=2OC(=O)C=C(C=2C=C1)C)C(=O)OCC1=CC=CC=C1 DLELKZFCVLJXKZ-GOTSBHOMSA-N 0.000 description 1
- UEEIPXGUWPDGAO-UHFFFAOYSA-N [1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]carbamic acid Chemical compound CC(C)CC(NC(O)=O)C(=O)NCC#N UEEIPXGUWPDGAO-UHFFFAOYSA-N 0.000 description 1
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 1
- SZPWXAOBLNYOHY-UHFFFAOYSA-N [C]1=CC=NC2=CC=CC=C12 Chemical group [C]1=CC=NC2=CC=CC=C12 SZPWXAOBLNYOHY-UHFFFAOYSA-N 0.000 description 1
- IFFQDGRVZMVCGD-ZFWWWQNUSA-N [H]N(C(=O)OCC1=CC=CC=C1)[C@@H](CC(C)C)C(=O)N[C@@H](C)C#N Chemical compound [H]N(C(=O)OCC1=CC=CC=C1)[C@@H](CC(C)C)C(=O)N[C@@H](C)C#N IFFQDGRVZMVCGD-ZFWWWQNUSA-N 0.000 description 1
- JWEQTGOHXKZMTC-VIFPVBQESA-N [H]N(C(C)=O)[C@@H](CC(C)C)C(=O)NCC#N Chemical compound [H]N(C(C)=O)[C@@H](CC(C)C)C(=O)NCC#N JWEQTGOHXKZMTC-VIFPVBQESA-N 0.000 description 1
- WUEDEMMMSRUQMN-UHFFFAOYSA-N [H]N(CC#N)C(=O)C(CC(C)C)N([H])C(=O)CC Chemical compound [H]N(CC#N)C(=O)C(CC(C)C)N([H])C(=O)CC WUEDEMMMSRUQMN-UHFFFAOYSA-N 0.000 description 1
- TUQYIODQEMPRGA-UHFFFAOYSA-N [H]N(CCOC)CC1=CC=CC(C)=C1 Chemical compound [H]N(CCOC)CC1=CC=CC(C)=C1 TUQYIODQEMPRGA-UHFFFAOYSA-N 0.000 description 1
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N [H]N1C=C(C)C2=CC=CC=C21 Chemical compound [H]N1C=C(C)C2=CC=CC=C21 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N [H]N1C=CC2=C(C)C=CC=C21 Chemical compound [H]N1C=CC2=C(C)C=CC=C21 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- OEHBPLUJFVZASA-HNNXBMFYSA-N [H]N1C=CC2=CC(C(=O)N([H])[C@@H](CC(C)C)C(=O)N([H])CC#N)=CC=C21 Chemical compound [H]N1C=CC2=CC(C(=O)N([H])[C@@H](CC(C)C)C(=O)N([H])CC#N)=CC=C21 OEHBPLUJFVZASA-HNNXBMFYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VCOVUYXJMHMVNV-FMYROPPKSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 VCOVUYXJMHMVNV-FMYROPPKSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 108010085937 benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000006269 biphenyl-2-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C(*)C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-O diethylammonium Chemical compound CC[NH2+]CC HPNMFZURTQLUMO-UHFFFAOYSA-O 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000024693 gingival disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000053907 human CTSB Human genes 0.000 description 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000006301 indolyl methyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- MTPXRXOMKRLUMU-UHFFFAOYSA-N methyl 1-aminocyclohexane-1-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1(N)CCCCC1 MTPXRXOMKRLUMU-UHFFFAOYSA-N 0.000 description 1
- ORUCTBNNYKZMSK-UHFFFAOYSA-N methyl 1h-pyrazole-5-carboxylate Chemical compound COC(=O)C=1C=CNN=1 ORUCTBNNYKZMSK-UHFFFAOYSA-N 0.000 description 1
- WTRCBQUCEFNDML-LYNSQETBSA-N methyl 3-[(4s)-4,5-diamino-5-oxopentan-2-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C(C)C[C@H](N)C(N)=O)=C1 WTRCBQUCEFNDML-LYNSQETBSA-N 0.000 description 1
- FBLSCPLNSLOKKK-MERQFXBCSA-N methyl 3-[(4s)-4,5-diamino-5-oxopentyl]benzoate;hydrochloride Chemical compound [Cl-].COC(=O)C1=CC=CC(CCC[C@H]([NH3+])C(N)=O)=C1 FBLSCPLNSLOKKK-MERQFXBCSA-N 0.000 description 1
- WFHKGQHRXHBLTG-AWEZNQCLSA-N methyl 3-[(4s)-5-amino-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentyl]benzoate Chemical compound COC(=O)C1=CC=CC(CCC[C@H](NC(=O)OC(C)(C)C)C(N)=O)=C1 WFHKGQHRXHBLTG-AWEZNQCLSA-N 0.000 description 1
- KMFJVYMFCAIRAN-UHFFFAOYSA-N methyl 3-bromobenzoate Chemical compound COC(=O)C1=CC=CC(Br)=C1 KMFJVYMFCAIRAN-UHFFFAOYSA-N 0.000 description 1
- 229940120152 methyl 3-hydroxybenzoate Drugs 0.000 description 1
- QVDXUKJJGUSGLS-LURJTMIESA-N methyl L-leucinate Chemical compound COC(=O)[C@@H](N)CC(C)C QVDXUKJJGUSGLS-LURJTMIESA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- PHHUDJQYUVMKFT-UHFFFAOYSA-N n-[1-(2-cyanopropan-2-ylamino)-4-methyl-1-oxopentan-2-yl]naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)NC(CC(C)C)C(=O)NC(C)(C)C#N)=CC=C21 PHHUDJQYUVMKFT-UHFFFAOYSA-N 0.000 description 1
- SBZLZNWFSWCYLJ-UHFFFAOYSA-N n-[1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]-4-(2-pyrrolidin-1-ylethylsulfanyl)benzamide Chemical compound C1=CC(C(=O)NC(CC(C)C)C(=O)NCC#N)=CC=C1SCCN1CCCC1 SBZLZNWFSWCYLJ-UHFFFAOYSA-N 0.000 description 1
- HKWGCLYQSBYKKQ-UHFFFAOYSA-N n-[1-(cyanomethylamino)-4-methyl-1-oxopentan-2-yl]-5-nitroquinoline-2-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC2=NC(C(=O)NC(CC(C)C)C(=O)NCC#N)=CC=C21 HKWGCLYQSBYKKQ-UHFFFAOYSA-N 0.000 description 1
- UGSBLIXIVCTIAP-UHFFFAOYSA-N n-[1-[(1-cyano-3-methylbutyl)amino]-4-methyl-1-oxopentan-2-yl]-4-(imidazol-1-ylmethyl)benzamide Chemical compound C1=CC(C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C#N)=CC=C1CN1C=NC=C1 UGSBLIXIVCTIAP-UHFFFAOYSA-N 0.000 description 1
- GQDZIGLYDFSVFF-UHFFFAOYSA-N n-[1-[[1-cyano-2-(1h-indol-3-yl)ethyl]amino]-4-methyl-1-oxopentan-2-yl]naphthalene-2-carboxamide Chemical compound C1=CC=C2C(CC(NC(=O)C(NC(=O)C=3C=C4C=CC=CC4=CC=3)CC(C)C)C#N)=CNC2=C1 GQDZIGLYDFSVFF-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJGSXYOJTGTZAV-UHFFFAOYSA-N pinacolone Chemical compound CC(=O)C(C)(C)C PJGSXYOJTGTZAV-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 125000005400 pyridylcarbonyl group Chemical group N1=C(C=CC=C1)C(=O)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- DRDCQJADRSJFFD-UHFFFAOYSA-N tris-hydroxymethyl-methyl-ammonium Chemical class OC[N+](C)(CO)CO DRDCQJADRSJFFD-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
- C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
- C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D333/40—Thiophene-2-carboxylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06043—Leu-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Definitions
- This invention relates to inhibitors of cysteine proteases, in particular to dipeptide nitrile cathepsin inhibitors and to their pharmaceutical use for the treatment or prophylaxis of diseases or medical conditions in which cathepsins are implicated.
- the cysteine cathepsins are a class of lysosomal enzymes which are implicated in various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization), autoimmune diseases, respiratory diseases, infectious diseases and immununologically mediated diseases (including transplant rejection).
- dipeptide nitrites are particularly useful as cysteine cathepsin inhibitors and can be used for the treatment of the above-cited cysteine cathepsin dependent conditions.
- the present invention provides an N-terminal-substituted dipeptide nitrile, i.e. a dipeptide in which the C-terminal carboxy group of the dipeptide is replaced by a nitrile group (—C ⁇ N) and in which the N-terminal nitrogen atom is substituted via a peptide or pseudopeptide linkage which optionally additionally comprises a —methylene-hetero atom—linker or an additional hetero atom, directly by aryl, lower alkyl, lower alkenyl, lower alkynyl or heterocyclyl, or a physiologically-acceptable and -cleavable ester or a salt thereof, for use as a pharmaceutical.
- a peptide or pseudopeptide linkage which optionally additionally comprises a —methylene-hetero atom—linker or an additional hetero atom, directly by aryl, lower alkyl, lower alkenyl, lower alkynyl or heterocyclyl, or a physiologically-acceptable and
- the invention further provides a pharmaceutical composition comprising an N-terminal-substituted dipeptide nitrile as defined above as an active ingredient.
- the invention also provides a method of treating a patient suffering from or susceptible to a disease or medical condition in which a cathepsin is implicated, comprising administering an effective amount of an N-terminal-substituted dipeptide nitrile as defined above to the patient.
- the invention further includes the use of an N-terminal-substituted dipeptide nitrile as defined above for the preparation of a medicament for therapeutic or prophylactic treatment of a disease or medical condition in which a cathepsin is implicated.
- the dipeptide nitrile of the invention conveniently comprises ⁇ -amino acid residues, including both natural and unnatural ⁇ -amino acid residues.
- naturally ⁇ -amino acid residues denote the 20 amino acids obtainable by translation of RNA according to the genetic code or the corresponding nitrites thereof, as appropriate.
- “Unnatural ⁇ -amino acid residues” are ⁇ -amino acids which have ⁇ -substituents other than those found in “natural ⁇ -amino acid residues.
- Preferred a-amino acid residues are the nitrites of tryptophan, 2-benzyloxymethyl-2-amino-acetic acid, 2,2-dimethyl-2-amino-acetic acid, 2-butyl-2-amino-acetic acid, methionine, leucine, lysine, alanine, phenylalanine, and glycine and derivatives thereof, e.g. as hereinafter described.
- Preferred amino acid residues as the N-terminal amino acid residue of the dipeptide nitrile are 1-amino-cyclohexanecarboxylic acid, 1-amino-cycloheptanecarboxylic acid, phenylalanine, histidine, tryptophan and leucine and derivatives thereof, e.g. as hereinafter described.
- the aryl, lower alkyl, lower alkenyl, lower alkynyl or heterocyclyl substituent (hereinafter referred to as R) is attached to the N-terminal nitrogen atom of the dipeptide via a peptide linkage, i.e. as R—C(O)—NH—, or via a pseudopeptide linkage.
- Suitable pseudopeptide linkages include sulphur in place of oxygen and sulphur and phosphorous in place of carbon, e.g. as R—C(S)—NH—, R—S(O)—NH—, R—S(O) 2 NH— or R—P(O) 2 —NH and analogues thereof.
- the peptide or pseudopeptide linkage between the R substituent and the N-terminal nitrogen atom may comprise an additional hetero atom, e.g. as R-Het-C(O)—NH—, or a —methylene-hetero atom—linker, e.g. as R-Het-CH 2 —C(O)—NH— or R—CH 2 -Het-C(O)—NH—, wherein Het is a hetero atom selected from O, N or S, and pseudopeptide containing alternatives thereof, e.g. as defined above.
- the linkage between the aryl substituent and the N-terminal nitrogen atom comprises a —methylene-hetero atom—linker
- the methylene group and the hetero atom may be optionally further substituted, e.g. as hereinafter described.
- the R substituent may be further substituted, e.g. by up to 3 substituents selected from halogen, hydroxy, amino, nitro, optionally substituted C 1-4 alkyl (e.g. alkyl substituted by hydroxy, alkyloxy, amino, optionally substituted alkylamino, optionally substituted dialkylamino, aryl or heterocyclyl), C 1-4 alkoxy, C 2-6 alkenyl, CN, trifluoromethyl, trifluoromethoxy, aryl, (e.g. phenyl or phenyl substituted by CN, CF 3 , halogen, OCH 3 ), aryloxy, (e.g. phenoxy or phenoxy substituted by CN, CF 3 , halogen, OCH 3 ), benzyloxy or a heterocyclic residue.
- substituents selected from halogen, hydroxy, amino, nitro, optionally substituted C 1-4 alkyl (e.g. alkyl substituted
- the invention provides a compound of formula I, or a physiologically-acceptable and -cleavable ester or a salt thereof
- R is optionally substituted (aryl, lower alkyl, lower alkenyl, lower alkynyl, or heterocyclyl);
- R 2 and R 3 are independently hydrogen, or optionally substituted [lower alkyl, cycloalkyl; bicycloalkyl, or (aryl, biaryl, cycloalkyl or bicycloalkyl)-lower alkyl]; or
- R 2 and R 3 together represent lower alkylene, optionally interrupted by O, S or NR 6 , so as to form a ring with the carbon atom to which they are attached
- R 6 is hydrogen, lower alkyl or aryl-lower alkyl
- R 2 or R 3 are linked by lower alkylene to the adjacent nitrogen to form a ring;
- R 4 and R 5 are independently H, or optionally substituted (lower alkyl, aryl-lower alkyl), —C(O)OR 7 , or —C(O)NR 7 R 8 ,
- R 7 is optionally substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl or heterocyclyl), and
- R 8 is H, or optionally substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl or heterocyclyl), or
- R 4 and R 5 together represent lower alkylene, optionally interrupted by O, S or NR 6 , so as to form a ring with the carbon atom to which they are attached
- R 6 is hydrogen, lower alkyl or aryl-lower alkyl, or
- R 4 is H or optionally substituted lower alkyl and R 5 is a substituent of formula —X 2 —(Y 1 ) n —(Ar) p -Q-Z
- Y 1 is O, S, SO, SO 2 , N(R 6 )SO 2 , N—R 6 , SO 2 NR 6 , CONR 6 or NR 6 CO;
- n zero or one
- p is zero or one
- X 2 is lower alkylene; or when n is zero, X 2 is also C 2 -C 7 -alkylene interrupted by O, S, SO, SO 2 , NR 6 , SO 2 NR 6 , CONR 6 or NR 6 CO;
- Ar is arylene
- Z is hydroxy, acyloxy, carboxyl, esterified carboxyl, amidated carboxyl, aminosulfonyl, (lower alkyl or aryl-lower alkyl)aminosulfonyl, or (lower alkyl or aryl-lower alkyl)sulfonylaminocarbonyl; or Z is tetrazolyl, triazolyl or imidazolyl;
- Q is a direct bond, lower alkylene, Y 1 -lower alkylene or C 2 -C 7 -alkylene interrupted by Y 1 ;
- X 1 is —C(O)—, —C(S)—, —S(O)—, —S(O) 2 —, —P(O)(OR 6 )—
- R 6 is as defined above;
- Y is oxygen or sulphur
- L is optionally substituted -Het-, -Het-CH 2 — or —CH 2 -Het-,
- Het is a hetero atom selected from O, N or S, and
- x is zero or one
- aryl in the above definitions represents carbocyclic or heterocyclic aryl
- composition comprising a compound of formula I as defined above as an active ingredient
- a method of treating a patient suffering from or susceptible to a disease or medical condition in which a cathepsin is implicated comprising administering an effective amount of a compound of formula I as defined above to the patient;
- the invention also provides novel dipeptide nitriles.
- the invention further provides a compound of formula I as defined above provided that when R is lower alkyl not substituted by aryl,
- R 4 or R 5 is a substituent of formula —X 2 —(Y 1 ) n —(Ar) p -Q-Z,
- L is —O—, or —CH 2 —O— and X 1 is —C(O)—,
- R 4 or R 5 is a substituent of formula —X 2 —(Y 1 ) n —(Ar) p -Q-Z, or R is not unsubstituted phenyl,
- R 3 is not H, —CH 3 , —CH(CH 3 ) 2 , —CH 2 —CH—(CH 3 ) 2 , —CH 2 —COOH, or —CH 2 —COO—CH 2 —CH 3 , when R is unsubstituted phenyl,
- R 3 is not H, —CH(CH 3 ) 2 , or —CH 2 —CH—(CH 3 ) 2 , when R is 4-aminophenyl or 4-nitrophenyl,
- R 3 is not H when R is 3-aminophenyl, 3-nitrophenyl 2-chloropyridin-4-yl, or vinyl or
- R 3 is not —CH 2 —CH 2 —S—CH 3 when R is pyridin-3-yl or 2-chloropyridin-4-yl,
- R 5 is not —CH(CH 3 ) 2 ,
- R 3 ⁇ R 4 ⁇ H R 5 is —CH 2 —CH 2 —COOH, x is zero and X 1 is —C(O)—,
- R 2 does not form a heterocyclic ring with the adjacent nitrogen atom, and provided that when R 2 ⁇ R 3 ⁇ R 4 ⁇ R 5 ⁇ H, x is zero and X 1 is —SO 2 —,
- R is not 4-methylphenyl.
- R, R 2 , R 3 , R 4 , R 5 and L may be further substituted by one or more, e.g. up to 3, substituents independently selected from lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, heterocyclyl, —CN, -halogen, —OH, —NO 2 , —NR 9 R 10 , —X 3 —R 7 , lower alkyl-X 3 —R 8 , halo-substituted lower alkyl,
- R 7 and R 8 are as defined above,
- the invention provides a compound of formula II, or a physiologically-acceptable and -cleavable ester or a salt thereof
- R 20 is optionally substituted (aryl, aryl-lower alkyl, lower alkenyl, lower alkynyl, heterocyclyl, or heterocyclyl-lower alkyl);
- R 22 is H, or optionally substituted lower alkyl
- R 23 is optionally substituted (lower alkyl, aryl-lower alkyl, or cyloalkyl-lower alkyl) or
- R 22 and R 23 together with the carbon atom to which they are attached form an optionally substituted (cycloalkyl group or heterocycloalkyl group);
- R 24 and R 25 are independently H, or optionally substituted (lower alkyl, or aryl-lower alkyl), —C(O)OR 7 , or —C(O)NR 7 R 8
- R 7 and R 8 are as defined above, or
- R 24 and R 25 together with the carbon atom to which they are attached form an optionally substituted (cycloalkyl group or heterocycloalkyl group);
- X 1 is as defined above;
- Y is oxygen or sulphur
- L′ is optionally substituted (-Het-CH 2 — or —CH 2 -Het-),
- x 1 or 0,
- L is —CH 2 —O— and X 1 is —C(O)—
- R 23 is not H, —CH 3 , —CH(CH 3 ) 2 , —CH 2 —CH—(CH 3 ) 2 , —CH 2 —COOH, or —CH 2 —COO—CH 2 —CH 3 , when R 20 is unsubstituted phenyl,
- R 23 is not —CH 2 —CH 2 —S—CH 3 when R 20 is pyridin-3-yl or 2-chloropyridin-4-yl,
- R 25 is not —CH(CH 3 ) 2 ,
- R 23 ⁇ R 24 ⁇ H R 25 is —CH 2 —CH 2 —COOH, x is zero and X 1 is —C(O)—,
- R 22 does not form a heterocyclic ring with the adjacent nitrogen atom
- R 20 is not 4-methylphenyl.
- R 22 is hydrogen
- R 24 and R 25 are:
- R 24 and R 25 are both H or —CH 3 , or
- R 24 is H and R 25 is optionally substituted (—CH 2 -phenyl, —CH 2 -indolyl, —(CH 2 ) 2 —S—CH 3 , —CH 2 —CH(CH 3 ) 2 , —(CH 2 ) 4 —NH 2 or —(CH 2 ) 3 -CH 3 ), or yet more preferably R 4 and R 5 are both —CH 3 , or especially R 4 and R 5 are both H.
- Y is ⁇ O.
- x is 0, or when x is 1 L′ is —CH 2 —O—, —NH—CH 2 —, —O—CH 2 — or —S—CH 2 .
- the invention provides a compound of formula II′ or a physiologically-acceptable and -cleavable ester or a salt thereof
- R 20 ′ is optionally substituted (C 6 -C 18 aryl or C 4 -C 18 heteroaryl);
- R 24 ′ and R 25 ′ are independently H, or optionally substituted (C 1 -C 8 alkyl, C 7 -C 14 aralkyl, or C 5 -C 14 heteroaralkyl), —C(O)OR 6 ′, or —C(O)NR 6 ′R 7 ′,
- R 6 ′ is optionally substituted (C 1 -C 8 alkyl, C 7 -C 14 aralkyl, C 3 -C 8 cycloalkyl, C 4 -C 7 heterocycloalkyl, C 5 -C 14 heteroaralkyl, C 6 -C 14 aryl, or C 4 -C 14 heteroaryl), and
- R 24 ′ and R 25 ′ together with the carbon atom to which they are attached form an optionally substituted (C 3 -C 8 cycloalkyl group or C 4 -C 7 heterocycloalkyl group);
- X is —C(O)—, —C(S)—, —S(O)—, —S(O) 2 —, —P(O)(OR 6 ′)—
- Y is oxygen or sulphur
- L′ is optionally substituted (-Het-CH 2 — or —CH 2 -Het-),
- x 1 or 0,
- L′ is —CH 2 —O— and X, is —C(O)—
- R 20 ,′ is not unsubstituted phenyl
- R 23 ′ is not H, —CH 3 , —CH(CH 3 ) 2 , —CH 2 —CH—(CH 3 ) 2 , —CH 2 —COOH, or —CH 2 —COO—CH 2 —CH 3 , when R 20 ′ is unsubstituted phenyl,
- R 23 ′ is not H, —CH(CH 3 ) 2 , or —CH 2 —CH—(CH 3 ) 2 , when R 20 ′ is 4-aminophenyl or 4-nitrophenyl,
- R 23 ′ is not H when R 20 ′ is 3-aminophenyl, 3-nitrophenyl, 2-chloropyridin-4-yl, or vinyl, or
- R 23 ′ is not —CH 2 —CH 2 —S—CH 3 when R 20 ′ is pyridin-3-yl or 2-chloropyridin-4-yl, provided that when R 22 ′ ⁇ R 23 ′ ⁇ R 24 ′ ⁇ H, x is zero and X 1 is —C(O)— and R 20 ′ is phenyl,
- R 25 ′ is not —CH(CH 3 ) 2 ,
- R 23 ′ ⁇ R 24 ′ ⁇ H R 25 ′ is —CH 2 —CH 2 COOH, x is zero and X 1 is —C(O)—,
- R 20 ′ does not form a heterocyclic ring with the adjacent nitrogen atom, and provided that when R 22 ′ ⁇ R 23 ′ ⁇ R 24 ′ ⁇ R 25 ′ H, x is zero and X 1 is —SO 2 —,
- R 20 ′ is not 4-methylphenyl.
- Compounds of formula II′ are typically selective inhibitors of cathepsin K.
- R 30 is an acyl group derived from an organic carboxylic, carbonic, carbamic or sulfonic acid
- R 32 and R 33 are independently hydrogen, lower alkyl, cycloalkyl, bicycloalkyl, or (aryl, biaryl, cycloalkyl or bicycloalkyl)-lower alkyl; or R 32 and R 33 together represent lower alkylene so as to form a ring together with the carbon to which they are attached;
- R 34 is hydrogen or lower alkyl
- X 2 , Y 1 , Ar, Q, Z, n and p are as previously defined;
- the invention further provides a compound of formula III as defined above, wherein R 30 is an acyl group derived from an organic carboxylic, carbamic or sulfonic acid
- Compounds of formula III are typically selective inhibitors of cathepsin B and/or L.
- Y 1 is O, S, SO, SO 2 , N(R 6 )SO 2 or N—R 6 ;
- R 6 is as defined above and pharmaceutically acceptable salts thereof.
- Preferred compounds of formula III are those in which Z is carboxyl or carboxyl derivatized as a pharmaceutically acceptable ester.
- a particular embodiment of the invention relates to the compounds of formula III wherein n is zero, in particular those of formula III′
- R 30 , X 2 , Ar, Q, and p are as defined above; and wherein
- R 33 ′ is carbocyclic or heterocyclic aryl-lower alkyl
- Z′ is bydroxy, acyloxy, carboxyl, carboxyl derivatized as a pharmaceutically acceptable ester or amide, or 5-tetrazolyl;
- R 30 is carboxylic acid derived acyl
- R 33 ′ is carbocyclic or heterocyclic aryl-lower alkyl
- X 2 is C 1 -C 5 -alkylene, or X 2 is C 2 -C 4 -alkylene interrupted by O or S
- p is one
- Ar is carbocyclic arylene
- Q is a direct bond or C 1 -C 4 -alkylene
- Z is carboxyl or carboxyl derivatized as a pharmaceutically acceptable ester; and pharmaceutically acceptable salts thereof.
- R 30 is aroyl, R 33 ′ is carbocyclic aryl-methyl; X 2 is C 3 -alkylene; or X 2 is C 2 -alkylene interrupted by O; p is one; Ar is phenylene; Q is a direct bond; and Z is carboxyl; and pharmaceutically acceptable salts thereof.
- a further particular embodiment of the invention relates to the compounds of formula III wherein n is one, in particular those of formula III′′
- R 30 , R 33 ′, Y 1 , Ar, and Z′ are as defined above;
- X 2 ′ is lower alkylene
- Q′ is a direct bond or lower alkylene; and pharmaceutically acceptable salts thereof.
- a specific embodiment of the invention is directed to the compounds of formula III′′ wherein R 30 is carboxylic acid derived acyl; R 33 ′ is carbocyclic or heterocyclic aryl-lower alkyl; X 2 ′ is C 1 -C 4 -alkylene; Y 1 is O or S; Ar is carbocyclic arylene; Q′ is a direct bond or C 1 -C 4 -alkylene; and Z′ is carboxyl or carboxyl derivatized as a pharmaceutically acceptable ester; and pharmaceutically acceptable salts thereof.
- a more specific embodiment of the invention is directed to said compounds of formula III′′ wherein R 30 is aroyl, R 33 ′ is carbocyclic aryl-methyl; X 2 ′ is C 2 -alkylene; Y, is O; Ar is phenylene; Q′ is a direct bond; and Z′ is carboxyl, and pharmaceutically acceptable salts thereof.
- a yet further aspect of the invention is directed to a compound of formula IV
- R 40 is substituted phenyl or heterocyclic aryl, (mono- or di-carbocyclic or heterocyclic aryl)-lower alkyl or lower alkenyl, or heterocyclyl;
- R 42 is hydrogen or lower alkyl
- R 43 is carbocyclic or heterocyclic aryl-lower alkyl
- R 44 and R 45 are independently hydrogen or lower alkyl
- R 44 and R 45 combined represent lower alkylene
- R 40 is morpholino, substituted phenyl or heterocyclic aryl;
- R 42 is hydrogen;
- R 43 is carbocyclic or heterocyclic aryl-lower alkyl;
- R 44 and R 45 are hydrogen or lower alkyl; or
- R 44 and R 45 combined represent ethylene to form a cyclopropyl ring.
- R 40 is pyrazolyl or pyrazolyl substituted by 1-3 lower alkyl
- R 42 is hydrogen
- R 43 is carbocyclic or heterocyclic aryl-C 1 -C 4 -alkyl
- R 44 and R 45 are hydrogen
- R 44 and R 45 combined are ethylene.
- Compounds of formula IV are typically selective inhibitors of cathepsin L and/or S.
- the compounds of formulae I, II, III and IV depending on the nature of substituents, possess one or more asymmetric carbon atoms.
- the resulting diastereomers and enantiomers are encompassed by the instant invention.
- the compounds of formulae I, II, III and IV are provided in pure or substantially pure epimeric form, e.g. as compositions in which the compounds are present in a form comprising at least 90%, e.g. preferably at least 95% of a single epimer (i.e. comprising less than 10%, e.g. preferably less than 5% of other epimeric forms).
- Preferred compounds of formula I are those wherein the asymmetric carbon to which are attached R 2 and/or R 3 corresponds to that of an L-amino acid precursor and the asymmetric carbon to which is attached the cyano group also corresponds to that of an L-amino acid and is generally assigned the (S)-configuration.
- Preferred compounds of formula I wherein R 3 and R 4 represent hydrogen can be represented by formulae V, V′ and V′′, corresponding to preferred compounds of formulae II, III and IV respectively
- the invention provides a compound of formula V, V′ or V′′
- lower referred to above and hereinafter in connection with organic radicals or compounds respectively defines such as branched or unbranched with up to and including 7, preferably up to and including 4 and advantageously one or two carbon atoms.
- a lower alkyl group is branched or unbranched and contains 1 to 7 carbon atoms, preferably 1-4 carbon atoms.
- Lower alkyl represents for example methyl, ethyl, propyl, butyl, isopropyl or isobutyl.
- Lower alkenyl represents either straight chain or branched alkenyl of 2 to 7 carbon atoms, preferably 2-4 carbon atoms, e.g. as vinyl, propenyl, isopropenyl, butenyl, isobutenyl or butadienyl.
- Lower alkynyl represents either straight chain or branched alkynyl of 2 to 7 carbon atoms, preferably 2-4 carbon atoms, e.g. as acetylenyl, propenyl, isopropynyl, butynyl or isobutynyl.
- Lower alkyl, lower alkenyl and lower alkynyl may be substituted by up to 3 substituents selected from lower alkoxy, aryl, hydroxy, halogen, cyano, or trifluoromethyl.
- Lower alkylene represents either straight chain or branched alkylene of 1 to 7 carbon atoms and represents preferably straight chain alkylene of 1 to 4 carbon atoms, e.g. a methylene, ethylene, propylene or butylene chain, or said methylene, ethylene, propylene or butylene chain mono-substituted by C 1 -C 3 -alkyl, (advantageously methyl) or disubstituted on the same or different carbon atoms by C 1 -C 3 -alkyl (advantageously methyl), the total number of carbon atoms being up to and including 7.
- a lower alkoxy (or alkyloxy) group preferably contains 1-4 carbon atoms, advantageously 1-3 carbon atoms, and represents for example ethoxy, propoxy, isopropoxy, or most advantageously methoxy.
- Halogen preferably represents chloro or fluoro but may also be bromo or iodo.
- An acyl group as represented by R 30 is preferably derived from an organic carbonic acid, an organic carboxylic acid, a carbamic acid or an organic sulfonic acid.
- Acyl which is derived from a carboxylic acid represents, for example, carbocyclic or heterocyclic aroyl, cycloalkylcarbonyl, (oxa or thia)-cycloalkylcarbonyl, lower alkanoyl, (lower alkoxy, hydroxy or acyloxy)-lower alkanoyl, (mono- or di-carbocyclic or heterocyclic)-(lower alkanoyl or lower alkoxy-, hydroxy- or acyloxy-substituted lower alkanoyl), or biaroyl.
- Carbocyclic aroyl represents, for instance, benzoyl, benzoyl substituted, by one to three substituents selected independently from e.g. halo, trifluoromethyl, lower alkyl, lower alkoxy, hydroxy, methylenedioxy, nitro, di-lower alkylamino, cyano, or carbocyclic aroyl represents e.g. 1- or 2-naphthoyl.
- Heterocyclic aroyl represents, for instance, 2-, 3- or 4-pyridylcarbonyl (such as nicotinoyl), furoyl, thienoyl, oxazoloyl, isoxazoloyl, quinoxaloyl, each optionally substituted by e.g. halo, lower alkyl, lower alkoxy or nitro.
- (Oxa- or thia)-cyclolalkylcarbonyl is, for example, tetrahydrofuranoyl or tetrahydrothienoyl.
- Di-(carbocyclic or heterocyclic)aryl-lower alkanoyl is, for example, diphenylacetyl or dipyridylacetyl.
- Aryl-(lower alkoxy, hydroxy or acyloxy substituted) lower alkanoyl is, for example, phenyl-(2-alkoxy, hydroxy or acyloxy)-acetyl.
- Biaroyl is, for example, 2, 3 or 4-biphenylcarbonyl.
- Acyl which is derived from an organic carbonic acid is, for example, alkoxycarbonyl, especially lower alkoxycarbonyl, which is unsubstituted or substituted by carbocyclic or heterocyclic aryl or is cycloalkoxycarbonyl, especially C 3 -C 7 -cycloalkyloxycarbonyl, which is unsubstituted or substituted by lower alkyl.
- Acyl which is derived from a carbamic acid is, for example, aminocarbonyl which is optionally substituted on nitrogen by one or two of lower alkyl, carbocyclic or heterocyclic aryl-lower alkyl, carbocyclic or heterocyclic aryl, or by lower alkylene or lower alkylene interrupted by O or S.
- Acyl which is derived from an organic sulfonic acid represents, for example, lower alkylsulfonyl, carbocyclic or heterocyclic arylsulfonyl, carbocyclic or heterocyclic aryl-lower alkysulfonyl, in which aryl is e.g. phenyl, naphthyl or thienyl, such being optionally substituted by, for example, lower alkyl, lower alkoxy, halo, nitro, trifluoromethyl, carboxyl or lower alkoxycarbonyl.
- Aryl represents carbocyclic or heterocyclic aryl.
- Oxy-C 2 -C 3 -alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, e.g. oxyethylene or oxypropylene.
- phenyl e.g. oxyethylene or oxypropylene.
- An example for oxy-C 2 -C 3 -alkylene-phenyl is 2,3-dihydrobenzofuran-5-yl.
- carbocyclic aryl is naphthyl, phenyl or phenyl mono- or disubstituted by lower alkoxy, phenyl, halogen, lower alkyl or trifluoromethyl, especially phenyl or phenyl mono- or disubstituted by lower alkoxy, halogen or trifluoromethyl, and in particular phenyl.
- substituted phenyl groups as R are, e.g. 4-chlorophen-1-yl, 3,4-dichlorophen-1yl, 4-methoxyphen-1-yl, 4-methylphen-1-yl, 4-aminomethylphen-1-yl, 4-methoxyethylaminomethylphen-1-yl, 4-hydroxyethylaminomethylphen-1-yl, 4-hydroxyethyl (methyl)-aminomethylphen-1-yl, 3-aminomethylphen-1-yl, 4-N-acetylaminomethylphen-1-yl, 4-aminophen-1-yl, 3-aminophen-1-yl, 2-aminophen-1-yl, 4-phenyl-phen-1-yl, 4-(imidazol-1-yl)-phen-I-yl, 4-(imidazol-1-ylmethyl)-phen-1-yl, 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-ylmethyl)-phen-1
- Heterocyclic aryl represents monocyclic or bicyclic heteroaryl, for example pyridyl, indolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, benzopyranyl, benzothiopyranyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any said radical substituted, especially mono- or di-substituted, by e.g. lower alkyl, nitro or halogen.
- Pyridyl represents 2-, 3- or 4-pyridyl, advantageously 2- or 3-pyridyl.
- Thienyl represents 2- or 3-thienyl.
- Quinolinyl represents preferably 2-, 3- or 4-quinolinyl.
- Isoquinolinyl represents preferably 1-, 3- or 4-isoquinolinyl.
- Benzopyranyl, benzothiopyranyl represent preferably 3-benzopyranyl or 3-benzothiopyranyl, respectively.
- Thiazolyl represents preferably 2- or 4-thiazolyl, advantageously 4-thiazolyl.
- Triazolyl is preferably 1-, 2- or 5-(1,2,4-triazolyl).
- Tetrazolyl is preferably 5-tetrazolyl.
- heterocyclic aryl is pyridyl, indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any said radical substituted, especially mono-or di-substituted, by lower alkyl or halogen; and in particular pyridyl.
- Arylene (Ar in formula III) is an aryl linking group in which aryl is heterocyclic or carbocyclic aryl, preferably monocyclic as defined above.
- a heterocyclic aryl linking group is for instance (but not limited thereto) 1,3-pyrazolyl, 2,4-or 2,5-pyridyl or 1,4-imidazolyl in which the groups as depicted in formula III are attached to the ring at the indicated positions.
- a carbocyclic aryl linking group is for instance (but not limited thereto) optionally substituted phenyl in which the two groups as depicted in formula I are attached ortho, meta or para to each other.
- Biaryl may be carbocyclic biaryl, preferably e.g. biphenyl, namely 2, 3 or 4-biphenyl, advantageously 4-biphenyl, each optionally substituted by e.g. lower alkyl, lower alkoxy, halogen, trifluoromethyl or cyano, or heterocyclic-carbocyclic biaryl, preferably e.g. thienylphenyl, pyrrolylphenyl and pyrazolylphenyl.
- Cycloalkyl represents a saturated cyclic hydrocarbon optionally substituted by lower alkyl which contains 3 to 10 ring carbons and is advantageously cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl optionally substituted by lower alkyl.
- Bicycloalkyl is for example norbornanyl.
- Heterocyclyl represents a saturated cyclic hydrocarbon containing one or more, preferably 1 or 2, hetero atoms selected from O, N or S, and from 3 to 10, preferably 5 to 8, ring atoms; for example, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholino.
- Aryl-lower alkyl represents preferably (carbocyclic aryl or heterocylic aryl)-lower alkyl.
- Carbocyclic aryl-lower alkyl represents preferably straight chain or branched aryl-C 1-4 -alkyl in which carbocyclic aryl has meaning as defined above, e.g. benzyl or phenyl-(ethyl, propyl of butyl), each unsubstituted or substituted on phenyl ring as defined under carbocyclic aryl above, advantageously optionally substituted benzyl, e.g. benzyl substituted or phenyl lay lower alkyl.
- Heterocyclic aryl-lower alkyl represents preferably straight chain or branched heterocyclic aryl-C 1-4 -alkyl in which heterocyclic aryl has meaning as defined above, e.g. 2-, 3- or 4-pyridylmethyl or (2, 3- or 4-pyridyl)-(ethyl, propyl or butyl); or 2- or 3-thienylmethyl or (2- or 3-thienyl)-(ethyl, propyl or butyl); 2-, 3- or 4-quinolinylmethyl or (2-, 3- or 4-quinolinyl)-(ethyl, propyl or butyl); or 2- or 4-thiazolylmethyl or (2- or 4-thiazolyl)-(ethyl, propyl or butyl).
- Cycloalkyl-lower alkyl represents e.g. (cyclopentyl- or cyclohexyl)-(methyl or ethyl).
- Biaryl-lower alkyl represents e.g. 4-biphenylyl-(methyl or ethyl).
- Acyl as in acyloxy is derived from an organic carboxylic acid, carbonic acid or carbamic acid.
- Acyl represents e.g. lower alkanoyl, carbocyclic aryl-lower alkanoyl, lower alkoxycarbonyl, aroyl, di-lower alkylaminocarbonyl or di-lower alkylamino-lower alkanoyl.
- acyl is lower alkanoyl.
- Lower alkanoyl represents e.g. C 1-7 -alkanoyl including formyl, and is preferably C 2-4 -alkanoyl such as acetyl or propionyl.
- Aroyl represents e.g. benzoyl or benzoyl mono- or di-substituted by one or two radicals selected from lower alkyl, lower alkoxy, halogen, cyano and trifluoromethyl; or 1- or 2-naphthoyl; and also e.g. pyridylcarbonyl.
- Lower alkoxycarbonyl represents preferably C 1-4 -alkoxycarbonyl, e.g. ethoxycarbonyl.
- Esterified carboxyl is carboxyl derivatized as a pharmaceutically acceptable ester, for example lower alkoxycarbonyl, benzyloxycarbonyl or allyloxycarbonyl.
- Amidated carboxyl is carboxyl derivatized as a pharmaceutically acceptable amide, for example aminocarbonyl, mono- or di-lower alkylaminocarbonyl.
- salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethyl ammonium, and tris-(hydroxymethyl)-methyl-ammonium salts.
- bases namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethyl ammonium, and tris-(hydroxymethyl)-methyl-ammonium salts.
- cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium
- ammonium salts such as ammonium, trimethyl-ammonium, diethyl ammonium, and tris-(hydroxymethyl)-methyl-ammonium
- the compounds of the invention exhibit valuable pharmacological properties in mammals and are particularly useful as cysteine cathepsin inhibitors.
- the cathepsin inhibitory effects of the compound of the invention can be determined in vitro by measuring the inhibition of e.g. recombinant human cathepsins B, K, L and S.
- the buffer used in the cathepsin B, L and S assays is a 0.1 M pH 5.8 phosphate buffer containing EDTA (1.33 mM), DTT (2.7 mM) and Brij (0.03%).
- the in vitro assays are carried out as follows:
- Compounds of the Invention are particularly useful in mammals as agents for treatment and prophylaxis of diseases and medical conditions involving elevated levels of cathepsins.
- diseases include diseases involving infection by organisms such as pneumocystis carinii, trypsanoma cruzi; trypsanoma brucei, crithidia fusiculata, as well as parasitic diseases such as schistosomiasis-and malaria, tumours (tumour invasion and tumour metastasis), and other diseases such as metachromatic leukodystrophy, muscular dystrophy, amytrophy and similar diseases.
- Cathepsins in particular K
- Cathepsins have been implicated in diseases of excessive bone loss
- the Compounds of the Invention may be used for treatment and prophylaxis of such diseases, including osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget's disease, hypercalcemia of malignancy, e.g. tumour-induced hypercalcemia and metabolic bone disease.
- the Compounds of the Invention may be use for treatment or prophylaxis of diseases of excessive cartilage or matrix degradation, including osteoarthritis and rheumatoid arthritis as well as certain neoplastic diseases involving expression of high levels of proteolytic enzymes and matrix degradation.
- Compounds of the Invention are also indicated for preventing or treating coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization), autoimmune diseases, respiratory diseases and immunologically mediated diseases (including transplant rejection).
- Compounds of the Invention are particularly indicated for preventing or treating osteoporosis of various genesis (e.g. juvenile, menopausal, post-menopausal, post-traumatic, caused by old age or by cortico-steroid therapy or inactivity).
- various genesis e.g. juvenile, menopausal, post-menopausal, post-traumatic, caused by old age or by cortico-steroid therapy or inactivity.
- compositions e.g. preferably aqueous solutions or suspensions, and in vivo either enterally or parenterally, advantageously orally, e.g. as a suspension or in aqueous solution, or as a solid capsule formulation.
- the dosage in vitro may range between about 10 ⁇ 5 molar and 10 ⁇ 9 molar concentrations.
- the dosage in vivo may range, depending on the route of administration, between about 0.1 and 100 mg/kg.
- the antiarthritic efficacy of the compounds of the invention for the treatment of rheumatoid arthritis can be determined using models such as or similar to the rat model of adjuvant arthritis, as described previously (R. E. Esser, et. al. J. Rheumatology, 1993, 20, 1176.)
- the efficacy of the compounds of the invention for the treatment of osteoarthritis can be determined using models such as or similar to the rabbit partial lateral meniscectomy model, as described previously (Colombo et al. Arth. Rheum. 1993 26, 875-886).
- the efficacy of the compounds in the model can be quantified using histological scoring methods, as described previously (O'Byrne et al. Inflamm Res 1995, 44, S117-S118).
- the efficacy of the compounds of the invention for the treatment of osteoporosis can be determined using an animal model such as the ovarectomised rat or other similar species in which test compounds are administered to the animal and the presence of markers of bone resorption are measured in urine or serum.
- the compounds of the invention are prepared by:
- R, R 2 , R 3 , R 4 and R 5 have meaning as previously defined for the compounds of formula I to a nitrile of formula I;
- R, R 2 and R 3 have meaning as defined above; or with a reactive derivative thereof; or
- R 2 , R 3 , R 4 and R 5 have meaning as defined hereinabove with an acid corresponding to the group R-[L] x -X 1 — or with a reactive derivative thereof; and in the above processes, if required, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting any resulting compound into another compound of the invention; and/or if desired, converting a resulting compound into a salt or a resulting salt into the free acid or base or into another salt.
- the conversion of primary amides of formula V to the nitriles of formula I, according to process (a), can be carried out according to methods well known in the art for the dehydration of a primary amide to a nitrile, e.g. with thionyl chloride in the presence of a base.
- a preferred procedure involves the treatment with oxalyl chloride and pyridine in DMF at or below room temperature as illustrated in the examples.
- the starting materials of formula VI can be prepared by condensing an amino acid amide of formula IX
- R 4 , and R 5 have meaning as defined above with an acid of the formula VIII, in protected form as appropriate.
- the condensation can be carried out according to methods well-known in the art, e.g. by reacting a mixed anhydride or an acyl halide of the acid of formula VIII e.g. the acid chloride, with an amino acid amide of formula IX, in an inert solvent such as methylene chloride, in the presence of a base, such as an amine like triethylamine or pyridine.
- acylation of an acid of formula VIII with an amino acid amide of formula IX can also be carried out in the presence of a condensing agent such as N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide, optionally in the presence of e.g. hydroxybenzotriazole or 1-hydroxy-7-azabenzo-triazole, and a base such as N-methylmorpholine.
- a condensing agent such as N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide
- amino acid amides of formula IX are either known or can be prepared according to methodology known in the art and illustrated herein.
- Acidic Compounds of the Invention may be converted into metal salts with pharmaceutically acceptable bases, e.g. an aqueous alkali metal hydroxide, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained. Ammonium salts are obtained by reaction with the appropriate amine, e.g. diethylamine, and the like.
- Compounds of the Invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, for example, with inorganic acids, such as mineral acids, for example sulfuric acid, a phosphoric or hydrohalic acid, or with organic carboxylic acids, such as (C 1 -C 4 )alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, succinic, maleic or fumaric acid, such as hydroxycarboxylic acids, for example glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or with organic sulfonic acids, such as (C 1 -C 4 )-alkylsulfonic acids (for example methanesulfonic acid) or arylsulfonic acids which are unsubstituted or
- the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal, topical, and parenteral administration to mammals, including man, to inhibit cathepsin activity, and for the treatment of cathepsin dependent disorders, in particular inflammation, osteoporosis, rheumatoid arthritis and osteoarthritis, and comprise an effective amount of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers.
- compositions comprise an effective cathepsin inhibiting amount of a Compound of the Invention.
- the pharmacologically active Compounds of the Invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application.
- Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders e.g.
- Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
- compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- adjuvants such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.
- Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.
- Tablets may be either film coated or enteric coated according to methods known in the art.
- Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier.
- Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- Matrix transdermal formulations may also be used.
- Suitable formulations for topical application are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- the pharmaceutical formulations contain an effective cathepsin inhibiting amount of a Compound of the Invention as defined above, either alone or in combination with another therapeutic agent.
- a Compound of the Invention may be administered either simultaneously, before or after the other active ingredient, either separately by the same or different route of administration or together in the same pharmaceutical formulation.
- the dosage of active compound administered is dependent on the species of warm-blooded animal (mammal), the body weight, age and individual condition, and on the form of administration.
- a unit-dosage for oral administration to a mammal of about 50 to 70 kg may contain between about 5 and 500 mg of the active ingredient.
- the present invention also relates to methods of using Compounds of the Invention and their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in mammals for inhibiting cathepsins, such as cathepsin B, K, L and/or S, and for the treatment of cathepsin dependent conditions, such as cathepsin B, K, L and/or S dependent conditions, described herein, e.g. inflammation, osteoporosis, rheumatoid arthritis and osteoarthritis.
- cathepsins such as cathepsin B, K, L and/or S
- cathepsin dependent conditions such as cathepsin B, K, L and/or S dependent conditions, described herein, e.g. inflammation, osteoporosis, rheumatoid arthritis and osteoarthritis.
- the present invention relates to a method of selectively inhibiting cathepsin activity in a mammal which comprises administering to a mammal in need thereof an effective cathepsin inhibiting amount of a Compound of the Invention.
- Such relates to a method of treating rheumatoid arthritis, osteoarthritis, and inflammation (and other diseases as identified above) in mammals comprises administering to a mammal in need thereof a correspondingly effective amount of a Compound of the Invention.
- the title compound is prepared from 1-cyclohexane carboxylic acid (7 mmol), Fmoc-CI (7.7 mmol) and NaOH (14 mmol) in the usual manner in 18% yield.
- Boc-2-Aminoisobutyric acid amide is dissolved in 4N hydrochloride in dioxane. The reaction mixture is stirred at room temperature for 60 min. Diethylether is added to the solution to give a white precipitate, which is collected in 91% yield by filtration. The crude product is used for the next coupling without further purification.
- N-Tertbutyloxycarbonyl-isoleucine semihydrate (3 g, 12.5 mmol), HOBt (3.71 g, 27.5 mmol, 2.2 eq.) and aminoacetonitrile hydrochloride (1.27 g, 13.7 mmol, 1.1 eq.) are dissolved in dimethylformamide (36 ml) and WSCD (2.5 ml, 13.7 mmol, 1.1 eq.) is added. After stirring for 1 hour at rt, 4% sodium bicarbonate solution is added and the mixture is extracted with ethyl acetate. The organic layer is washed with sodium bicarbonate and dilute hydrochloric acid, dried over magnesium sulfate and evaporated, to give the product in quantitative yield.
- N-(Naphthalene-2-carbonyl)-isoleucine methylester (3.14 g, 10.5 mmol) is stirred in a mixture of methanol (35 ml) and 1 N aqueous sodium hydroxide (16.8 ml; 1.6 eq.). After 3 hours at rt the mixture is heated for 1 hour at 40° C. 1 N hydrochloric acid and brine is added and the mixture is extracted with ethyl acetate. The organic layer is dried over magnesium sulfate and evaporated to give the product in quantitative yield (partly epimerized).
- N-(Naphthalene-2-carbonyl)-isoleucine 250 mg, 0.87 mmol
- (S)-1-cyano-3-methyl-butylamine 143 mg, 0.96 mmol, Meq.
- HOBt 260 mg, 1.93 mmol, 2.2 eq.
- dimethylfonnamide 5 ml
- WSCD 0.17 ml, 0.96 mmol, 1.1 eq.
- 4% sodium bicarbonate solution is added and the mixture is extracted with ethyl acetate.
- the organic layer is washed with sodium bicarbonate and dilute hydrochloric acid, dried over magnesium sulfate and evaporated. Chromatography on silica gel (hexane/ethyl acetate 2/1) gives the product in 68% yield (mixture of epimers).
- the title compound is prepared analogously is prepared similar to N-(Naphthalene-2-carbonyl)-isoleucine (see above) in 98% yield, starting from leucine methylester.
- N-(Naphthalene-2-carbonyl)-leucine 250 mg, 0.88 mmol
- (S)-1-cyano-3-methyl-butylamine 143 mg, 0.96 mmol, 1.1 eq.
- HOBt 260 mg, 1.93 mmol, 2.2 eq.
- dimethylformamide 5 ml
- WSCD 0.18 ml, 0.97 mmol, 1.1 eq.
- the title compound is prepared analogously to the compound of Example 22.
- N-(Naphthalene-2-carbonyl)-leucine and 1-cyano-2-(1H-indol-3-yl)-ethylamine (CAS 169545-97-5) are reacted by the same procedure as for Naphthalene-2-carboxylic acid [1-(1-cyano-3-methyl-butylcarbamoyl)-3-methyl-butyl]-amide, to give the product in 36% yield after chromatography on silica gel (hexane/ethyl acetate 1/1) (mixture of epimers).
- N-tert-Butyloxycarbonyl-1-cyano-1-methyl-ethylamine (3.09 g, 16.8 mmol) is dissolved in dioxane (15 ml) and 4N hydrochloric acid-dioxane (25 ml) is added at 0°.
- the reaction mixture is stirred at 0° for 1.5 hours, then at rt for 1 hour.
- the mixture is concentrated and diethyl ether is added.
- the resulting white precipitate is washed with diethyl ether and dried to give the product in 83% yield.
- the crude product is used for the next coupling without further purification.
- Boc-1-aminocyclohexane carboxylic acid (40 mmol), HOBt (40 mmol) and WSCD (42 mmol) are dissolved in dimethylformamide (75 ml) and stirred for 15 min. at RT.
- 2-aminoacetonitrile hydrochloride (40mmol) and triethylamine (40 mmol) are suspended in DMF (25 ml) and added to the reaction mixture which is stirred at 25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate and evaporated.
- the reaction mixture is diluted with CH 2 Cl 2 (40 ml), washed with water and dried over magnesium sulfate and evaporated. The residue was suspended in diethylether and the solid filtered of.
- Boc-Leu-OH (62 mmol), HOBt (62 mmol) and WSCD (62 mmol) are dissolved in dimethylformamide (150 ml) and stirred for 15 min. at RT.
- 2-Amino-2-methyl-propionamide hydrochloride (62 mmol) and triethylamine (62 mmol) are suspended in DMF (25 ml) and added to the reaction mixture which is stirred at 25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate and evaporated.
- Boc-Leu-Leu-OH (Bachem, 43.6 mmol) is dissolved in THF (250 ml) and N-methylmorpholine (43.6 mmol) is added. The mixture is cooled to ⁇ 20° C. and isobutyl chloroformate (43.6 mmol) is added dropwise. The mixture is stirred for 10 min. and then a 25% aqueous solution of ammonia (52.3 mmol) is added at ⁇ 20° C. The mixture is stirred for 3 hours at ⁇ 20° C. to ⁇ 10° C. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water and dried over magnesium sulfate and evaporated.
- Compounds of Examples 1 to 153 are typically selective inhibitors of cathepsin K and generally have IC 50 s for inhibition of human cathepsin K of from about 100 to about 1 nM or less, e.g. about 0.5 nM.
- the cathepsin K selective compounds of the invention are particularly indicated for preventing or treating osteoporosis of various genesis (e.g. juvenile, menopausal, post-menopausal, post-traumatic, caused by old age or by cortico-steroid therapy or inactivity).
- various genesis e.g. juvenile, menopausal, post-menopausal, post-traumatic, caused by old age or by cortico-steroid therapy or inactivity.
- the compounds of Table 9 are typically selective inhibitors for cathepsin L, having IC 50 s for cathepsin L inhibition which are preferably in the range from about 100 to about 1 nM.
- IC 50 s for cathepsin L inhibition which are preferably in the range from about 100 to about 1 nM.
- the compounds of Table 10 are inhibitors of cathepsin L and cathepsin S, having IC 50 s for inhibition of cathepsin L in the range from about 100 to about 50 nM and IC 20 s for inhibition of cathepsin S in the range from about 50 to about 10 nM.
- Oxalyl chloride (0.057 mL, 0.084 g, 0.66 mmol) is added dropwise to DMF (10 ML), and the resulting solution is cooled to 0° C. After the solution becomes clear, pyridine (0.11 mL, 0.10 g, 1.31 mmol) is added, followed by N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-O-[[3 (methoxy-carbonyl)-phenyl]methyl]-L-serinamide (0.20 g, 0.329 mmol), in one portion. The yellow reaction solution is stirred at 0° C.
- reaction mixure is cooled to 0° C. and 1 N HCl (800 mL) is added.
- the organic phase is washed with 1 N HCl (2 ⁇ 700 mL), then washed with saturated NaHCO 3 (700 mL), then dried (MgSO 4 ) and evaporated in vacuo to yield O-[[3-(allyloxycarbonyl)phenyl]methyl]-N-(t-butoxycarbonyl)-L-serinamide as a thick oil, which is used as is in the subsequent step.
- Oxalyl chloride (0.046 mL, 0.36 mmol) is added dropwise to DMF (5 mL), and the resulting solution is cooled to 0° C. After the solution is clear, pyridine (0.032 mL, 0.40 mmol) is added, followed by N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-O-[[5-(methoxycarbonyl)-fur-2-yl]-methyl]-L-serinamide (0.20 g, 0.33 mmol), in one portion. The yellow reaction solution is stirred at 0° C.
- Oxalyl chloride (0.29 mL, 2.90 mmol) is added dropwise to DMF (20 mL), and the resulting solution is cooled to 0° C. After the solution becomes clear, pyridine (0.54 mL, 5.8 mmol) is added, followed by N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-S-[[3-(methoxycarbonyl)-phenyl]-methyl]-L-cysteinamide (0.90 g,1.51 mmol), in one portion. The yellow reaction solution is stirred at 0° C.
- Oxalyl chloride (0.082 mL, 0.94 mmol) is added dropwise to DMF (20 mL), and the resulting solution is cooled to 0° C. After the solution becomes clear, pyridine (0.15 mL, 1.88 mmol) is added, followed by N-[4-(3-methoxycarbonyl-1H-pyrazol-1-yl)-1(S)-(aminocarbonyl)butyl]-3methyl-N ⁇ -(2,2-diphenyl-acetyl)-L-phenylalaninamide (0.28 g, 0.47 mmol), in one portion. The yellow reaction solution is stirred at 0° C.
- N-(t-butoxycarbonyl)-(S)-propargylglycine (2.44 g, 11.45 mmol) in CH 2 Cl 2 (50 mL) is added N-methylmorpholine (3.78 mL, 34.4 mmol) in one portion.
- N-methylmorpholine (3.78 mL, 34.4 mmol)
- ammonia gas is bubbled into the reaction mixture at a moderately vigorous rate for 15 minutes.
- Oxalyl chloride (0.12 mL, 1.39 mmol) is added dropwise to DMF (10 mL), and the resulting solution is cooled to 0° C. After the solution is clear, pyridine (0.22 mL, 2.78 mmol) is added, followed by N-[4-(3-methoxycarbonylphenyl)-1(S)-(aminocarbonyl)butyl]-3-methyl-N ⁇ -(2,2-diphenylacetyl)-L-phenylalaninamide (0.42 g, 0.70 mmol), in one portion. The yellow reaction solution is stirred at 0° C.
- the compounds of Examples 302 to 419 are selective inhibitors of cathepsin B, having IC 50 s for inhibition of cathepsin B, in the in vitro cathepsin B assay described above, which are typically in the range from about 5 nM to about 1000 nM.
- the IC 50 in the in vitro cathepsin B assay is about 5 nM for the compound of example 303.
- the Compounds of the Invention described above in Examples 154 to 419 may be used for treatment or prophylaxis of diseases or medical conditions mediated by cathepsin L, S or B; for instance as hereinbefore described.
- Example 420 Preparation of 1,000 capsules each containing 25 mg of a Compound of the Invention, using the following ingredients: Compound of the Invention 25.00 g Lactose 192.00 g Modified starch 80.00 g Magnesium stearate 3.00 g
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof
wherein: the symbols are as defined.
In particular it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.
Description
- This application is a continuation of application Ser. No. 10/694,672, filed on Oct. 28, 2003, which is a continuation of application Ser. No. 10/342,872, filed on Jan. 15, 2003, which is a continuation of application Ser. No. 10/054,590, filed on Jan. 22, 2002, which is a continuation of application Ser. No. 09/643,639, filed on Aug. 22, 2000, which is a continuation of application Ser. No. 09/186,223, filed on Nov. 4, 1998, which claims the benefit of provisional application Ser. No. 60/108,160, filed on Dec. 5, 1997, which was converted from application Ser. No. 08/985,973, all of which are incorporated herein by reference.
- This invention relates to inhibitors of cysteine proteases, in particular to dipeptide nitrile cathepsin inhibitors and to their pharmaceutical use for the treatment or prophylaxis of diseases or medical conditions in which cathepsins are implicated.
- The cysteine cathepsins, e.g. cathepsins B, K, L and S, are a class of lysosomal enzymes which are implicated in various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization), autoimmune diseases, respiratory diseases, infectious diseases and immununologically mediated diseases (including transplant rejection).
- In accordance with the invention it has been found that dipeptide nitrites are particularly useful as cysteine cathepsin inhibitors and can be used for the treatment of the above-cited cysteine cathepsin dependent conditions.
- Accordingly the present invention provides an N-terminal-substituted dipeptide nitrile, i.e. a dipeptide in which the C-terminal carboxy group of the dipeptide is replaced by a nitrile group (—C≡N) and in which the N-terminal nitrogen atom is substituted via a peptide or pseudopeptide linkage which optionally additionally comprises a —methylene-hetero atom—linker or an additional hetero atom, directly by aryl, lower alkyl, lower alkenyl, lower alkynyl or heterocyclyl, or a physiologically-acceptable and -cleavable ester or a salt thereof, for use as a pharmaceutical.
- The invention further provides a pharmaceutical composition comprising an N-terminal-substituted dipeptide nitrile as defined above as an active ingredient.
- The invention also provides a method of treating a patient suffering from or susceptible to a disease or medical condition in which a cathepsin is implicated, comprising administering an effective amount of an N-terminal-substituted dipeptide nitrile as defined above to the patient.
- The invention further includes the use of an N-terminal-substituted dipeptide nitrile as defined above for the preparation of a medicament for therapeutic or prophylactic treatment of a disease or medical condition in which a cathepsin is implicated.
- The dipeptide nitrile of the invention conveniently comprises α-amino acid residues, including both natural and unnatural α-amino acid residues. Herein the “natural α-amino acid residues” denote the 20 amino acids obtainable by translation of RNA according to the genetic code or the corresponding nitrites thereof, as appropriate. “Unnatural α-amino acid residues” are α-amino acids which have α-substituents other than those found in “natural α-amino acid residues. Preferred a-amino acid residues, as the C-terminal amino acid residue of the dipeptide nitrile, are the nitrites of tryptophan, 2-benzyloxymethyl-2-amino-acetic acid, 2,2-dimethyl-2-amino-acetic acid, 2-butyl-2-amino-acetic acid, methionine, leucine, lysine, alanine, phenylalanine, and glycine and derivatives thereof, e.g. as hereinafter described. Preferred amino acid residues as the N-terminal amino acid residue of the dipeptide nitrile are 1-amino-cyclohexanecarboxylic acid, 1-amino-cycloheptanecarboxylic acid, phenylalanine, histidine, tryptophan and leucine and derivatives thereof, e.g. as hereinafter described.
- The aryl, lower alkyl, lower alkenyl, lower alkynyl or heterocyclyl substituent (hereinafter referred to as R) is attached to the N-terminal nitrogen atom of the dipeptide via a peptide linkage, i.e. as R—C(O)—NH—, or via a pseudopeptide linkage. Suitable pseudopeptide linkages include sulphur in place of oxygen and sulphur and phosphorous in place of carbon, e.g. as R—C(S)—NH—, R—S(O)—NH—, R—S(O)2NH— or R—P(O)2—NH and analogues thereof. Additionally the peptide or pseudopeptide linkage between the R substituent and the N-terminal nitrogen atom may comprise an additional hetero atom, e.g. as R-Het-C(O)—NH—, or a —methylene-hetero atom—linker, e.g. as R-Het-CH2—C(O)—NH— or R—CH2-Het-C(O)—NH—, wherein Het is a hetero atom selected from O, N or S, and pseudopeptide containing alternatives thereof, e.g. as defined above. When the linkage between the aryl substituent and the N-terminal nitrogen atom comprises a —methylene-hetero atom—linker, the methylene group and the hetero atom may be optionally further substituted, e.g. as hereinafter described.
- The R substituent may be further substituted, e.g. by up to 3 substituents selected from halogen, hydroxy, amino, nitro, optionally substituted C1-4alkyl (e.g. alkyl substituted by hydroxy, alkyloxy, amino, optionally substituted alkylamino, optionally substituted dialkylamino, aryl or heterocyclyl), C1-4alkoxy, C2-6alkenyl, CN, trifluoromethyl, trifluoromethoxy, aryl, (e.g. phenyl or phenyl substituted by CN, CF3, halogen, OCH3), aryloxy, (e.g. phenoxy or phenoxy substituted by CN, CF3, halogen, OCH3), benzyloxy or a heterocyclic residue.
-
- wherein:
- R is optionally substituted (aryl, lower alkyl, lower alkenyl, lower alkynyl, or heterocyclyl);
- R2 and R3 are independently hydrogen, or optionally substituted [lower alkyl, cycloalkyl; bicycloalkyl, or (aryl, biaryl, cycloalkyl or bicycloalkyl)-lower alkyl]; or
- R2 and R3 together represent lower alkylene, optionally interrupted by O, S or NR6, so as to form a ring with the carbon atom to which they are attached
- wherein R6 is hydrogen, lower alkyl or aryl-lower alkyl; or
- either R2 or R3 are linked by lower alkylene to the adjacent nitrogen to form a ring;
- R4 and R5 are independently H, or optionally substituted (lower alkyl, aryl-lower alkyl), —C(O)OR7, or —C(O)NR7R8,
- wherein
- R7 is optionally substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl or heterocyclyl), and
- R8 is H, or optionally substituted (lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, bicycloalkyl or heterocyclyl), or
- R4 and R5 together represent lower alkylene, optionally interrupted by O, S or NR6, so as to form a ring with the carbon atom to which they are attached
- wherein R6 is hydrogen, lower alkyl or aryl-lower alkyl, or
- R4 is H or optionally substituted lower alkyl and R5 is a substituent of formula —X2—(Y1)n—(Ar)p-Q-Z
- wherein
- Y1 is O, S, SO, SO2, N(R6)SO2, N—R6, SO2NR6, CONR6 or NR6CO;
- n is zero or one;
- p is zero or one;
- X2 is lower alkylene; or when n is zero, X2 is also C2-C7-alkylene interrupted by O, S, SO, SO2, NR6, SO2NR6, CONR6 or NR6CO;
-
- wherein R6 is hydrogen, lower alkyl or aryl-lower alkyl;
- Ar is arylene;
- Z is hydroxy, acyloxy, carboxyl, esterified carboxyl, amidated carboxyl, aminosulfonyl, (lower alkyl or aryl-lower alkyl)aminosulfonyl, or (lower alkyl or aryl-lower alkyl)sulfonylaminocarbonyl; or Z is tetrazolyl, triazolyl or imidazolyl;
- Q is a direct bond, lower alkylene, Y1-lower alkylene or C2-C7-alkylene interrupted by Y1;
- X1 is —C(O)—, —C(S)—, —S(O)—, —S(O)2—, —P(O)(OR6)—
- wherein R6 is as defined above;
- Y is oxygen or sulphur;
- L is optionally substituted -Het-, -Het-CH2— or —CH2-Het-,
- wherein Het is a hetero atom selected from O, N or S, and
- x is zero or one;
- and aryl in the above definitions represents carbocyclic or heterocyclic aryl,
- for use as a pharmaceutical;
- a pharmaceutical composition comprising a compound of formula I as defined above as an active ingredient;
- a method of treating a patient suffering from or susceptible to a disease or medical condition in which a cathepsin is implicated, comprising administering an effective amount of a compound of formula I as defined above to the patient; and
- use of a compound of formula I as defined above for the preparation of a medicament for therapeutic or prophylactic treatment of a disease or medical condition in which a cathepsin is implicated.
- The invention also provides novel dipeptide nitriles.
- Accordingly the invention further provides a compound of formula I as defined above provided that when R is lower alkyl not substituted by aryl,
- one of R4 or R5 is a substituent of formula —X2—(Y1)n—(Ar)p-Q-Z,
- provided that when x is one, L is —O—, or —CH2—O— and X1 is —C(O)—,
- either one of R4 or R5 is a substituent of formula —X2—(Y1)n—(Ar)p-Q-Z, or R is not unsubstituted phenyl,
- provided that when R2═R4═R5═H, x is zero and X1 is —C(O)—,
- R3 is not H, —CH3, —CH(CH3)2, —CH2—CH—(CH3)2, —CH2—COOH, or —CH2—COO—CH2—CH3, when R is unsubstituted phenyl,
- R3 is not H, —CH(CH3)2, or —CH2—CH—(CH3)2, when R is 4-aminophenyl or 4-nitrophenyl,
- R3 is not H when R is 3-aminophenyl, 3-nitrophenyl 2-chloropyridin-4-yl, or vinyl or
- R3 is not —CH2—CH2—S—CH3 when R is pyridin-3-yl or 2-chloropyridin-4-yl,
- provided that when R2═R3═R4═H, x is zero and X1 is —C(O)— and R is phenyl,
- R5 is not —CH(CH3)2,
- provided that when R3═R4═H, R5 is —CH2—CH2—COOH, x is zero and X1 is —C(O)—,
- R2 does not form a heterocyclic ring with the adjacent nitrogen atom, and provided that when R2═R3═R4═R5═H, x is zero and X1 is —SO2—,
- R is not 4-methylphenyl.
- In formula I R, R2, R3, R4, R5 and L may be further substituted by one or more, e.g. up to 3, substituents independently selected from lower alkyl, aryl, aryl-lower alkyl, cycloalkyl, heterocyclyl, —CN, -halogen, —OH, —NO2, —NR9R10, —X3—R7, lower alkyl-X3—R8, halo-substituted lower alkyl,
- wherein R7 and R8 are as defined above,
-
- X3 is —O—, —S—, —NR8—, —C(O)—, —C(S)—, —S(O)—, —S(O)2—, —C(O)O—, —C(S)O—, —C(O)NR8—,
- wherein R8 is as defined above,
- R9 and R10 are independently as defined above for R8, or —X4—R8,
- wherein X4 is —C(O)—, —C(S)—, —S(O)—, —S(O)2—, —C(O)O—, —C(S)O—, —C(O)NR6-
- wherein R6 and R7 are as defined above, or
- R9 and R10 together with N form a heteroaryl group or a saturated or unsaturated heterocycloalkyl group; optionally containing one or more additional heteroatoms selected from O, N or S.
- X3 is —O—, —S—, —NR8—, —C(O)—, —C(S)—, —S(O)—, —S(O)2—, —C(O)O—, —C(S)O—, —C(O)NR8—,
- Compounds of formula I exhibit valuable pharmacological properties in mammals, in particular as cysteine cathepsin inhibitors. In accordance with the present invention it has been found that by appropriate choice of groups R, R2, R3, R4, R5, X1, Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.
-
- wherein:
- R20 is optionally substituted (aryl, aryl-lower alkyl, lower alkenyl, lower alkynyl, heterocyclyl, or heterocyclyl-lower alkyl);
- R22 is H, or optionally substituted lower alkyl, and
- R23 is optionally substituted (lower alkyl, aryl-lower alkyl, or cyloalkyl-lower alkyl) or
- R22 and R23 together with the carbon atom to which they are attached form an optionally substituted (cycloalkyl group or heterocycloalkyl group);
- R24 and R25 are independently H, or optionally substituted (lower alkyl, or aryl-lower alkyl), —C(O)OR7, or —C(O)NR7R8
- wherein R7 and R8 are as defined above, or
- R24 and R25 together with the carbon atom to which they are attached form an optionally substituted (cycloalkyl group or heterocycloalkyl group);
- X1 is as defined above;
- Y is oxygen or sulphur;
- L′ is optionally substituted (-Het-CH2— or —CH2-Het-),
-
- wherein Het is a hetero atom selected from O, N or S, and
- x is 1 or 0,
- provided that when x is one, L is —CH2—O— and X1 is —C(O)—,
- R20 is not unsubstituted phenyl,
- provided that when R22═R24═R25═H, x is zero and X1 is —C(O)—,
- R23 is not H, —CH3, —CH(CH3)2, —CH2—CH—(CH3)2, —CH2—COOH, or —CH2—COO—CH2—CH3, when R20 is unsubstituted phenyl,
- R23 is not H, —CH(CH3)2, or —CH2—CH—(CH3)2, when R20 is 4-aminophenyl or 4-nitrophenyl,
- R23 is not H when R20 is 3-aminophenyl, 3-nitrophenyl 2-chloropyridin-4-yl, or vinyl, or
- R23 is not —CH2—CH2—S—CH3 when R20 is pyridin-3-yl or 2-chloropyridin-4-yl,
- provided that when R22═R23═R24═H, x is zero and X1 is —C(O)— and R20 is phenyl,
- R25 is not —CH(CH3)2,
- provided that when R23═R24═H, R25 is —CH2—CH2—COOH, x is zero and X1 is —C(O)—,
- R22 does not form a heterocyclic ring with the adjacent nitrogen atom, and
- provided that when R22═R23═R24═R25═H, x is zero and X1 is —SO2—,
- R20 is not 4-methylphenyl.
- Compounds of formula II are typically inhibitors of cathepsins K, L or S, especially selective inhibitors of catepsin K or cathepsin L or cathepsin S, or in some case inhibitors of, e.g. cathepsins L and S.
- The substituents of the compounds of formula II have the following preferred significances. Preferred compounds of formula II comprise compounds having preferred substituents, singly or in any combination.
- Preferably when R20 comprises aryl, the aryl is optionally substituted (phenyl, naphthylenyl, phenanthrenyl, thiophenyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, pyridinyl, indolyl, quinolinyl, isoquinolinyl, benzothienyl and benzofuranyl).
- Preferably R22 is hydrogen.
- Preferably R23 is optionally substituted (lower alkyl, aryl-lower alkyl or cycloalkyl-lower alkyl), or R23 and R22 together with the carbon atom to which they are attached form a C5-C8, especially a C6 or C7, cycloalkylgroup. More preferably R23 is —CH2—CH(CH3)2, or optionally substituted benzyl, cyclohexylmethyl, naphthalenylmethyl, indolylmethyl, benzothienylmethyl or benzofuranylmethyl, or R23 and R22 together with the carbon atom to which they are attached form a cyclohexane ring.
- Preferred significances for R24 and R25 are:
- R24 and R25 are both H or —CH3, or
- R24 is H and R25 is aryl-lower alkyl, lower alkyl, both optionally substituted by up to 3 substituents selected from amino, halogen (e.g. fluorine or preferably chlorine) or S—CH3, or
- R24 and R25 together with the carbon atom to which they are attached form a C3-C7 cycloalkyl ring.
- More preferably R24 is H and R25 is optionally substituted (—CH2-phenyl, —CH2-indolyl, —(CH2)2—S—CH3, —CH2—CH(CH3)2, —(CH2)4—NH2 or —(CH2)3-CH3), or yet more preferably R4 and R5 are both —CH3, or especially R4 and R5 are both H.
- Preferably —X1— is —C(O)—.
- Preferably Y is ═O.
-
- wherein:
- R20′ is optionally substituted (C6-C18 aryl or C4-C18 heteroaryl);
- R22′ is H, or optionally substituted C1-C8 alkyl, and
- R23′ is optionally substituted (C2-C8 alkyl, or C7-C14 aralkyl), or
- R22′ and R23′ together with the carbon atom to which they are attached form an optionally substituted (C3-C8 cycloalkyl group or C4-C7 heterocycloalkyl group);
- R24′ and R25′ are independently H, or optionally substituted (C1-C8 alkyl, C7-C14 aralkyl, or C5-C14 heteroaralkyl), —C(O)OR6′, or —C(O)NR6′R7′,
- wherein
- R6′ is optionally substituted (C1-C8 alkyl, C7-C14 aralkyl, C3-C8 cycloalkyl, C4-C7 heterocycloalkyl, C5-C14 heteroaralkyl, C6-C14 aryl, or C4-C14 heteroaryl), and
- R7′ is H, or optionally substituted (C1-C8 alkyl, C7-C14 aralkyl, C3-C8 cycloalkyl, C4-C7 heterocycloalkyl, C5-C14 heteroaralkyl, C6-C14 aryl, or C4-C14 heteroaryl), or
- R24′ and R25′ together with the carbon atom to which they are attached form an optionally substituted (C3-C8 cycloalkyl group or C4-C7 heterocycloalkyl group);
- X, is —C(O)—, —C(S)—, —S(O)—, —S(O)2—, —P(O)(OR6′)—
-
- wherein R6′ is as defined above;
- Y is oxygen or sulphur;
- L′ is optionally substituted (-Het-CH2— or —CH2-Het-),
-
- wherein Het is a hetero atom selected from O, N or S, and
- x is 1 or 0,
- provided that when x is one, L′ is —CH2—O— and X, is —C(O)—
- R20,′ is not unsubstituted phenyl,
- provided that when R22′═R24′═R25′═H, x is zero and X1 is —C(O)—,
- R23′ is not H, —CH3, —CH(CH3)2, —CH2—CH—(CH3)2, —CH2—COOH, or —CH2—COO—CH2—CH3, when R20′ is unsubstituted phenyl,
- R23′ is not H, —CH(CH3)2, or —CH2—CH—(CH3)2, when R20′ is 4-aminophenyl or 4-nitrophenyl,
- R23′ is not H when R20′ is 3-aminophenyl, 3-nitrophenyl, 2-chloropyridin-4-yl, or vinyl, or
- R23′ is not —CH2—CH2—S—CH3 when R20′ is pyridin-3-yl or 2-chloropyridin-4-yl, provided that when R22′═R23′═R24′═H, x is zero and X1 is —C(O)— and R20′ is phenyl,
- R25′ is not —CH(CH3)2,
- provided that when R23′═R24′═H, R25′ is —CH2—CH2 COOH, x is zero and X1 is —C(O)—,
- R20′ does not form a heterocyclic ring with the adjacent nitrogen atom, and provided that when R22′═R23′═R24′═R25′ H, x is zero and X1 is —SO2—,
- R20′ is not 4-methylphenyl.
- Compounds of formula II′ are typically selective inhibitors of cathepsin K.
-
- wherein
- R30 is an acyl group derived from an organic carboxylic, carbonic, carbamic or sulfonic acid;
- R32 and R33 are independently hydrogen, lower alkyl, cycloalkyl, bicycloalkyl, or (aryl, biaryl, cycloalkyl or bicycloalkyl)-lower alkyl; or R32 and R33 together represent lower alkylene so as to form a ring together with the carbon to which they are attached;
- R34 is hydrogen or lower alkyl;
- X2, Y1, Ar, Q, Z, n and p are as previously defined;
- and pharmaceutically acceptable salts and esters thereof
- for use as a pharmaceutical.
- In preferred embodiments the invention further provides a compound of formula III as defined above, wherein R30 is an acyl group derived from an organic carboxylic, carbamic or sulfonic acid
- Compounds of formula III are typically selective inhibitors of cathepsin B and/or L.
- Particular embodiments relate to the compounds of formula III wherein R30, R32, R33, R34, Q, Z and n are as defined above; and wherein
- (a) p is one;
- (b) Y1 is O, S, SO, SO2, N(R6)SO2 or N—R6; and
- (c) X2 is lower alkylene; or when n is zero, X2 is also C2-C7-alkylene interrupted by O, S, SO, SO2 or NR6;
- wherein R6 is as defined above and pharmaceutically acceptable salts thereof.
- Further particular embodiments relate to the compounds of formula III wherein R30, R32, R33, R34, R35, Ar, Z and Q have meaning as defined above; and wherein
-
- (a) p is one, n is zero, and X2 is lower alkylene or C2-C7-alkylene interrupted by O, S, SO, SO2NR6, NR6SO2, SO2NR6, CONR6 or NR6CO; or
- (b) p is one, n is one, X2 is lower alkylene and Y, is O, S, SO, SO2, N(R6)SO2 or NR6, SO2NR6, CONR6, NR6CO; or
- (c) p is one, n is zero and X2 is lower alkylene; or
- (d) p is one, n is zero and X2 is C2-C7-alkylene interrupted by O, S, SO, SO2 or NR6, SO2NR6, CONR6 or NR6CO; or
- (e) p is zero, n is one, X2 is lower alkylene and Y1 is O, S, SO, SO2, N(R6)SO2 or NR6, SO2NR6, CONR6 or NR6CO; or
- (f) p is zero, n is zero and X2 is C2-C7-alkylene interrupted by O, S, SO, SO2 or NR6, SO2NR6, CONR6 or NR6CO;
- and pharmaceutically acceptable salts thereof; or
- Preferred compounds of formula III are those in which Z is carboxyl or carboxyl derivatized as a pharmaceutically acceptable ester.
-
- wherein
- R30, X2, Ar, Q, and p are as defined above; and wherein
- R33′ is carbocyclic or heterocyclic aryl-lower alkyl;
- Z′ is bydroxy, acyloxy, carboxyl, carboxyl derivatized as a pharmaceutically acceptable ester or amide, or 5-tetrazolyl;
- and pharmaceutically acceptable salts thereof.
- In a specific embodiment of the compounds of formula III′, R30 is carboxylic acid derived acyl; R33′ is carbocyclic or heterocyclic aryl-lower alkyl; X2 is C1-C5-alkylene, or X2 is C2-C4-alkylene interrupted by O or S; p is one; Ar is carbocyclic arylene; Q is a direct bond or C1-C4-alkylene; and Z is carboxyl or carboxyl derivatized as a pharmaceutically acceptable ester; and pharmaceutically acceptable salts thereof.
- In a more specific embodiment of the compounds of formula III′, R30 is aroyl, R33′ is carbocyclic aryl-methyl; X2 is C3-alkylene; or X2 is C2-alkylene interrupted by O; p is one; Ar is phenylene; Q is a direct bond; and Z is carboxyl; and pharmaceutically acceptable salts thereof.
-
- wherein
- R30, R33′, Y1, Ar, and Z′ are as defined above;
- X2′ is lower alkylene;
- Q′ is a direct bond or lower alkylene; and pharmaceutically acceptable salts thereof.
- A specific embodiment of the invention is directed to the compounds of formula III″ wherein R30 is carboxylic acid derived acyl; R33′ is carbocyclic or heterocyclic aryl-lower alkyl; X2′ is C1-C4-alkylene; Y1 is O or S; Ar is carbocyclic arylene; Q′ is a direct bond or C1-C4-alkylene; and Z′ is carboxyl or carboxyl derivatized as a pharmaceutically acceptable ester; and pharmaceutically acceptable salts thereof.
- A more specific embodiment of the invention is directed to said compounds of formula III″ wherein R30 is aroyl, R33′ is carbocyclic aryl-methyl; X2′ is C2-alkylene; Y, is O; Ar is phenylene; Q′ is a direct bond; and Z′ is carboxyl, and pharmaceutically acceptable salts thereof.
-
- wherein
- R40 is substituted phenyl or heterocyclic aryl, (mono- or di-carbocyclic or heterocyclic aryl)-lower alkyl or lower alkenyl, or heterocyclyl;
- R42 is hydrogen or lower alkyl;
- R43 is carbocyclic or heterocyclic aryl-lower alkyl;
- R44 and R45 are independently hydrogen or lower alkyl; or
- R44 and R45 combined represent lower alkylene;
- and pharmaceutically acceptable salts and esters thereof.
- Preferred are compounds of formula IV wherein R40 is morpholino, substituted phenyl or heterocyclic aryl; R42 is hydrogen; R43 is carbocyclic or heterocyclic aryl-lower alkyl; R44 and R45 are hydrogen or lower alkyl; or R44 and R45 combined represent ethylene to form a cyclopropyl ring.
- Particularly preferred are compounds of formula IV wherein R40 is pyrazolyl or pyrazolyl substituted by 1-3 lower alkyl; R42 is hydrogen; R43 is carbocyclic or heterocyclic aryl-C1-C4-alkyl; and R44 and R45 are hydrogen; or R44 and R45 combined are ethylene.
- Compounds of formula IV are typically selective inhibitors of cathepsin L and/or S.
- The compounds of formulae I, II, III and IV, depending on the nature of substituents, possess one or more asymmetric carbon atoms. The resulting diastereomers and enantiomers are encompassed by the instant invention. Preferably, however, e.g. for pharmaceutical use in accordance with the invention, the compounds of formulae I, II, III and IV are provided in pure or substantially pure epimeric form, e.g. as compositions in which the compounds are present in a form comprising at least 90%, e.g. preferably at least 95% of a single epimer (i.e. comprising less than 10%, e.g. preferably less than 5% of other epimeric forms).
- Preferred compounds of formula I are those wherein the asymmetric carbon to which are attached R2 and/or R3 corresponds to that of an L-amino acid precursor and the asymmetric carbon to which is attached the cyano group also corresponds to that of an L-amino acid and is generally assigned the (S)-configuration. Preferred compounds of formula I wherein R3 and R4 represent hydrogen can be represented by formulae V, V′ and V″, corresponding to preferred compounds of formulae II, III and IV respectively
-
- wherein the symbols are as defined above, and
- physiologically-acceptable and -cleavable esters or salts thereof.
- The compounds of formula I, II, II′, III, III′, III″, IV, V, V′ and V″ as defined above are hereinafter referred to as Compounds of the Invention.
- The general definitions used herein have the following meaning within the scope of the invention, unless otherwise specified.
- The term “lower” referred to above and hereinafter in connection with organic radicals or compounds respectively defines such as branched or unbranched with up to and including 7, preferably up to and including 4 and advantageously one or two carbon atoms.
- A lower alkyl group is branched or unbranched and contains 1 to 7 carbon atoms, preferably 1-4 carbon atoms. Lower alkyl represents for example methyl, ethyl, propyl, butyl, isopropyl or isobutyl.
- Lower alkenyl represents either straight chain or branched alkenyl of 2 to 7 carbon atoms, preferably 2-4 carbon atoms, e.g. as vinyl, propenyl, isopropenyl, butenyl, isobutenyl or butadienyl. Lower alkynyl represents either straight chain or branched alkynyl of 2 to 7 carbon atoms, preferably 2-4 carbon atoms, e.g. as acetylenyl, propenyl, isopropynyl, butynyl or isobutynyl.
- Lower alkyl, lower alkenyl and lower alkynyl may be substituted by up to 3 substituents selected from lower alkoxy, aryl, hydroxy, halogen, cyano, or trifluoromethyl.
- Lower alkylene represents either straight chain or branched alkylene of 1 to 7 carbon atoms and represents preferably straight chain alkylene of 1 to 4 carbon atoms, e.g. a methylene, ethylene, propylene or butylene chain, or said methylene, ethylene, propylene or butylene chain mono-substituted by C1-C3-alkyl, (advantageously methyl) or disubstituted on the same or different carbon atoms by C1-C3-alkyl (advantageously methyl), the total number of carbon atoms being up to and including 7.
- A lower alkoxy (or alkyloxy) group preferably contains 1-4 carbon atoms, advantageously 1-3 carbon atoms, and represents for example ethoxy, propoxy, isopropoxy, or most advantageously methoxy.
- Halogen (halo) preferably represents chloro or fluoro but may also be bromo or iodo.
- An acyl group as represented by R30 is preferably derived from an organic carbonic acid, an organic carboxylic acid, a carbamic acid or an organic sulfonic acid.
- Acyl which is derived from a carboxylic acid represents, for example, carbocyclic or heterocyclic aroyl, cycloalkylcarbonyl, (oxa or thia)-cycloalkylcarbonyl, lower alkanoyl, (lower alkoxy, hydroxy or acyloxy)-lower alkanoyl, (mono- or di-carbocyclic or heterocyclic)-(lower alkanoyl or lower alkoxy-, hydroxy- or acyloxy-substituted lower alkanoyl), or biaroyl.
- Carbocyclic aroyl represents, for instance, benzoyl, benzoyl substituted, by one to three substituents selected independently from e.g. halo, trifluoromethyl, lower alkyl, lower alkoxy, hydroxy, methylenedioxy, nitro, di-lower alkylamino, cyano, or carbocyclic aroyl represents e.g. 1- or 2-naphthoyl.
- Heterocyclic aroyl represents, for instance, 2-, 3- or 4-pyridylcarbonyl (such as nicotinoyl), furoyl, thienoyl, oxazoloyl, isoxazoloyl, quinoxaloyl, each optionally substituted by e.g. halo, lower alkyl, lower alkoxy or nitro.
- (Oxa- or thia)-cyclolalkylcarbonyl is, for example, tetrahydrofuranoyl or tetrahydrothienoyl. Di-(carbocyclic or heterocyclic)aryl-lower alkanoyl is, for example, diphenylacetyl or dipyridylacetyl.
- Aryl-(lower alkoxy, hydroxy or acyloxy substituted) lower alkanoyl is, for example, phenyl-(2-alkoxy, hydroxy or acyloxy)-acetyl.
- Biaroyl is, for example, 2, 3 or 4-biphenylcarbonyl.
- Acyl which is derived from an organic carbonic acid is, for example, alkoxycarbonyl, especially lower alkoxycarbonyl, which is unsubstituted or substituted by carbocyclic or heterocyclic aryl or is cycloalkoxycarbonyl, especially C3-C7-cycloalkyloxycarbonyl, which is unsubstituted or substituted by lower alkyl.
- Acyl which is derived from a carbamic acid is, for example, aminocarbonyl which is optionally substituted on nitrogen by one or two of lower alkyl, carbocyclic or heterocyclic aryl-lower alkyl, carbocyclic or heterocyclic aryl, or by lower alkylene or lower alkylene interrupted by O or S.
- Acyl which is derived from an organic sulfonic acid represents, for example, lower alkylsulfonyl, carbocyclic or heterocyclic arylsulfonyl, carbocyclic or heterocyclic aryl-lower alkysulfonyl, in which aryl is e.g. phenyl, naphthyl or thienyl, such being optionally substituted by, for example, lower alkyl, lower alkoxy, halo, nitro, trifluoromethyl, carboxyl or lower alkoxycarbonyl.
- Aryl represents carbocyclic or heterocyclic aryl.
- Carbocyclic aryl represents monocyclic, bicyclic or tricyclic aryl, for example phenyl or phenyl mono-, di- or tri-substituted by one, two or three radicals selected from lower alkyl, lower alkoxy, aryl, hydroxy, halogen, cyano, trifluoromethyl, lower alkylenedioxy and oxy-C2-C3 alkylene; or 1- or 2-naphthyl; or 1- or 2-phenanthrenyl. Lower alkylenedioxy is a divalent substituent attached to two adjacent carbon atoms of phenyl, e.g. methylenedioxy or ethylenedioxy. Oxy-C2-C3-alkylene is also a divalent substituent attached to two adjacent carbon atoms of phenyl, e.g. oxyethylene or oxypropylene. An example for oxy-C2-C3-alkylene-phenyl is 2,3-dihydrobenzofuran-5-yl.
- Preferred as carbocyclic aryl is naphthyl, phenyl or phenyl mono- or disubstituted by lower alkoxy, phenyl, halogen, lower alkyl or trifluoromethyl, especially phenyl or phenyl mono- or disubstituted by lower alkoxy, halogen or trifluoromethyl, and in particular phenyl.
- Examples of substituted phenyl groups as R are, e.g. 4-chlorophen-1-yl, 3,4-dichlorophen-1yl, 4-methoxyphen-1-yl, 4-methylphen-1-yl, 4-aminomethylphen-1-yl, 4-methoxyethylaminomethylphen-1-yl, 4-hydroxyethylaminomethylphen-1-yl, 4-hydroxyethyl (methyl)-aminomethylphen-1-yl, 3-aminomethylphen-1-yl, 4-N-acetylaminomethylphen-1-yl, 4-aminophen-1-yl, 3-aminophen-1-yl, 2-aminophen-1-yl, 4-phenyl-phen-1-yl, 4-(imidazol-1-yl)-phen-I-yl, 4-(imidazol-1-ylmethyl)-phen-1-yl, 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-ylmethyl)-phen-1-yl, 4-(2-methoxyethylaminomethyl)-phen-1-yl and 4-(pyrrolidin-1-ylmethyl)-phen-1-yl, 4-(2-thiophenyl)-phen-1-yl, 4-(3-thiophenyl)-phen-1-yl, 4-(4-methylpiperazin-1-yl)-phen-1-yl, and 4-(piperidinyl)-phenyl and 4-(pyridinyl)-phenyl optionally substituted in the heterocyclic ring.
- Heterocyclic aryl represents monocyclic or bicyclic heteroaryl, for example pyridyl, indolyl, quinoxalinyl, quinolinyl, isoquinolinyl, benzothienyl, benzofuranyl, benzopyranyl, benzothiopyranyl, furanyl, pyrrolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any said radical substituted, especially mono- or di-substituted, by e.g. lower alkyl, nitro or halogen. Pyridyl represents 2-, 3- or 4-pyridyl, advantageously 2- or 3-pyridyl. Thienyl represents 2- or 3-thienyl. Quinolinyl represents preferably 2-, 3- or 4-quinolinyl. Isoquinolinyl represents preferably 1-, 3- or 4-isoquinolinyl. Benzopyranyl, benzothiopyranyl represent preferably 3-benzopyranyl or 3-benzothiopyranyl, respectively. Thiazolyl represents preferably 2- or 4-thiazolyl, advantageously 4-thiazolyl. Triazolyl is preferably 1-, 2- or 5-(1,2,4-triazolyl). Tetrazolyl is preferably 5-tetrazolyl.
- Preferably, heterocyclic aryl is pyridyl, indolyl, quinolinyl, pyrrolyl, thiazolyl, isoxazolyl, triazolyl, tetrazolyl, pyrazolyl, imidazolyl, thienyl, or any said radical substituted, especially mono-or di-substituted, by lower alkyl or halogen; and in particular pyridyl.
- Arylene (Ar in formula III) is an aryl linking group in which aryl is heterocyclic or carbocyclic aryl, preferably monocyclic as defined above.
- A heterocyclic aryl linking group is for instance (but not limited thereto) 1,3-pyrazolyl, 2,4-or 2,5-pyridyl or 1,4-imidazolyl in which the groups as depicted in formula III are attached to the ring at the indicated positions.
- A carbocyclic aryl linking group is for instance (but not limited thereto) optionally substituted phenyl in which the two groups as depicted in formula I are attached ortho, meta or para to each other.
- Biaryl may be carbocyclic biaryl, preferably e.g. biphenyl, namely 2, 3 or 4-biphenyl, advantageously 4-biphenyl, each optionally substituted by e.g. lower alkyl, lower alkoxy, halogen, trifluoromethyl or cyano, or heterocyclic-carbocyclic biaryl, preferably e.g. thienylphenyl, pyrrolylphenyl and pyrazolylphenyl.
- Cycloalkyl represents a saturated cyclic hydrocarbon optionally substituted by lower alkyl which contains 3 to 10 ring carbons and is advantageously cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl optionally substituted by lower alkyl.
- Bicycloalkyl is for example norbornanyl.
- Heterocyclyl represents a saturated cyclic hydrocarbon containing one or more, preferably 1 or 2, hetero atoms selected from O, N or S, and from 3 to 10, preferably 5 to 8, ring atoms; for example, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyrrolyl, piperidinyl, piperazinyl or morpholino.
- Aryl-lower alkyl represents preferably (carbocyclic aryl or heterocylic aryl)-lower alkyl.
- Carbocyclic aryl-lower alkyl represents preferably straight chain or branched aryl-C1-4-alkyl in which carbocyclic aryl has meaning as defined above, e.g. benzyl or phenyl-(ethyl, propyl of butyl), each unsubstituted or substituted on phenyl ring as defined under carbocyclic aryl above, advantageously optionally substituted benzyl, e.g. benzyl substituted or phenyl lay lower alkyl.
- Heterocyclic aryl-lower alkyl represents preferably straight chain or branched heterocyclic aryl-C1-4-alkyl in which heterocyclic aryl has meaning as defined above, e.g. 2-, 3- or 4-pyridylmethyl or (2, 3- or 4-pyridyl)-(ethyl, propyl or butyl); or 2- or 3-thienylmethyl or (2- or 3-thienyl)-(ethyl, propyl or butyl); 2-, 3- or 4-quinolinylmethyl or (2-, 3- or 4-quinolinyl)-(ethyl, propyl or butyl); or 2- or 4-thiazolylmethyl or (2- or 4-thiazolyl)-(ethyl, propyl or butyl).
- Cycloalkyl-lower alkyl represents e.g. (cyclopentyl- or cyclohexyl)-(methyl or ethyl).
- Biaryl-lower alkyl represents e.g. 4-biphenylyl-(methyl or ethyl).
- Acyl as in acyloxy is derived from an organic carboxylic acid, carbonic acid or carbamic acid. Acyl represents e.g. lower alkanoyl, carbocyclic aryl-lower alkanoyl, lower alkoxycarbonyl, aroyl, di-lower alkylaminocarbonyl or di-lower alkylamino-lower alkanoyl. Preferably, acyl is lower alkanoyl.
- Lower alkanoyl represents e.g. C1-7-alkanoyl including formyl, and is preferably C2-4-alkanoyl such as acetyl or propionyl.
- Aroyl represents e.g. benzoyl or benzoyl mono- or di-substituted by one or two radicals selected from lower alkyl, lower alkoxy, halogen, cyano and trifluoromethyl; or 1- or 2-naphthoyl; and also e.g. pyridylcarbonyl.
- Lower alkoxycarbonyl represents preferably C1-4-alkoxycarbonyl, e.g. ethoxycarbonyl.
- Esterified carboxyl is carboxyl derivatized as a pharmaceutically acceptable ester, for example lower alkoxycarbonyl, benzyloxycarbonyl or allyloxycarbonyl.
- Amidated carboxyl is carboxyl derivatized as a pharmaceutically acceptable amide, for example aminocarbonyl, mono- or di-lower alkylaminocarbonyl.
- Pharmaceutically acceptable salts of the acidic compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethyl ammonium, and tris-(hydroxymethyl)-methyl-ammonium salts. Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids e.g. hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.
- The compounds of the invention exhibit valuable pharmacological properties in mammals and are particularly useful as cysteine cathepsin inhibitors.
- The cathepsin inhibitory effects of the compound of the invention can be determined in vitro by measuring the inhibition of e.g. recombinant human cathepsins B, K, L and S. The buffer used in the cathepsin B, L and S assays is a 0.1 M pH 5.8 phosphate buffer containing EDTA (1.33 mM), DTT (2.7 mM) and Brij (0.03%).
- The in vitro assays are carried out as follows:
- (a) For cathepsin B:
-
- To a microtiter well is added 100 uL of a 20 uM solution of inhibitor in assay buffer followed by 50 uL of a 6.4 mM solution of Z-Arg-Arg-AMC substrate (Peptides International) in assay buffer. After mixing, 50 uL of a 0.544 nM solution of recombinant human cathepsin B in assay-buffer is added to the well, yielding a final inhibitor concentration of 10 uM. Enzyme activity is determined by measuring fluorescence of the liberated aminomethylcoumarin at 440 nM using 380 nM excitation, at 20 minutes. % Enzyme inhibition is determined by comparison of this activity to that of a solution containing no inhibitor. Compounds are subsequently subjected to a dose response curve analysis to determine IC50 values.
- (b) For cathepsin K:
-
- The assay is performed in 96 well microtiter plates at ambient temperature using recombinant human cathepsin K. Inhibition of cathepsin K is assayed at a constant enzyme (0.16 nM) and substrate concentration (54 mM Z-Phe-Arg-MCA—Peptide Institute Inc. Osaka, Japan) in 100 mM sodium phosphate buffer, pH 7.0, containing 2 mM dithiothreitol, 20 mM Tween 80 and 1 mM EDTA. Cathepsin K is preincubated with the inhibitors for 30 min, and the reaction is initiated by the addition of substrate. After 30 min incubation the reaction is stopped by the addition of E-64 (2 mM), and fluorescence intensity is read on a multi-well plate reader at excitation and emission wavelengths of 360 and 460 nm, respectively.
- (c) For cathepsin L:
-
- Recombinant human cathepsin L is activated prior to use in this assay: To 500 uL of a 510 nM solution of cathepsin L in a 50 mM pH 5.0 acetate buffer containing 1 mM EDTA, 3 mM DTT and 150 mM NaCl is added 10 uL of a 625 uM solution of dextran sulfate (ave. mw=8000), and the resulting solution is incubated on ice for 30 min. 4 uL of this solution is then diluted into 46 uL assay buffer, yielding a 40 nM enzyme solution. To perform the assay, 100 uL of a 20 uM solution of inhibitor in assay buffer is added to a microtiter well. 50 uL of a 20 uM solution of Z-Phe-Arg-AMC (Peptides International) is then added. After mixing, 50 uL of the activated 40 nM solution of recombinant human cathepsin L in assay buffer is then added to the well, yielding a final inhibitor concentration of 10 uM. Enzyme activity is determined by measuring fluorescence of the liberated aminomethylcoumarin at 440 nM using 380 nM excitation of 20 minutes. % Enzyme inhibition is determined by comparison of this activity to that of a solution containing no inhibitor. Compounds are subsequently subjected to a dose response curve analysis to determine IC50 values.
- (d) For cathepsin S:
-
- To a microtiter well is added 100 uL of a 20 uM solution of inhibitor is assay buffer. 50 uL of a 700 uM solution of Z-Val-Val-Arg-AMC substrate (Peptides International) is then added. After mixing, 50 UL of a 5.2 nM solution of recombinant human cathepsin S in assay buffer is then added to the well, yielding a final inhibitor concentration of 10 uM. Enzyme activity is determined by measuring fluorescence of the liberated aminomethylcoumarin at 440 nM using 380 nM excitation at 200 minutes. % Enzyme inhibition is determined by comparison of this activity to that of a solution containing no inhibitor. Compounds are subsequently subjected to a dose response curve analysis to determine IC50 values.
- In view of their activity as inhibitors of cysteine cathepsin enzymes, Compounds of the Invention are particularly useful in mammals as agents for treatment and prophylaxis of diseases and medical conditions involving elevated levels of cathepsins. Such diseases include diseases involving infection by organisms such as pneumocystis carinii, trypsanoma cruzi; trypsanoma brucei, crithidia fusiculata, as well as parasitic diseases such as schistosomiasis-and malaria, tumours (tumour invasion and tumour metastasis), and other diseases such as metachromatic leukodystrophy, muscular dystrophy, amytrophy and similar diseases.
- Cathepsins, in particular K, have been implicated in diseases of excessive bone loss, and thus the Compounds of the Invention may be used for treatment and prophylaxis of such diseases, including osteoporosis, gingival diseases such as gingivitis and periodontitis, Paget's disease, hypercalcemia of malignancy, e.g. tumour-induced hypercalcemia and metabolic bone disease. Also the Compounds of the Invention may be use for treatment or prophylaxis of diseases of excessive cartilage or matrix degradation, including osteoarthritis and rheumatoid arthritis as well as certain neoplastic diseases involving expression of high levels of proteolytic enzymes and matrix degradation.
- Compounds of the Invention, are also indicated for preventing or treating coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization), autoimmune diseases, respiratory diseases and immunologically mediated diseases (including transplant rejection).
- Compounds of the Invention, in particular cathepsin K selective inhibitor compounds, are particularly indicated for preventing or treating osteoporosis of various genesis (e.g. juvenile, menopausal, post-menopausal, post-traumatic, caused by old age or by cortico-steroid therapy or inactivity).
- Beneficial effects are evaluated in in vitro and in vivo pharmacological tests generally known in the art, and as illustrated herein.
- The above cited properties are demonstrable in in vitro and in vivo tests, using advantageously mammals, e.g. rats, mice, dogs, or isolated organs and tissues, as well as mammalian enzyme preparations, either natural or prepared by e.g. recombinant technology. Compounds of the Invention can be applied in vitro in the form of solutions, e.g. preferably aqueous solutions or suspensions, and in vivo either enterally or parenterally, advantageously orally, e.g. as a suspension or in aqueous solution, or as a solid capsule formulation. The dosage in vitro may range between about 10−5 molar and 10−9 molar concentrations. The dosage in vivo may range, depending on the route of administration, between about 0.1 and 100 mg/kg.
- The antiarthritic efficacy of the compounds of the invention for the treatment of rheumatoid arthritis can be determined using models such as or similar to the rat model of adjuvant arthritis, as described previously (R. E. Esser, et. al. J. Rheumatology, 1993, 20, 1176.)
- The efficacy of the compounds of the invention for the treatment of osteoarthritis can be determined using models such as or similar to the rabbit partial lateral meniscectomy model, as described previously (Colombo et al. Arth. Rheum. 1993 26, 875-886). The efficacy of the compounds in the model can be quantified using histological scoring methods, as described previously (O'Byrne et al. Inflamm Res 1995, 44, S117-S118).
- The efficacy of the compounds of the invention for the treatment of osteoporosis can be determined using an animal model such as the ovarectomised rat or other similar species in which test compounds are administered to the animal and the presence of markers of bone resorption are measured in urine or serum.
- The compounds of the invention are prepared by:
-
- wherein R, R2, R3, R4 and R5 have meaning as previously defined for the compounds of formula I to a nitrile of formula I; or
-
-
- wherein R, R2 and R3 have meaning as defined above; or with a reactive derivative thereof; or
-
- wherein R2, R3, R4 and R5 have meaning as defined hereinabove with an acid corresponding to the group R-[L]x-X1— or with a reactive derivative thereof; and in the above processes, if required, temporarily protecting any interfering reactive groups and then isolating the resulting compound of the invention; and, if desired, converting any resulting compound into another compound of the invention; and/or if desired, converting a resulting compound into a salt or a resulting salt into the free acid or base or into another salt.
- Appropriate protecting groups are used for starting compounds and intermediates, for instance as hereinafter described in the Examples.
- The conversion of primary amides of formula V to the nitriles of formula I, according to process (a), can be carried out according to methods well known in the art for the dehydration of a primary amide to a nitrile, e.g. with thionyl chloride in the presence of a base. A preferred procedure involves the treatment with oxalyl chloride and pyridine in DMF at or below room temperature as illustrated in the examples.
-
- wherein R4, and R5 have meaning as defined above with an acid of the formula VIII, in protected form as appropriate.
- The condensation can be carried out according to methods well-known in the art, e.g. by reacting a mixed anhydride or an acyl halide of the acid of formula VIII e.g. the acid chloride, with an amino acid amide of formula IX, in an inert solvent such as methylene chloride, in the presence of a base, such as an amine like triethylamine or pyridine.
- The acylation of an acid of formula VIII with an amino acid amide of formula IX can also be carried out in the presence of a condensing agent such as N-(3-dimethylaminopropyl)-N′-ethyl-carbodiimide, optionally in the presence of e.g. hydroxybenzotriazole or 1-hydroxy-7-azabenzo-triazole, and a base such as N-methylmorpholine.
- The amino acid amides of formula IX are either known or can be prepared according to methodology known in the art and illustrated herein.
- Alternative procedures and conditions may be used; for instance as described in the Examples.
- Compounds of the invention are either obtained in the free form, or as a salt thereof if salt forming groups are present.
- Acidic Compounds of the Invention may be converted into metal salts with pharmaceutically acceptable bases, e.g. an aqueous alkali metal hydroxide, advantageously in the presence of an ethereal or alcoholic solvent, such as a lower alkanol. Resulting salts may be converted into the free compounds by treatment with acids. These or other salts can also be used for purification of the compounds obtained. Ammonium salts are obtained by reaction with the appropriate amine, e.g. diethylamine, and the like.
- Compounds of the Invention having basic groups can be converted into acid addition salts, especially pharmaceutically acceptable salts. These are formed, for example, with inorganic acids, such as mineral acids, for example sulfuric acid, a phosphoric or hydrohalic acid, or with organic carboxylic acids, such as (C1-C4)alkanecarboxylic acids which, for example, are unsubstituted or substituted by halogen, for example acetic acid, such as saturated or unsaturated dicarboxylic acids, for example oxalic, succinic, maleic or fumaric acid, such as hydroxycarboxylic acids, for example glycolic, lactic, malic, tartaric or citric acid, such as amino acids, for example aspartic or glutamic acid, or with organic sulfonic acids, such as (C1-C4)-alkylsulfonic acids (for example methanesulfonic acid) or arylsulfonic acids which are unsubstituted or substituted (for example by halogen). Preferred are salts formed with hydrochloric acid, methanesulfonic acid and maleic acid.
- In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is referred to in this context, a corresponding salt is also intended, provided such is-possible or appropriate under the circumstances.
- The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- The pharmaceutical compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal, topical, and parenteral administration to mammals, including man, to inhibit cathepsin activity, and for the treatment of cathepsin dependent disorders, in particular inflammation, osteoporosis, rheumatoid arthritis and osteoarthritis, and comprise an effective amount of a pharmacologically active compound of the invention, alone or in combination, with one or more pharmaceutically acceptable carriers.
- More particularly, the pharmaceutical compositions comprise an effective cathepsin inhibiting amount of a Compound of the Invention.
- The pharmacologically active Compounds of the Invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 75%, preferably about 1 to 50%, of the active ingredient.
- Tablets may be either film coated or enteric coated according to methods known in the art.
- Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin. Matrix transdermal formulations may also be used.
- Suitable formulations for topical application, e.g. to the skin and eyes, are preferably aqueous solutions, ointments, creams or gels well-known in the art. Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- The pharmaceutical formulations contain an effective cathepsin inhibiting amount of a Compound of the Invention as defined above, either alone or in combination with another therapeutic agent.
- In conjunction with another active ingredient, a Compound of the Invention may be administered either simultaneously, before or after the other active ingredient, either separately by the same or different route of administration or together in the same pharmaceutical formulation. The dosage of active compound administered is dependent on the species of warm-blooded animal (mammal), the body weight, age and individual condition, and on the form of administration. A unit-dosage for oral administration to a mammal of about 50 to 70 kg may contain between about 5 and 500 mg of the active ingredient.
- The present invention also relates to methods of using Compounds of the Invention and their pharmaceutically acceptable salts, or pharmaceutical compositions thereof, in mammals for inhibiting cathepsins, such as cathepsin B, K, L and/or S, and for the treatment of cathepsin dependent conditions, such as cathepsin B, K, L and/or S dependent conditions, described herein, e.g. inflammation, osteoporosis, rheumatoid arthritis and osteoarthritis.
- Particularly the present invention relates to a method of selectively inhibiting cathepsin activity in a mammal which comprises administering to a mammal in need thereof an effective cathepsin inhibiting amount of a Compound of the Invention.
- More specifically such relates to a method of treating rheumatoid arthritis, osteoarthritis, and inflammation (and other diseases as identified above) in mammals comprises administering to a mammal in need thereof a correspondingly effective amount of a Compound of the Invention.
- The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon. Temperatures are given in degrees Centigrade. If not mentioned otherwise, all evaporations are performed under reduced pressure, preferably between about 15 and 100 mm Hg (=20-133 mbar). The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g. microanalysis and spectroscopic characteristics (e.g. MS, IR, NMR). Abbreviations used are those conventional in the art.
-
- Fmoc-Leucine (0.27 mmol) and aminoacetonitrile hydrochloride (32.4 mmol) are dissolved in dimethylformamide (300 ml) and cooled with ice-salt. HOBt (32.4 mmol) and WSCD (32.4 mmol) are added, and the reaction mixture is stirred at 4-25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with saturated sodium bicarbonate, IN hydrochloric acid and brine, dried over magnesium sulfate and the solvent is evaporated. Chromatography on silica gel using n-hexane/ethyl acetate=1/1 (v/v) gives the product in 90% yield.
- mp. 173-175° C., Rf=0.68 (chloroform:methanol:acetic acid=90:10:1).
- Fmoc-Leu-Gly(CN) (18 mmol) is dissolved in 20% piperidine in dimethylformamide (36 ml). The reaction mixture is stirred at room temperature for 60 min. After evaporation of the solvent and chromatography on silica gel using n-hexane, n-hexane/ethyl acetate=1/1 and 10% methanol in chloroform, the product is obtained in 93% yield.
- oil, Rf=0.73 (n-propanol:water:ethyl acetate:ammonia=5:1:2:1).
- Indol-5-ylcarboxylic acid (1.0 eq.) and H-Leu-Gly(CN) (1.2 eq.) are dissolved in dimethylformamide and cooled with ice-salt. HOBt (1.2 eq.) and WSCD (1.2 eq.) are added and the reaction mixture is stirred at 4-25° C. over night. After ethyl acetate is added to the reaction mixture, the organic layer is washed with saturated sodium bicarbonate, 1N hydrochloric acid and brine, dried over magnesium sulfate and evaporated. Chromatography on silica gel gives the title product in 70% yield.
- mp. 201-204° C., Rf=0.39 (n-hexane:AcOEt=1:2)
- 5-Nitro-quinoline-2-carboxylic acid [1-(cyanomethyl-carbamoyl)-3-methyl-butyl]-amide (0.35 mmol) is dissolved in tetrahydrofuran (10 ml) and methanol (10 ml) at room temperature. Na2S2O4 aq * (7 mmol) is added to the solution, and the reaction, mixture is heated at reflux for 90 min. The crude product is isolated by filtration and purified by chromatography on silica gel using 2% methanol in chloroform. The product is obtained in 33% yield. mp.190-194° C., Rf=0.60 (n-hexane:ethyl acetate=1:5). *A. S. Kende et al., Tetrahedron Lett., 25, 923-926, (1984).
- p-Aminomethylbenzoyl-Leu-Gly(CN) (see Example 14 below) (0.33 mmol) and acetic acid (3.3 mmol) are dissolved in dimethylformamide (10 ml) and cooled in an ice bath. HOBt (0.4 mmol) and WSCD (0.4 mmol) are added and the reaction mixture is stirred at 4-25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with saturated sodium bicarbonate, 1N hydrochloric acid and brine, dried over magnesium sulfate and evaporated. Diethylether is added to the residue to give a precipitate, which is collected by filtration and precipitated again from ethyl acetate with diethylether to give the product in 32% yield.
- mp. 176-184.5° C., Rf=0.24 (chloroform:methanol=9:1).
- By repeating the procedures described in the above Examples using appropriate starting materials and conditions the following compounds of formula XI are obtained as identified below in Table 1.
TABLE 1 XI Example No. Rx mp. (° C.) Rf (solvent) 4 52-70 0.24 (n-hexane:AcOEt = 1:1) 5 150-160 0.30 (n-hexane:AcOEt = 1:2) 6 170-194 0.77 (n-hexane:AcOEt = 1:2) 7 169-184.5 0.43 (n-hexane:AcOEt = 1:1) 8 210-235.5 0.39 (n-hexae:AcOEt = 1:1) 9 174.5-176.5 0.48 (n-hexane:AcOEt = 1:2) 10 163-167 0.42 (n-hexane:AcOEt = 1:1) 11 234-242 0.43 (n-hexane:AcOEt = 1:1) 12 156-158.5 0.31 (n-hexane:AcOEt = 1:1) 13 191.5-199 0.45 (n-hexane:AcOEt = 1:1) 14 57-64 0.80 (n-hexane:AcOEt = 1:2) 15 0.31 (chloroform:MeOH = 7:3) 16 89-95 0.61 (n-hexane:AcOEt = 1:2) 17 223-224 0.23 (n-hexane:AcOEt = 1:2) 18 143-144 0.70 (n-hexane:AcOEt = 1:2) 19 0.33 (n-hexane:AcOEt = 1:1) 20 0.47 (n-hexane:AcOEt = 1:1) 21 122-126 0.18 (CH2Cl2:MeOH = 9:1) 22 oil 0.17 (CH2Cl2/MeOH/NH3 = 9:1) 23 248-250 0.35 (CH2Cl2/MeOH = 9:1) 24 136-138 0.21 (CH2Cl2/MeOH = 95:5) 25 225-227 0.10 (CH2Cl2/MeOH = 9:1) 26 97-99 0.41 (CH2Cl2/MeOH = 9:1) 27 164-168 0.27 (CH2Cl2/MeOH = 9:1) 28 114-116 0.16 (CH2Cl2/MeOH = 95:5) 29 <70 0.16 (CH2Cl2/MeOH = 9:1) 30 89-91 0.19 (CH2Cl2/MeOH = 9:1) - The title compound is prepared from 1-cyclohexane carboxylic acid (7 mmol), Fmoc-CI (7.7 mmol) and NaOH (14 mmol) in the usual manner in 18% yield. Rf=0.17 (n-hexane:ethyl acetate=1:2).
- 28% aqueous ammonia (66 mmol) is added to the mixed anhydride (prepared from 22 mmol of Boc-2-aminobutyric acid and 22 mmol of iso-butylcholoroformate by customary procedures) at 20° C. The reaction mixture is stirred at 4-25° C. overnight. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with saturated sodium bicarbonate, 1N hydrochloric acid and brine, dried over magnesium sulfate and evaporated. The crude product is purified by chromatography on silica gel using n-hexane/ethyl acetate=1/1 and n-hexane/ethyl acetate=1/2, to give the product in 31% yield.
- mp. 168-177.5° C., Rf=0.41 (chloroforrn:methanol=9:1).
- Boc-2-Aminoisobutyric acid amide is dissolved in 4N hydrochloride in dioxane. The reaction mixture is stirred at room temperature for 60 min. Diethylether is added to the solution to give a white precipitate, which is collected in 91% yield by filtration. The crude product is used for the next coupling without further purification.
- Rf=0.28 (n-PrOH:H2O:ethyl acetate:NH3=5:1:2:1).
- Fmoc-1-aminocyclohexane carboxylic acid (2.2 mmol) and 2-aminobutyric acid amide hydrochloride (2.2 mmol) are dissolved in dimethylformamide (30 ml) and cooled with ice-salt. HOBt (2.6 mmol) and WSCD (2.6 mmol) are added and the reaction mixture is stirred at 4-25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with saturated sodium bicarbonate, IN hydrochloric acid and brine, dried over magnesium sulfate and evaporated. The crude product is purified by chromatography on silica gel using n-hexane/ethyl acetate=1/4 and n-hexane/ethyl acetate=1/6, to give the product in quantitative yield.
- mp. 177.5-178.5° C., Rf=0.24 (n-hexane:ethyl acetate=1:5)
- Thionyl chloride (2.6 mmol) is added to the solution of Fmoc-1-amino-cyclohexanecarboxylic acid (1-carbamoyl-1-methyl-ethyl)-amide (0.86 mmol) in dimethylformamide (10 ml) at 4° C. The reaction mixture is stirred at 4° C. for 2 h., ethyl acetate and saturated sodium bicarbonate solution are added and the organic layer is washed with brine, dried over magnesium sulfate and evaporated. The crude product is purified by chromatography on silica gel using n-hexane/ethyl acetate=3/1, to give the product in quantitative yield.
- Rf=0.57 (n-hexane:ethyl acetate=1:1.).
- Fmoc-1-Amino-cyclohexanecarboxylic acid (cyano-dimethyl-methyl)-amide (2.1 mmol) is dissolved in 20% piperidin in dimethylformamide (6.3 ml). The reaction mixture is stirred at room temperature for 60 min. After evaporation of the solvent, the crude product is purified by chormatography on silica gel using n-hexane, n-hexane/ethyl acetate=1/1 and 10% methanol in chloroform, to give the product in 31% yield. oil,
- RF=0.84 (n-propanol:water:ethyl acetate:ammonia=5:1:2:1)
- 2-Indole carboxylic acid (0.51 mmol) and 1-amino-cyclohexanecarboxylic acid (cyano-dimethyl-methyl)-amide (0.61 mmol) are dissolved in dimethylformamide (15 ml) and cooled in an ice bath. HOBt (0.61 mmol) and WSCD.HCl (0.61 mmol) are added and the reaction mixture is stirred at 4-25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with saturated sodium bicarbonate, 1N hydrochloric acid and brine, dried over magnesium sulfate and evaporated. The crude product is purified by chromatography on silica using n-hexane/ethyl acetate=4/1 and n-hexane/ethyl acetate=2/1, to give the product in 71% yield.
- mp. 200-202° C., Rf=0.55 (n-hexane:ethyl acetate=1:1)
- N-Tertbutyloxycarbonyl-isoleucine semihydrate (3 g, 12.5 mmol), HOBt (3.71 g, 27.5 mmol, 2.2 eq.) and aminoacetonitrile hydrochloride (1.27 g, 13.7 mmol, 1.1 eq.) are dissolved in dimethylformamide (36 ml) and WSCD (2.5 ml, 13.7 mmol, 1.1 eq.) is added. After stirring for 1 hour at rt, 4% sodium bicarbonate solution is added and the mixture is extracted with ethyl acetate. The organic layer is washed with sodium bicarbonate and dilute hydrochloric acid, dried over magnesium sulfate and evaporated, to give the product in quantitative yield.
- mp. 125-133.5° C., Rf=0.44 (hexanes:ethyl acetate=1:1)
- 2-tert-Butyloxycarbonylamino-3-methyl-pentanoic acid cyanomethyl-amide (2 g, 7.4 mmol) is dissolved in 4N hydrochloride in dioxane (10 ml). After 15 min. at rt the solvent is evaporated to give the product in quantitative yield. The crude product is used for the next step without further purification.
- Rf (free amine)=0.33 (ethyl acetate:methanol=10:1)
- 2-Naphthoylchloride (255 mg, 1.34 mmol, 1.1 eq.) is added to the solution of 2-amino-3-methyl-pentanoic acid cyanomethyl-amide hydrochloride (250 mg, 1.22 mmmo) and triethylamine (0.42 ml, 3.04 mmol, 2.5 eq.) in 5 ml dichloromethane. After 1 hour at rt 1 N hydrochloric acid is added and the reaction mixture is extracted with ethyl acetate. The organic layer is washed with saturated sodium bicarbonate solution, dried over magnesium sulfate and evaporated. Chromatography on silica gel (hexane/ethyl acetate 10/1 to 5/1, followed by ethyl acetate) gives the product in 97% yield (381 mg).
- mp. 203.5-207° C., Rf=0.44 (hexanes:ethyl acetate=1:1).
- L-isoleucine methylester hydrochloride (2.0 g, 11.0 mmol) and triethylamine (3.1 ml, 22.0 mmol, 2 eq.) are dissolved in dichloromethane (40 ml). The solution is cooled in an icebath and 2-naphthoylchloride (2.1 g, 11.0 mmol, 1 eq.) is added. The reaction mixture is allowed to warm up to rt and after 1 hour 1N hydrochloric acid is added. The mixture is extracted with ethyl acetate, the organic layer is washed with saturated sodium bicarbonate solution, dried over magnesium sulfate and evaporated to give the product in 98% yield.
- Rf=0.50 (hexanes:ethyl acetate=2:1)
- N-(Naphthalene-2-carbonyl)-isoleucine methylester (3.14 g, 10.5 mmol) is stirred in a mixture of methanol (35 ml) and 1 N aqueous sodium hydroxide (16.8 ml; 1.6 eq.). After 3 hours at rt the mixture is heated for 1 hour at 40° C. 1 N hydrochloric acid and brine is added and the mixture is extracted with ethyl acetate. The organic layer is dried over magnesium sulfate and evaporated to give the product in quantitative yield (partly epimerized).
- Rf=0.32 (hexane:ethyl acetate=1:2)
- (S)—N-tent-Butyloxycarbonyl-1-cyano-3-methyl-butylamine (CAS 115654-59-6) (3.7 g, 17.4 mmol) is dissolved in 4N hydrogenchloride in dioxane (20 ml). After 15 minutes at rt the solvent is evaporated, the residue is taken up in diethylether, the solid is filtered and dried in vacuum to give the product in 81% yield.
- Rf (free amine)=0.34 (hexane:ethyl acetate=1:1)
- N-(Naphthalene-2-carbonyl)-isoleucine (250 mg, 0.87 mmol), (S)-1-cyano-3-methyl-butylamine (143 mg, 0.96 mmol, Meq.) and HOBt (260 mg, 1.93 mmol, 2.2 eq.) are dissolved in dimethylfonnamide (5 ml) and WSCD (0.17 ml, 0.96 mmol, 1.1 eq.) is added. After stirring for 1 hour at rt, 4% sodium bicarbonate solution is added and the mixture is extracted with ethyl acetate. The organic layer is washed with sodium bicarbonate and dilute hydrochloric acid, dried over magnesium sulfate and evaporated. Chromatography on silica gel (hexane/ethyl acetate 2/1) gives the product in 68% yield (mixture of epimers).
- R.f=0.43 (hexanes:ethyl acetate=2:1)
- The title compound is prepared analogously is prepared similar to N-(Naphthalene-2-carbonyl)-isoleucine (see above) in 98% yield, starting from leucine methylester.
- Rf=0.34 (hexanes:ethyl acetate=1:1)
- N-(Naphthalene-2-carbonyl)-leucine (250 mg, 0.88 mmol), (S)-1-cyano-3-methyl-butylamine (143 mg, 0.96 mmol, 1.1 eq.) and HOBt (260 mg, 1.93 mmol, 2.2 eq.) are dissolved in dimethylformamide (5 ml) and WSCD (0.18 ml, 0.97 mmol, 1.1 eq.) is added. After stirring for 1 hour at rt, 4% sodium bicarbonate solution is added and the mixture is extracted with ethyl acetate. The organic layer is washed with sodium bicarbonate and dilute hydrochloric acid, dried over magnesium sulfate and evaporated. Chromatography on silica gel (hexane/ethyl acetate 2/1) gives the product in 79% yield (mixture of epimers).
- Rf=0.44 (hexane:ethyl acetate=2:1)
- The title compound is prepared analogously to the compound of Example 22. N-(Naphthalene-2-carbonyl)-leucine and 1-cyano-2-(1H-indol-3-yl)-ethylamine (CAS 169545-97-5) are reacted by the same procedure as for Naphthalene-2-carboxylic acid [1-(1-cyano-3-methyl-butylcarbamoyl)-3-methyl-butyl]-amide, to give the product in 36% yield after chromatography on silica gel (hexane/ethyl acetate 1/1) (mixture of epimers).
- Rf=0.59 (hexane:ethyl acetate=1:1)
-
- Boc-2-aminoisobutyric acid amide (4.58 g, 22.6 mmol) and triethylamine (7 ml, 50 mmol, 2.2 eq.) are dissolved in THF (100 ml) and trifluoroacetic acid anhydride (3.5 ml, 25 mmol, 1.1 eq.) is added at 0. The reaction mixture is stirred at 0° for 1 hour. The mixture is concentrated and water is added. The organic layer is extracted with ethyl acetate, washed with brine, dried over sodium sulfate and evaporated. The crude product is purified by chromatography on silica gel using n-hexane/ethyl acetate=20/1, 10/1, 5/1 and 1/1 to give the product in 74% yield.
- Rf=0.45 (n-hexane/ethyl acetate=3/1)
-
- N-tert-Butyloxycarbonyl-1-cyano-1-methyl-ethylamine (3.09 g, 16.8 mmol) is dissolved in dioxane (15 ml) and 4N hydrochloric acid-dioxane (25 ml) is added at 0°. The reaction mixture is stirred at 0° for 1.5 hours, then at rt for 1 hour. The mixture is concentrated and diethyl ether is added. The resulting white precipitate is washed with diethyl ether and dried to give the product in 83% yield. The crude product is used for the next coupling without further purification.
- Rf=0.66 (n-PrOH/H2O/ethyl acetate/NH3=5/1/2/1)
-
- N-(Naphthalene-2-carbonyl)-leucine (279 mg, 0.98 mmol), 1-cyano-1-methyl-ethylamine hydrochloride (137 mg, 1.14 mmol, 1.2 eq.) and HOBt (297 mg, 2.20 mmol, 2.2 eq.) are dissolved in dimethylformamide (5 ml) and WSCD (0.2 ml, 1.09 mmol, 1.1 eq.) is added at −10°. After stirring for 1.5 hours at −10°, 5% sodium bicarbonate solution is added and the mixture is extracted with ethyl acetate. The organic layer is washed with brine, dried over sodium sulfate and evaporated. Chromatography on silica gel (n-hexane/ethyl acetate=20/1, 10/1, 5/1, 3/1 and 1/1) gives the product in 8.7% yield (mixture of enantiomers).
- Rf=0.54 (n-hexane/ethyl acetate=1/1)
-
- 28% aqueous ammonia (34 mmol) is added to the mixed anhydride (prepared from 16.8 mmol of Boc-homophenylalanine and 17.0 mmol of isobutylchloroformate as usual) at −10. The reaction mixture is stirred at rt for 4.5 hours. The mixture is concentrated, washed with saturated sodium bicarbonate, 1N hydrochloric acid and brine, dried over sodium sulfate and evaporated to give the product in quantitative yield. The crude product is used for the next reaction without further purification.
- Rf=0.60 (chloroform/mathanol=10/1)
-
- Rf=0.81 (n-hexane/ethyl acetate=1/1)
-
- 1-Amino-cyclohexanecarboxylic acid methyl ester hydrochloride (1 g, 5.2 mmol) and triethylamine (1.44 ml, 10.3 mmol, 2 eq.) are dissolved in dichloromethane (15 ml) and 2-naphthoyl chloride (1 g, 5.2 mmol, 1 eq.) is added at 0°. The reaction mixture is stirred at 0°-25° for 2 hours and 1N hydrochloric acid is added. The mixture is extracted with ethyl acetate, the organic layer is washed with saturated sodium bicarbonate solution, dried over sodium sulfate and evaporated. Chromatography on silica gel (n-hexane/ethyl acetate=10/1, 5/1, 3/1 and 1/1) gives the product in 93% yield.
- Rf=0.30 (n-hexane/ethyl acetate=3/1)
-
- Starting from Naphthalene-2-carboxylic acid [(1-methoxycarbonyl)-cyclohexyl]-amide, the product is prepared analogously to N-(naphthalene-2-carbonyl)-isoleucine in quantitative yield. It is used for the next coupling without further purification.
- Rf=60 (chloroform/methanol=10/1)
-
- N-(2-Naphthoyl)-1-amino-cyclohexanecarboxylic acid (67 mg, 0.22 mmol), 1-cyano-3-phenyl-propylamine hydrochloride (47 mg, 0.24 mmol, 1.1 eq.) and HOAt (65 mg, 0.48 mmol, 2.2 eq.) are dissolved in dimethylformamide (2 ml) and WSCD (0.044 ml, 0.24 mmol, 1.1 eq.) is added at −10°. After stirring at 0°-25° overnight, 5% sodium bicarbonate solution is added and the mixture is extracted with ethyl acetate. The organic layer is washed with brine, dried over sodium sulfate and evaporated. Chromatography on silica gel(chloroform/acetone=200/1 and 100/1) gives the product in 63% yield.
- Rf=0.73 (chloroforrn/acetone=9/1)
- 1-Amino-cyclohexancarboxylic acid cyanomethyl-amide (136 mg, 0.50 mmol), indol-5-carboxylic acid (80 mg, 0.50 mmol, 1.0 eq.) and HOBt (74 mg, 0.55 mmol, 1.1 eq.) are dissoved in dimethylfonnamide (5 ml) and WSCD (0.10 ml, 0.55 mmol, 1.1 eq.) is added. After stirring for 20 hour at rt, 4% sodium bicarbonate solution is added and the mixture is extraced with ethyl acetate. The organic layer is washed with sodium bicarbonate, dried over magnesium sulfate and evaporated. Chromatography on silica gel (hexanes/ethyl acetate 2/1, then ethyl acetate) gives the product in 20% yield.
- Rf=0.31 (hexanes/ethyl acetate=3/1)
- The title compound is prepared from 1-cyclohexane carboxylic acid (140 mmol), Boc2O (154 mmol) and Na2CO3 (140 mmol) in 200 ml dioxane and 100 ml water by conventional methods. Mp. 157-161° C.; Rf=0.23 (CH2Cl2/MeOH=95:5)
- Boc-1-aminocyclohexane carboxylic acid (40 mmol), HOBt (40 mmol) and WSCD (42 mmol) are dissolved in dimethylformamide (75 ml) and stirred for 15 min. at RT. 2-aminoacetonitrile hydrochloride (40mmol) and triethylamine (40 mmol) are suspended in DMF (25 ml) and added to the reaction mixture which is stirred at 25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate and evaporated. The residue is suspended in diethylether and the solid filtered of and dried (vacuum). 7.35 g of a white powder with mp. 160-162° C., Rf=0.28 (n-hexane:ethyl acetate=1:1) is obtained.
- HCl in Diethylether (3-4N, 50 ml) is added to the solution Boc-1-amino-cyclohexane-carboxylic acid (1-(cyanomethyl-carbamoyl)-amide (33 mmol) in THF (50 ml) at RT and stirred overnight. The reaction mixture is cooled with an ice bath to 0-4° C. and the solid filtered off and washed with diethylether. The white crystals are dried (vacuum). Mp. 205-209° C.; Rf=0.45 (CH2Cl2/MeOH=9:1).
- 4-Bromomethyl-benzoic acid (2.3 mmol) is suspended in CH2Cl2 (7 ml) and cooled to 0-5° C. Chlorenamine (2.3 mmol) is added and the mixture is stirred for 45 min. at 0-5° C. 1-Amino-cyclohexanecarboxylic acid (1-(cyanomethyl-carbamoyl)-amide hydrochloride (2.3 mmol) and N-ethyldiisopropyl-amine (4.6 mmol) in CH2Cl2 (7 ml) is added at low temperature. The mixture is stirred for 2 hours at 0-5° C. and at RT over night. The reaction mixture is diluted with CH2Cl2 (40 ml), washed with water and dried over magnesium sulfate and evaporated. The residue was suspended in diethylether and the solid filtered of. The crude product is purified by chromatography on silica using CH2Cl2/MeOH=97:3. The fractions containing the pure product were collected and evaporated. The residue was suspended in diethylether and the solid filtered of. A white powder with mp. 194-196° C., Rf=0.38 (CH2Cl2/MeOH=95:5) is obtained.
- N-[1-(cyanomethyl-carbamoyl)-cyclohexyl]-4-bromomethyl-benzamide (0.34 mmol) is dissolved in THF (2 ml) and sodium-imidazol (0.41 mmol) is added and the reaction mixture stirred at RT over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, dried over magnesium sulfate and evaporated. The residue was suspended in diethylether and the solid filtered of. The crude product is purified by chromatography on silica using CH2Cl2MeOH=9:1. The fractions containing the pure product were collected and evaporated. The residue was suspended in diethylether and the solid filtered of. A white powder with mp. 194-196° C., Rf=0.28 (CH2Cl2/MeOH=9:1) is obtained.
- By repeating the procedure described above in Examples 40, using appropriate starting materials and reaction conditions the following compounds of formula XII are obtained as identified below in Table 2.
TABLE 2 XII Example Rf (solvent) No. Rx Rz mp. (° C.) MS (M + 1) 41 0.26 (hexanes/EtOAc = 3/1) 42 0.50 (hexanes/EtOAc = 1/1) 43 H 126-128 0.19 (CH2Cl2/MeOH = 9:1) 44 H 162-165 0.27 (CH2Cl2/MeOH = 9:1) 45 H 147-149 0.24 (CH2Cl2/MeOH = 9:1) 46 0.26 (hexanes/EtOAc = 3/1) 47 ″ 0.50 (hexanes/EtOAc = 1/1) 48 H 0.31 (hexanes/EtOAc = 3/1) 49 0.31 (n-hexane/EtOAc = 2/1) 50 ″ 0.42 (n-hexane/EtOAc = 2/1) 51 ″ 0.42 (n-hexane/EtOAc = 2/1) 52 ″ 0.42 (n-hexane/EtOAc = 2/1) 53 H 0.69 (EtOAc) 54 ″ 0.69 (EtOAc) 55 0.58 (n-hexane/EtOAc = 1/1) 56 H 0.47 (EtOAc) 57 H 0.72 (EtOAc) 58 ″ 0.73 (EtOAc) 59 ″ 0.66 (EtOAc) 60 ″ 0.66 (EtOAc) 61 ″ 0.67 (EtOAc) 62 0.24 (toluene/acetone 7/3) 436 63 199-201 446 64 ″ 184-185 459 65 ″ 0.14 (CH2Cl2/MeOH 10/0.2) 445 66 ″ 0.54 (petroleum ether/EtOAc 1/1) 67 ″ 154-155 522 - Boc-Leu-OH (62 mmol), HOBt (62 mmol) and WSCD (62 mmol) are dissolved in dimethylformamide (150 ml) and stirred for 15 min. at RT. 2-Amino-2-methyl-propionamide hydrochloride (62 mmol) and triethylamine (62 mmol) are suspended in DMF (25 ml) and added to the reaction mixture which is stirred at 25° C. over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate and evaporated. The residue is suspended in diethylether and the solid filtered of and dried (vacuum). 14.78 g of a white powder with mp. 182-184° C., Rf=0.39 (CH2Cl2/MeOH=9:1) is obtained.
- {1-[(Cyano-dimethyl-methyl)-carbamoyl]-3-methyl-butyl}-carbamic acid .tert.-butyl ester (47 mmol) is dissolved in THF (150 ml) and cooled to −10° C. Trifluoroacetic acid anhydride (56 mmol) and triethylamine (94 mmol) are added at −10° C. and the stirred mixture is slowly warmed up to 0° C. over 2 hours. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water and dried over magnesium sulfate and evaporated. The residue is suspended in diethylether/ pentane and the solid filtered of and dried (vacuum). 9.93 g of a white powder with mp. 166-168° C., Rf=0.55 (n-hexane:ethyl acetate=1:1) is obtained.
- {1-[(Cyano-dimethyl-methyl)-carbamoyl]-3-methyl-butyl)-carbamic acid .tert. butyl ester (19 mmol) is dissolved in ethyl acetate containing HCl (3-4N, water free) and the mixture is stirred at RT overnight. After evaporation of the solvent, the crude product is purified by chromatography on silica using CH2Cl2/MeOH=9:1. The fractions containing the pure product were collected and evaporated. 2.3 g of a yellowish oil, Rf=0.36 (CH2Cl2/MeOH=9:1) is obtained.
- 4-Bromomethylbenzoic acid (4.1 mmol), HOBt (4.1 mmol) and WSCD.HCl (4.1 mmol) are dissolved in dimethylformamide (7 ml) and stirred for 10 min. 2-Amino-4-methyl-pentanoic acid (cyano-dimethyl-methyl)-amide (4.1 mmol) is added in DMF (3 ml) and the reaction mixture is stirred at RT overnight. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate and evaporated. The crude product is suspended in diethylether and the solid filtered of and dried (vacuum). A white powder with mp. 185-187° C., Rf=0.43 (n-hexane:ethyl acetate=1:1) is obtained.
- N-{1-[(Cyano-dimethyl-methyl)-carbamoyl]-3-methyl-butyl)-4-bromomethyl-benzamide (0.18 mmol) is dissolved in THF (1 ml) and sodium-imidazol (0.41 mmol) is added and the reaction mixture stirred at RT over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, dried over magnesium sulfate and evaporated. An oil with Rf=0.44 (CH2Cl2/MeOH=9:1) is obtained.
- By repeating the procedure described above in Examples 68, using appropriate starting materials and conditions the following compounds of formula XIII are obtained as identified below in Table 3.
TABLE 3 XIII Example yield (%) No. Rx (step B) mp. (° C.) Rf (solvent) 69 58 135-137 0.29 (CH2Cl2/MeOH = 9:1) 70 51 160-162 0.16 (CH2Cl2/MeOH = 9:1) 71 44 186-188 0.23 (CH2Cl2/MeOH = 9:1) - 4-Mercaptobenzoic acid (65 mmol) and 1-Bromo-2-chloro-ethane (71 mmol) are dissolved in acetone (120 ml) and powdered potassium carbonate (71 mmol) is added. The mixture is warmed up to 40° C. and stirred for 7 hours. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water and dried over sodium sulfate and evaporated. The crude product is suspended in diethylether and the solid filtered of and dried (vacuum). 7.8 g of a white powder with mp. 142-144° C., Rf=0.37 (methylenchlorid/methanol=9/1) is obtained.
- 4-(2-Chloroethylsulfanyl)-benzoic acid (18.5 mmol), HOBt (18.5 mmol) and WSCD.HCl (19.4 mmol) are dissolved in dimethylformamide (50 ml) and stirred for 15 min. H-Leu-Gly((CN) (18.5 mmol) is added and the reaction mixture is stirred at RT overnight. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate. After evaporation of the solvent, the crude product is purified by chromatography on silica using CH2Cl2/MeOH=95:5. The fractions containing the pure product were collected and evaporated. The product is suspended in diethylether and the solid filtered of and dried (vacuum). 3.15 g of a yellowish powder with mp. 108-110° C., Rf=0.33 (n-hexane: ethyl acetate=1:1) is obtained.
- 4-(2-Chloroethylsulfanyl)-benzoyl-Leu-Gly(CN) (1.36 mmol) is dissolved DMF (2 ml) and pyrrolidine (3 mmol) is added. The reaction mixture is stirred for 8 hours at RT, then a catalytic amount of potassium iodide is added and again stirred at 50° C. overnight. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water and dried over magnesium sulfate and evaporated. The crude material is applied to a column of silica gel. Elution with CH2Cl2/MeOH=93:7 gives the product in 24% yield (Rf=0.12 (CH2Cl2/MeOH=95:5).
- 4-(2-Chloroethylsulfanyl)-benzoic acid (18.4 mmol) is suspended in methylene chloride (60 ml) and cooled to −10° C. m-Chloroperbenzoic acid (38.6 mmol) are added dropwise in methylene chloride (60 ml) and the mixture is stirred for e hours at −10° C. The mixture is diluted methylene chloride (100 ml) and a 5% solution of sodium thiosulfate in water is added and the mixture vigorously stirred. The mixture is extracted, washed with water and dried over sodium sulfate and evaporated. The crude product is recrystallized from ethylacetate and the solid filtered of and dried (vacuum). 2.19 g of a pale powder with mp. 142-144° C., Rf=0.37 (CH2Cl2/MeOH=9:1) is obtained.
- 4-(2-Chloroethylsulfonyl)-benzoic acid (8.8 mmol), HOBt (8.8 mmol) and WSCD.HCl (8.8 mmol) are dissolved in dimethylformamide (25 ml) and stirred for 15 min. H-Leu-Gly((CN) (18.5 mmol) is added and the reaction mixture is stirred at RT overnight. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate. After evaporation of the solvent, the crude product is purified by chromatography on silica using CH2Cl2NeOH=95:5. The fractions containing the pure product were collected and evaporated. The product is suspended in diethylether and the solid filtered of and dried (vacuum). 0.3 g of a white powder, Rf=0.25 (CH2Cl2/MeOH=95:5) is obtained.
- 4-(2-Chloroethylsulfonyl)-benzoyl-Leu-Gly(CN) (0.4 mmol) is in pyrrolidine (1 ml. The reaction mixture is stirred for 1.5 hours at RT. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water and dried over magnesium sulfate and evaporated. The crude material is applied to a column of silica gel. Elution with CH2Cl2/MeOH=95:5 gives the product in 43% yield (Rf=0.30 (CH2Cl2/MeOH=95:5).
- Boc-Leu-Leu-OH (Bachem, 43.6 mmol) is dissolved in THF (250 ml) and N-methylmorpholine (43.6 mmol) is added. The mixture is cooled to −20° C. and isobutyl chloroformate (43.6 mmol) is added dropwise. The mixture is stirred for 10 min. and then a 25% aqueous solution of ammonia (52.3 mmol) is added at −20° C. The mixture is stirred for 3 hours at −20° C. to −10° C. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water and dried over magnesium sulfate and evaporated. The crude product is suspended in diethylether and the solid filtered of and dried (vacuum). 14.28 of a white powder with mp. 155-156° C., Rf=0.5 (CH2Cl2/MeOH=9:1) is obtained.
- Boc-Leu-Leu-NH2 (41 mmol) is suspended in THF (200 ml) and triethylamine (83 mmol) and trifluoroacetic acid anhydride (41 mmol) is added at −5° C. The mixture is stirred for 2 hours at −5° C. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water and dried over magnesium sulfate and evaporated. A yellowish oil with Rf=0.59 (n-hexane:ethyl acetate=2:1) is obtained and deprotected without further purification (step C.).
- Boc-Leu-Leu(CN) (41 mmol) is dissolved in THF (50 ml) and HCl in diethylether (50 ml, 3-4N, water-free) is added at RT and the mixture stirred overnight. After evaporation of the solvent the residue is dissolved in methanol and ammonia in methanol (40 ml, 3-4N, water-free) is added and the solid material filtered of. The filtrate is evaporated and the crude product is purified by chromatography on silica using CH2Cl2/MeOH=95:5. The fractions containing the pure product were collected and evaporated. 5.07 g of a yellowish oil with Rf=0.43 (CH2Cl2/MeOH=9:1) is obtained.
- 4-Bromomethylbenzoic acid (6.67 mmol), HOBt (6.67 mmol) and WSCD.HCl (7.0 mmol) are dissolved in dimethylformamide, (15 ml) and stirred for 15 min. H-Leu-Leu(CN) (6.67 mmol) is added and the reaction mixture is stirred for 2.5 hours at RT. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate. After evaporation of the solvent, the crude product is purified by chromatography on silica using CH2Cl2/MeOH=97:3. The fractions containing the pure product were collected and evaporated. 1.74 g of a yellowish oil with Rf=0.59 (CH2Cl2/MeOH=95:5) is obtained.
- 4-Bromomethylbenzoyl-Leu-Leu(CN) (1.23 mmol) is dissolved in THF (5 ml) and sodium-imidazol (1.48 mmol) is added and the reaction mixture stirred at RT over night. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with water, dried over magnesium sulfate and evaporated. The crude product is purified by chromatography on silica using CH2Cl2/MeOH=95:5. The fractions containing the pure product were collected and evaporated. The product is suspended in diethylether and the solid filtered of and dried (vacuum). A white powder with mp. 100-103° C., Rf=0.36 (CH2Cl2/MeOH=9:1) is obtained.
- By repeating the procedure described above in Example 74, using appropriate starting materials and conditions the following compounds of formula XIV are obtained as identified below in Table 4.
TABLE 4 XIV Example yield (%) No. Rx (step B) mp. (° C.) Rf (solvent) 75 45 — 0.17 (CH2Cl2/MeOH = 95:5) 76 51 — 0.23 (CH2Cl2/MeOH = 9:1) 77 64 — 0.31 (CH2Cl2/MeOH = 9:1) - To a suspension of 0.975 g H-Ser(OBzl)-OH in 5 ml of methylene chloride is added 1.52 ml of trimethylchlorosilane. After ten minutes at room temperature 0.98 ml of N,N-diisopropylethyl amine and 1.81 g of benzyloxy leucine N-hydroxysuccinimidester is added. The reaction mixture is stirred for 2 hours at room temperature and diluted with ethyl acetate. Ethyl acetate is washed once with saturated NH4Cl-solution and once with H2O, then dried over sodium sulfate, the solvent is removed and the residue is crystallized from diethylether.
- 1H-NMR (CDCl3, ppm): 7.30 (m, 10H), 6.83 (d,1H), 5.32 (d,1H), 5.10 (s, 2H), 4.71 (m,1H), 4.50 (s,2H), 4.28 (m, 1H), 3.92 (m, 1H), 3.67 (m, 1 H), 1.46-1.79 (m, 3H), 0.92 (d, 6H).
- To a solution of 0.980 g of 3-benzyloxy-2-(2-benzyloxycarbonylamino-4-methyl-pentanoylamino)-propionic acid and 0.25 ml of N-methylmorpholine in 12 ml of tetrahydrofuran 0.3 ml of isobutylchloroformate is added dropwise at −15° C. The reaction mixture is stirred at −15° C. for 10 minutes, then 4 ml of aqueous NH3 (25%) is added dropwise over a time period of 5 minutes. The reaction mixture is stirred for additional 15 minutes and diluted with ethyl acetate. Ethyl acetate is washed once with saturated NH4Cl-solution and once with H2O, then dried sodium sulfate, the solvent is removed and the residue is triturated with diethylether.
- 1H-NMR (CDCl3, ppm): 7.38 (m, 10H), 6.87 (d, 1H), 6.60 (m (br.), 1H), 5.41 (m (br.), 1H), 5.12 (d, 1H), 5.08 (s, 2H), 4.50 (d, 2H), 4.20-3.92 (m, 2H), 3.50 (m, 1H), 1.70-1.41 (m, 3H), 0.90 (d, 6H).
- 0.3 ml of trifluoroacetic acid anhydride is added dropwise to a solution of 0.9 g of [1-(2-benzyloxy-1-carbamoyl-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester and 0.6 ml of triethylamine in 15 ml of tetrahydrofuran at −5° C. The reaction mixture is stirred at −5° C. for 3 hours and then for 12 hours at room temperature. The reaction mixture is then poured into H2O and the aqueous layer is extracted three times with ethyl acetate. The combined organic layers are washed once with H2O and once with brine, then dried over sodium sulfate, the solvent is removed and the residue is crystallized from diethylether/hexane. Mp.: 126-127° C.
-
- (4-Chloro-phenylamino)-acetic acid (0.5 g) and H-Leu-Gly((CN).HCl (0.55 g) are dissolved in dimethylformamide (4 ml). HOBt (0.44 g), WSCD.HCl (0.54 g), triethylamine (0.37 nil) is added and the reaction mixture is stirred for 18 hours. After evaporation of the solvent, the residue is extracted with ethyl acetate. The extract is washed with 10% citric acid, brine, sodium bicarbonate, brine and dried over magnesium sulfate and evaporated. The crude product is slurried in diethylether and the solid filtered of and dried (vacuum) yielding a white powder with mp. 131-134° C.
- By repeating the procedure described above in Example 86, using appropriate starting materials and conditions the following compounds of formula XVI are obtained as identified below in Table 6.
TABLE 6 XVI Example mp. No. R* (° C.) Rf (solvent) 87 foam 0.32 (CH2Cl2/ MeOH = 95:5) 88 110-115 89 foam 0.30 (CH2Cl2/ MeOH = 95:5) 90 130-133 91 amorph 0.42 (CH2Cl2/ MeOH = 95:5) 92 131-133 93 108-110 94 Resin 0.43 (CH2Cl2/ MeOH = 95:5) 95 77-79 96 Oil 97 Resin 0.53 (CH2Cl2/ MeOH = 95:5) 98 foam 0.47 (CH2Cl2/ MeOH = 95:5) 99 143-146 100 119-121 101 Resin 0.26 (CH2Cl2/ MeOH = 95:5) 102 146-149 - By repeating the procedures described in the above Examples using appropriate starting materials and reaction conditions the following compounds of formula XVII are obtained as identified below in Table 7.
TABLE 7 XVII Example No. Rx Ry Rz mp. (° C.) Rf (solvent)/MS (M + 1) 103 H 203.5-207 0.44 (hexanes/EtOAc = 1/1) 104 ″ 0.44 (hexanes/EtOAc = 2/1) 105 ″ 0.52 (n-hexane/EtOAc = 1/1) 106 ″ ″ 0.45 (n-hexane/EtOAc = 1/1) 107 ″ 0.30 (n-hexane/EtOAc = 3/1) 108 ″ ″ 0.40 (n-hexane/EtOAc = 2/1) 109 ″ ″ 0.24 (n-hexane/EtOAc = 4/3) 110 ″ 0.36 (n-hexane/EtOAc = 2/1) 111 ″ ″ 0-17 (n-hexane/EtOAc = 1/1) 112 ″ ″ 0.27 (n-hexane/EtOAc = 1/1) 113 ″ H 0.45 (EtOAc) 114 ″ ″ 0.58 (EtOAc) 115 ″ ″ 0.28 (n-hexane/EtOAc = 1/1) 116 ″ 0.46 (n-hexane/EtOAc = 1/1) 117 ″ ″ 0.41 (n-hexane/EtOAc = 2/1) 118 ″ H 0.79 (EtOAc) 119 ″ ″ 0.74 (EtOAc) 120 ″ 0.52 (n-hexane/EtOAc = 1/1) 121 ″ ″ 0.60 (n-hexane/EtOAc = 1/1) 122 ″ H 0.60 (EtOAc) 123 ″ 0.54 (n-hexane/EtOAc = 1/1) 124 ″ ″ H 0.26 (n-hexane/EtOAc = 1/1) 125 ″ 0.41 (n-hexane/EtOAc = 1/1) 126 ″ ″ 0.43 (n-hexane/EtOAc = 1/1) 127 ″ ″ 151-152 433 128 ″ ″ 137-138 447 129 ″ ″ 0.65 (toluene/acetone 7/3) 466 130 ″ ″ 163-165 470 131 ″ 214-215 447 132 ″ ″ 0.66 (CH2Cl2/CH3OH 10/0.5) 487 133 ″ ″ 176-178 466 134 ″ ″ 106-110 522 135 ″ ″ 0.46 (CH2Cl2/CH3OH 10/0.5) 477 136 ″ ″ 0.51 (CH2Cl2/CH3OH 10/0.5) 510 137 ″ ″ 0.26 (CH2Cl2/CH3OH 10/0.5) 491 138 ″ 121-126 560 139 ″ ″ 141-143 548 140 ″ ″ 233-234 529 141 ″ ″ 199-202 471 142 ″ 122-126 522 143 ″ ″ 0.40 (CH2Cl2/CH3OH 10/0.5) 506 144 ″ 131-133 515 145 ″ ″ 114-115 560 146 ″ ″ 180-182 485 147 ″ ″ 129-133 447 148 ″ ″ 0.50 (toluene/EtOH 9/1) 477 149 ″ 145-146 454 150 ″ ″ 152-153 408 151 ″ 210-211 499 152 ″ 148-149 506 153 ″ ″ 236-237 417 - Compounds of Examples 1 to 153 are typically selective inhibitors of cathepsin K and generally have IC50s for inhibition of human cathepsin K of from about 100 to about 1 nM or less, e.g. about 0.5 nM.
- Representative compounds e.g. as described in the above Example's typically have IC50s for inhibition of Cathepsin K in the range from less than 1 up to about 100 nm, and IC50s for inhibition of Cathepsin K which are at least 10 to about 1000 times less than their IC50s for inhibition of Cathepsin L and Cathepsin S, e.g. when tested in the assays described above.
- The cathepsin K selective compounds of the invention are particularly indicated for preventing or treating osteoporosis of various genesis (e.g. juvenile, menopausal, post-menopausal, post-traumatic, caused by old age or by cortico-steroid therapy or inactivity).
- By repeating the procedures described in the above Examples using appropriate starting materials and reaction conditions the following compounds of formula XVII are obtained as identified below in Tables 8, 9 and 10.
TABLE 8 XVII Example Rx Ry Rz mp (° C.) MS (M + 1) Rf (solvent) 154 H 169-170 574 (M − 1) 155 H 0.80 (n-hexane/EtOAC = 1/1) 156 H 0.63 (n-hexane/EtOAC = 1/2) 157 H 0.53 (n-hexane/EtOAC = 1/1) 158 H 0.38 (n-hexane/EtOAC = 1/1) 159 H 422.2 160 H 365.1 161 H 353 162 H 315.1 163 H 314.9 164 H 304.1 165 H 259.1 166 H 288.1 167 H 322 168 H 318.1 169 H 378.5 170 H 313.9 171 H 327.9 172 H 349.9 173 H 383.7 174 H 349.8 175 H 343.9 176 H 327.9 177 H 341.9 178 H 315.2 179 H 319.9 180 H 332 181 H 348.1 182 H 381.3 183 H 344.0 184 H 347.9 185 H 344.0 186 H 320 187 H 370 188 H 328 189 H 332 191 H 322.9 192 H 381.8 193 H 332 194 H 358.8 195 H 357.9 196 H 338.8 197 H 275.9 198 H 397.9 199 H 352.9 200 H 316.9 201 H 392 202 H 360.8 203 330 204 365 205 358 206 396 207 370 208 374 209 370 210 354 211 345.1 212 325 213 318 214 368 215 307.9
*Δ is cyclopropyl, i.e. Rz is ethylene and makes a cyclopropyl ring with the carbon atom to which it is attached.
- The compounds of Table 8 are typically selective inhibitors for cathepsin S, and normally have IC50s for cathepsin S inhibition in the range from about 100 to about 10 nM.
TABLE 9 Example Rx Ry Rz mp. (° C.) MS (M + 1) 216 H 184-185 432 217 H 181-182 412 218 H 188-189 448 219 H 168-169 364 220 Δ 208-209 438 221 H 146-148 413 222 H 194-195 483 223 H 186-187 418 224 H 176-177 418 225 H 174-175 391 226 H 390 227 H 180-181 440 228 H 352 229 H 139-140 562 230 180-181 440 231 151-153 485 232 H 112-114 407 233 H 424.3 234 H 399.4 235 H 382 236 H 468.0 237 H 394.2 238 H 444.3 239 H 444.2 240 H 411.9 241 H 390.1 242 H 445.9 243 H 406.0 244 H 461.9 245 H 443.7 246 H 411.7 247 H 435.8 248 H 511.9 249 H 445.5 250 H 429.4 251 H 376 252 H 356 253 H 372 254 H 427.9 255 H 410 256 H 477.9 257 H 402 258 H 478 259 H 409.9 260 H 134-135 350 (M − 1) 261 H 122-124 388 (M − 1) 262 H 360.0 263 H 385.9 264 H 461.9 265 H 393.8 266 H 411.7 267 H 408.0 268 H 480.0 269 H 411.8 270 H 385.9 271 H 369.9 272 H 402 273 Δ 408 274 H 394 275 H 421 276 H 409 277 H 437 278 H 307.9 279 H 341.7 280 H 333.9 281 H 302.1 282 H 150-151 382 283 H 393 284 Δ 433 285 H 458.3 286 H 450.2 287 —CH3 424.1 288 —CH3 457.3 289 —CH3 417.9 290 —CH3 449.8 291 —CH3 457.8 292 —CH3 449.9 293 —CH3 525.9 294 —CH3 457.7 295 —CH3 452.1 296 Δ 428.2 - The compounds of Table 9 are typically selective inhibitors for cathepsin L, having IC50s for cathepsin L inhibition which are preferably in the range from about 100 to about 1 nM.
TABLE 10 Example Rx Ry Rz mp. (° C.) MS (M + 1) 297 H 181-183 398 298 H 169-170 912 299 Δ 333.9 300 H 410.1 301 H 434.7 - The compounds of Table 10 are inhibitors of cathepsin L and cathepsin S, having IC50s for inhibition of cathepsin L in the range from about 100 to about 50 nM and IC20s for inhibition of cathepsin S in the range from about 50 to about 10 nM.
- To a solution of N-(t-butoxycarbonyl)-L-serine (16.1 g, 78.46 mmol) in DMF (90 mL) at −15° C. is added sodium hydride (6.9 g, 60% in mineral oil, 172.6 mmol) portionwise with vigorous stirring, over 0.5 hour. After all sodium hydride is added, the mixture is stirred for an additional 10 minutes at 0° C., and then at room temperature for 30 minutes. The solution is cooled back to 0° C., and a solution of methyl 3-bromomethylbenzoate (19.77 g, 86.30 mmol) in DMF (90 mL) is added dropwise over 15 minutes. The mixture is then warmed to room temperature for 16 hours. DMF is then evaporated (high vacuum, <40° C.), and the residue is diluted with cold water (200 mL) and acidified to pH 4-5 with 1 N HCl. The resulting mixture is extracted with EtOAc (4×150 mL). The combined extracts are washed with 0.1 N HCl (2×300 mL) and brine (2×300 mL), dried over MgSO4, and evaporated to give a yellowish syrup. Chromatography (silica, 5% MeOH/CH2Cl2) yields O-[[3-(methoxycarbonyl)-phenyl]methyl]-N-(t-butoxycarbonyl)-L-serine as a yellowish oil.
- A solution of O-[[3-(methoxycarbonyl)phenyl]methyl]-N-(t-butoxycarbonyl)-L-serine (3.0 g, 8.50 mmol) and N-methylmorpholine (2.8 mL, 2.58 g, 25.5 mmol) in CH2Cl2 (50 mL) is cooled to −10° C., and isobutyl chloroformate (1.1 mL, 1.16 g, 8.5 mmol) is added dropwise over 10 minutes. After stirring for 15 minutes, ammonia gas is bubbled into the solution at a moderately vigorous rate for 15 minutes. The solution is then warmed to room temperature over 30 minutes. CH2Cl2 is evaporated, and the residue is dissolved in EtOAc (50 mL). This solution is then extracted with 1 N HCl (2×50 mL), saturated NaHCO3 (50 mL), water (50 mL) and brine (50 mL), dried over MgSO4, and evaporated. Chromatography (silica, 75% EtOAc/hexane) yields O-[[3-methoxycarbonyl)phenyl]methyl]-N-(t-butoxycarbonyl)-L-serinamide as a thick oil.
- To a solution of O-[[3-(methoxycarbonyl)phenyl]methyl]-N-(t-butoxycarbonyl)-L-serinamide (2.4 g, 6.82 mmol) in EtOAc (50 mL) at 0° C. is bubbled HCl gas at a moderately vigorous rate for 5 minutes, during which time a lot of white precipitate is observed. The mixture is warmed to room temperature over 30 minutes, after which time EtOAc is removed, yielding O-[[3-(methoxycarbonyl)phenyl]methyl]-L-serinamide-HCl as a white solid.
- To a solution of 3-methyl-L-phenylalanine (1.8 g, 10.06 mmol) and Na2CO3 (3.2 g, 30.18 mmol) in water (150 mL) is added a solution of diphenylacetyl chloride (2.32 g, 10.06 mmol) in THF (150 mL), and the resulting solution is stirred vigorously at room temperature overnight. The THF is then evaporated and the aqueous layer is diluted with 6% aqueous Na2CO3 (100 mL), and washed with Et2O (3×150 mL). The aqueous layer is then acidified to pH 1 with conc. HCl, and the resulting slurry is extracted with EtOAc (3×100 mL). The organic phase is then washed with water (2×100 mL) and brine (1×100 mL), dried over MgSO4 and evaporated to yield 3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanine, as a white solid.
- To a solution of 3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanine (1.0 g, 2.68 mmol) and O-[[3-(methoxycarbonyl)phenyl]methyl]-L-serinamide HCl (0.774 g, 2.68 mmol), 1-hydroxybenzotriazole hydrate (0.452 g, 2.95 mmol, and N-methylmorpholine (1.18 mL, 1.085 g, 10.72 mmol) in CH2Cl2 (50 mL) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide HCl (0.771 g, 4.02 mmol) in one portion and the mixture is stirred at room temperature for 16 hours. The solution is then washed with 1 N HCl (100 mL), saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residual solid is triturated with hot methanol to yield N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-O-[[3-(methoxycarbonyl)phenyl]methyl]-L-serinamide as a white solid.
- Oxalyl chloride (0.057 mL, 0.084 g, 0.66 mmol) is added dropwise to DMF (10 ML), and the resulting solution is cooled to 0° C. After the solution becomes clear, pyridine (0.11 mL, 0.10 g, 1.31 mmol) is added, followed by N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-O-[[3 (methoxy-carbonyl)-phenyl]methyl]-L-serinamide (0.20 g, 0.329 mmol), in one portion. The yellow reaction solution is stirred at 0° C. for 1.5 hours, after which time the it is diluted with EtOAc (50 mL), and washed with saturated NaHCO3 (1×50 mL), saturated LiCl (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 80% EtOAc/hexane) to yield N-[2-[(3-(methoxy-carbonyl)-phenyl)-methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(2,2-diphenylacetyl )-L-phenyl-alaninamide as a white solid having the following structure
- A solution of N-[2-[(3-(methoxycarbonyl)phenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide (0.34 g, 0.58 mmol) in pinacolone (20 mL) is degassed with bubbling nitrogen for 10 minutes. Lithium iodide (0.78 g, 5.80 mmol) is then added, and the solution is refluxed in the dark for 24 hours, after which time it is cooled to room temperature, diluted with ethyl acetate (50 mL), and washed with 5% aq. sodium thiosulfate (2×50 mL), water (1×50 mL) and brine (1×50 mL). The organic layer is then dried over MgSO4, evaporated, and the residue is chromatographed (silica, 3% MeOH/CH2Cl2/0.05% acetic acid) to yield a clear glass, which is crystallized with an EtOAc/bexane (1:50) mixture to yield N-[2-[(3-carboxyphenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(diphenylacetyl)-L-phenylalaninamide as a white solid, m.p. 160-162° C.
- To a suspension of 3-methyl-L-phenylalanine (2.7 g, 15 mmol) in 85 mL 10% triethyl-amine/methanol is added di-t-butyldicarbonate (6.5 g, 30 mmol), and the solution is refluxed for 2.5 hours. After cooling, the methanol and triethylamine are evaporated and the residue is diluted with Et2O (250 mL) and extracted with saturated Na2CO3 (2×75 mL). The combined aqueous layers are again washed with Et2O (250 mL), and then acidified with cone. HCl to pH=2-3. The resulting mixture is then extracted with EtOAc (3×75 mL) and washed with water and brine, dried over MgSO4, and evaporated to yield 3-methyl-N-(t-butoxycarbonyl)-L-phenylalanine as a clear oil.
- A solution of 3-(chloromethyl)-benzoic acid (50.0 g, 0.293 mol), potassium carbonate (48.61 g, 0.352 mol) and allyl bromide (50.7 mL, 0.586 mol) in acetone (500 mL) is refluxed for 2 hours, after which time the solution was cooled to room temperature and filtered through celite. The filtrate is evaporated and the residue chromatographed (silica, 5% EtOAc/hexane) to yield allyl 3-(chloromethyl)-benzoate as a clear oil.
- A solution of allyl 3-(chloromethyl)-benzoate (54.5 g, 0.259 mmol) and sodium iodide (46.56 g, 0.311 mol) in acetone (500 mL) is stirred at room temperature for 6.5 hours, after which time the mixture is filtered. The filtrate is evaporated and the residue is dissolved in diethyl ether (500 mL), then washed with water (1×200 mL), 5% sodium sulfite solution (1×200 mL) and brine (1×200 mL), dried over magnesium sulfate, and evaporated to yield allyl 3-(iodomethyl)-benzoate as a white solid, which was is directly.
- Sodium hydride (19.4 g, 60% in mineral oil, 484.4 mmol) is washed with dry hexanes (2×30 mL) to remove the mineral oil and then suspended in anhydrous DMF (330 mL). To this suspension a solution of N-butoxycarbonyl-L-serine (45.2 g, 220.2 mmol) in DMF (110 mL) at 0° C. is added dropwise with vigorous stirring. The mixture is stirred for an additional 5 minutes at 0° C., and then at room temperature for 30 minutes. The solution is cooled back to 0° C., and a solution of allyl 3-iodomethylbenzoate (66.6 g, 220.2 mmol) in DMF (110 mL) is added dropwise over 15 minutes. The mixture is then warmed to room temperature for 30 minutes. The reaction mixture is poured into ice water (2.2 L) and acidified to pH 2 with 1 N HCl (270 mL). The mixture is extracted with ether (1×600 mL, then 3×300 mL) and the combined ether extracts are then washed with water (5×200 ml) and then dried (MgSO4) and evaporated in vacuo to yield O-[[3-(allyloxycarbonyl)-phenyl]methyl]-N-(t-butoxycarbonyl)-L-serine as a yellowish oil, which is used as is in the subsequent step.
- A solution of O-[[3-(allyloxycarbonyl)phenyl]methyl]-N-(t-butoxycarbonyl)-L-serine (79.2 g, 209 mmol) and N-methylmorpholine (68.9 mL, 63.4 g, 627 mmol) in CH2Cl2 (800 mL) is cooled to −10° C., and isobutyl chloroformate (32.5 mL, 34.2 g, 251 mmol) is added dropwise over 10 minutes. After stirring for 15 minutes, ammonia gas is bubbled into the solution at a moderately vigorous rate for 15 minutes, at −10° C. The solution is then warmed to room temperature and stirred for 30 minutes. The reaction mixure is cooled to 0° C. and 1 N HCl (800 mL) is added. The organic phase is washed with 1 N HCl (2×700 mL), then washed with saturated NaHCO3 (700 mL), then dried (MgSO4) and evaporated in vacuo to yield O-[[3-(allyloxycarbonyl)phenyl]methyl]-N-(t-butoxycarbonyl)-L-serinamide as a thick oil, which is used as is in the subsequent step.
- To a solution of O-[[3-(allyloxycarbonyl)phenyl]methyl]-N-(t-butoxycarbonyl)-L-serinamide (69 g, 182.5 mmol) in EtOAc (1000 mL) at 0° C. is slowly bubbled HCl gas for 1 hour, during which time a white precipitate is observed. The mixture is warmed to room temperature over 30 minutes, after which time EtOAc is removed by evaporation. The resulting residue is triturated with ether (500 mL) with vigorous stirring for 30 minutes. The precipitate is collected by vacuum filtration, washed with ether (2×100 mL) and then air dried to yield O-[[3-(allyloxycarbonyl)phenyl]-methyl]-L-serinamide-HCl as a free-flowing white solid.
- To a solution of O-[[3-(allyloxycarbonyl)phenyl]methyl]-L-serinamide.HCl (2.92 g, 10.46 mmol), 3-methyl-N-(t-butoxycarbonyl)-L-phenylalanine (3.29 g, 10.46 mmol), 1-hydroxybenzotriazole (1.92 g, 12.55 mmol), and N-methylmorpholine (4.6 mL, 4.23 g, 41.84 mmol) in CH2Cl2 (120 mL) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl (3.01 g, 15.69 mmol) in one portion. The solution is stirred for 16 hours, then washed with 1 N HCl (100 mL), saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residual solid is triturated with hot methanol to yield N-[3-methyl-N-(t-butoxycarbonyl)-L-phenylalanyl]-0-[[3-(allyloxycarbonyl)-phenylmethyl]-L-serinamide as a white solid.
- Oxalyl chloride (1.79 mL, 2.6 g, 20.48 mmol) is added dropwise to DMF (30 mL), and the resulting solution is cooled to 0° C. After the solution becomes clear, pyridine (3.31 mL, 3.24 g, 40.96 mmol) is added, followed by N-[3-methyl-N-(t-butoxycarbonyl)-L-phenylalanyl]-O-[[3 (allyloxy-carbonyl)phenyl]methyl]-L-serinamide (5.52 g, 10.24 mmol), in one portion. The yellow reaction solution is stirred at 0° C. for 1.5 hours, after which time it is diluted with EtOAc (50 mL), and washed with saturated NaHCO3 (1.×50 mL), saturated LiCl (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 40% EtOAc/hexane) to yield N-[2-[(3-(allyloxycarbonyl)-phenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(t-butoxycarbonyl)-L-phenylalaninamide as a white solid.
- A solution of N-[2-[(3-(allyloxycarbonyl)-phenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(t-butoxycarbonyl)-L-phenylalaninamide (3.18 g, 6.10 mmol) in 96% formic acid (40 mL) is stirred at room temperature for 5.5 hours. Formic acid is evaporated (high vacuum, 25° C.), and the residue is taken up in water (50 mL) and basified with saturated NaHCO3 (100 mL). The resulting mixture is extracted with EtOAc (3×50 mL), and then washed with water (2×100 mL) and brine (1×100 mL), dried over MgSO4, and evaporated to yield N-[2-[(3-(allyloxycarbonyl)-phenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-L-phenylalaninamide as a clear thick oil.
- To a solution of N-[2-[(3-(allyloxycarbonyl)phenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-L-phenylalaninamide.HCl (0.29 g, 0.69 mmol) and N-methylmorpholine (0.23 mL, 0.21 g, 2.07 mmol) in CH2Cl2 (10 mL) is added mopholinecarbonyl chloride (0.21 g, 0.23 mL, 2.065, mmol) in one portion, and the solution is stirred at room temperature for 16 hours. The solution is then diluted with additional CH2Cl2 (40 mL), and washed with 1 N HCl (50 mL), saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 80% EtOAc/hexane) to yield N-[2-[(3-(allyloxycarbonyl)-phenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(N-morpholinocarbonyl)-L-phenylalaninamide as a clear oil.
- The corresponding 3-carboxyphenylmethoxy compound is prepared as follows:
- To a solution of N-[2-[(3-(allyloxycarbonyl)-phenyl)methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(N-morpholinocarbonyl)-L-phenylalaninamide (see example 3, 0.2 g, 0.375 mmol) in anhydrous THF (20 mL) is added morpholine (0.327 mL, 0.326 g, 3.75 mmol), followed by Pd(PPh3)4(0.043 g, 0.0375 mmol). The solution is stirred at room temperature for 3 hours, after which time the THF is evaporated. The residue is taken up in EtOAc (100 mL) and washed with 1 N HCl (100 mL), saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 3% MeOH/CH2Cl2/0.05% acetic acid) to yield a clear glass, which is crystallized with an EtOAc/hexane (1:50) mixture to yield N-[2-[(3-carboxyphenyl)-methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(N-morpholinocarbonyl)-L-phenylalaninamide as a white solid, m.p. 100° C. (dec.).
- A solution of methyl 3-hydroxybenzoate (5.0 g, 32.86 mmol), 1,2-dibromoethane (11.3 mL, 131.44 mmol), and potassium carbonate (5.45 g, 39.43 mmol) in DMF (100 mL) is refluxed 16 hours, after which time the solution is cooled, concentrated in vacuo, and chromatographed to yield methyl 3-(2-bromoethoxy)-benzoate, as a yellow oil.
- A solution of methyl 3-(2-bromoethoxy)-benzoate (2.4 g, 9.26 mmol) and sodium iodide (2.78 g, 18.52 mmol) in acetone (50 mL) is refluxed for 2 hours. The resulting mixture is then filtered and concentrated. The residue is diluted with EtOAc (100 mL), washed with 5% Na2SO3 (50 mL), water (2×50 mL) and brine (50 mL), dried over MgSO4 and evaporated to yield methyl 3-(2-iodoethoxy)-benzoate, as a yellow oil, which is used directly.
- To a solution of sodium hexamethyldisilazide (8.82 mL of a 1.0 M solution, 8.82 mmol) in 90 mL THF at −78° C. is added a solution of N-(diphenylmethylene)aminoacetonitrile (1.90 g, 8.65 mmol) in THF (30 mL), via syringe. After stirring 30 minutes at −78° C., a solution of methyl 3-(2 iodoethoxy)-benzoate (2.7 g, 8.82 mmol) in THF (20 mL) is added in to the reaction solution via syringe. The solution is then warmed to room temperature, and allowed to stir for 3 hours. The mixture is then quenched with saturated NH4Cl (50 mL), and the aqueous layer is extracted with EtOAc (3×50 mL). The combined organic layers are washed with water (1×50 mL) and brine (1×50 mL), and chromatographed (silica, 12.5% EtOAc/hexane) to yield 2-(diphenylmethyleneamino)-4-[(3-methoxycarbonyl)-phenoxy]-butyronitrile, as a clear oil.
- 2-(Diphenylmethyleneamino)-4-[(3-methoxycarbonyl)-phenoxy]-butyronitrile (3.7 g, 6.78 mmol) is stirred vigorously for 16 hours in a biphasic mixture of 1 N HCl (7.5 mL) and Et2O (90 mL). The ether layer is removed, and the aqueous layer is washed with Et2O (3×50 mL), basified to pH 8 with 1 N NaOH, and extracted with EtOAc (3×50 mL). The combined organic layers are then washed with brine (1×50 mL), dried over MgSO4 and evaporated to yield 2-amino-4-[3-(methoxycarbonyl)-phenoxy]-butyronitrile, as a clear oil.
- To a solution of 2-amino-4-[3-(methoxycarbonyl)-phenoxy]-butyronitrile (0.5 g, 2.13 mmol), 3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanine (see example 1, 0.80 g, 2.13 mmol) and diisopropylethylamine (1.1 mL, 6.39 mmol) in CH2Cl2 (15 mL) is added benzotriazol-1-yloxy-tris (pyrrolidino)-phosphonium hexafluorophosphate (PyBop, 1.22 g, 2.34 mmol) in one portion. After stirring 1.5 hour, an additional portion of PyBop (0.61 g, 1.2 mmol) is added, and the solution is stirred overnight. The reaction mixture is washed with 1 N HCl (50 mL), saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 50% EtOAc/hexane) to yield N-[3-(3-(methoxycarbonyl)-phenoxy)-1-cyanopropyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide as a white solid, m.p. 152-153° C.
- The corresponding carboxyphenoxy compound is prepared as follows:
- To a solution of N-[3-(3-(methoxycarbonyl)-phenoxy)-1-cyanopropyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide (0.16 g, 0.272 mmol) in THF (3 mL) is added a solution of LiOH.H2O (22 mg, 0.544 mmol) in water (1.5 mL). The reaction is stirred for 1 hour, after which time the THF is evaporated. The residue is acidified with 1 N HCl and extracted with EtOAc (3×30 mL). The aqueous layer is washed with brine (30 mL), dried over MgSO4, evaporated and chromatographed (5% McOH, 0.05% AcOH, CH2Cl2) to yield N-[3-(3-carboxyphenoxy)-1-cyanopropyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide, as a white solid, m.p. 169-170° C.
- To a solution of 5-methylfurfural (5.0 g, 45.5 mmol) in CH2Cl2 (100 mL) is added pulverized N-bromosuccinimide (17.8 g, 100 mmol), and the solution is subjected to sun lamp irradiation. After 15 minutes, the solution begins to reflux vigorously, and then settles down after another 2-3 minutes. After an additional 10 minutes, the dark mixture is cooled to room temperature, and McOH (30 mL) is added. After 10 minutes, the solution is evaporated, and the residue is diluted with Et2O, and washed with saturated NaHCO3 (50 mL), water (50 mL) and brine (50 mL), dried over MgSO4 and evaporated. The residue is chromatographed (silica, 15% EtOAc/hexane) to yield methyl 5-(bromomethyl)-2-furoate, as a yellowish oil.
- To a solution of N-(t-butoxycarbonyl)-L-serine (2.5 8, 12.3 mmol) in DMF (50 ML) at −15° C. is added sodium hydride (1.22 g, 60% in mineral oil, 30.7 mmol) portionwise with vigorous stirring, over 0.5 hours. After all sodium hydride is added, the mixture is stirred for an additional 10 minutes at 0° C., and then at room temperature for 30 minutes. The solution is cooled back to 0° C., and a solution of methyl 5-(bromomethyl)-2-furoate (2.5 g, 12.3 mmol) in DMF (10 mL) is added dropwise over 2 minutes. The mixture is then warmed to room temperature for 16 hours, and the residue is quenched with 10% NaH2PO4 (100 mL) and acidified to pH 3 with 1 N HCl. 10% LiCl (30 mL) is added to the solution, and the resulting mixture is extracted with EtOAc (3×50 mL). The combined extracts are washed with brine (50 mL), dried over MgSO4, and evaporated to give a yellowish syrup. This residue is taken up in Et2O (50 mL), and extracted with saturated NaHCO3 (2×50 mL). The aqueous layer is acidified with conc. HCl, and extracted with Et2O (2×50 mL), dried (MgSO4), and evaporated. Chromatography (silica, 5% MeOH/CH2Cl2) yields O-[[(5-methoxycarbonyl)-fur-2-yl]-methyl]-Nα-(t-butoxycarbonyl)-L-serine as a yellowish oil.
- A solution of O-[[(5-methoxycarbonyl)-fur-2-yl]-methyl]-N-(t-butoxycarbonyl)-L-serine (0.70 g, 2.1 mmol) and N-methylmorpholine (0.46 mL, 4.2 mmol)) in CH2Cl2 (50, mL) is cooled to −10° C., and isobutyl chloroformate (0.27 mL, 2.1 mmol) is added dropwise over 10 minutes. After stirring for 15 minutes, ammonia gas is bubbled into the solution at a moderately vigorous rate for 15 minutes. The solution is then warmed to room temperature over 30 minutes. CH2Cl2 is evaporated, and the residue is dissolved in EtOAc (50 mL). This solution is then extracted with 1 N HCl (2×50 mL), saturated NaHCO3 (50 mL), water (50 mL) and brine (50 mL), dried over MgSO4, and evaporated to yield O-[[(5-methoxycarbonyl)-fur-2-yl]-methyl]-Nα-(t-butoxycarbonyl)-L-serinamide as a brownish solid.
- To a solution of O-[[(5-methoxycarbonyl)-fur-2-yl]-methyl]-Nα-(t-butoxycarbonyl)-L-serinamide (0.52 g, 1.58 mmol)) in EtOAc (50 mL) at 0° C. is bubbled HCl gas at a moderately vigorous rate for 1 minute, during which time a lot of white precipitate is observed. The mixture is stirred at 0° C. for 10 minutes, after which time ethyl acetate is removed, yielding O-[[(5-methoxycarbonyl)-fur-2-yl]-methyl]-L-serinamide-HCl as a yellowish solid.
- To a solution of 3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalanine (0.40 g, 1.5 mmol), O-[[(5-methoxycarbonyl)-fur-2-yl]methyl]-L-serinamide HCl (0.54 g, 1.5 mmol), 1-hydroxybenzo triazole hydrate (0.2 g, 1.5 mmol) and N-methylmorpholine (0.66 mL, 6.0 mmol) in CH2Cl2 (30 mL) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl (0.43 g, 2.3 mmol) in one portion, and the mixture is stirred at room temperature for 16 hours. The solution is then washed with 1 N HCl (100 mL), saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residual solid is triturated from ether to yield N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-O-[[5-(methoxycarbonyl)-fur-2-yl]-methyl]-L-serinamide as a light yellow solid.
- Oxalyl chloride (0.046 mL, 0.36 mmol) is added dropwise to DMF (5 mL), and the resulting solution is cooled to 0° C. After the solution is clear, pyridine (0.032 mL, 0.40 mmol) is added, followed by N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-O-[[5-(methoxycarbonyl)-fur-2-yl]-methyl]-L-serinamide (0.20 g, 0.33 mmol), in one portion. The yellow reaction solution is stirred at 0° C. for 1.5 hours, after which time it is diluted with EtOAc (50 mL), and washed with saturated NaHCO3 (1×50 mL), saturated LiCl (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 40% EtOAc/hexane) to yield N-[2-[(5-(methoxycarbonyl)-fur-2-yl)-methoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide as a white solid.
- To a solution of 3-methyl-N-(2,2-diphenylacetyl-L-phenylalanine (see example 302, 1.0 g, 2.68 mmol), 1-hydroxybenzotriazole hydrate (0.41 g, 2.68 mmol) and N-methylmorpholine (0.74 mL, 6.69 mmol) in CH2Cl2 (80 mL) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl (0.77 g, 4.02 mmol) in one portion. After stirring 30 minutes at room temperature, S-trityl-L-cysteinamide (0.97 g, 2.68 mmol) is added to the solution in one portion, and the solution is stirred for 16 hours. The solution is evaporated, and the residue partitioned between water (80 mL) and ethyl acetate (80 mL). The aqueous layer is washed with EtOAc (2×80 mL), and the combined organic layers are then washed with 1 N HCl (100 mL), saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residue is triturated with Et2O/hexane (1:1) to yield N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-S-trityl-L-cysteinamide as a white solid.
- To a solution of N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-S-trityl-L-cysteinamide (0.68 g, 0.95 mmol) in CH2Cl2 (20 mL) is added triethylsilane (0.30 mL, 1.9 mmol), in one portion, followed by dropwise addition of trifluoroacetic acid (10 mL). The yellow solution is stirred at room temperature for 1 hour, after which time solvent is evaporated, and the residue is suspended in water (30 mL), filtered, and the collected solid is washed with water and ether (100 mL each), and dried in vacuo, to yield of N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-L-cysteinamide, as a white solid.
- A solution of N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-L-cysteinamide (0.72 g, 1.51 mmol), methyl 3-(bromomethyl)-benzoate (0.35 g, 1.51 mmol), and diisopropylethylamine (0.27 mL, 1.53 mmol) is stirred at room temperature overnight. Solvent is evaporated, and the residue is treated with 1 N HCl (50 mL), and filtered to collect a white solid, which is washed with water and Et2O (100 mL each). Drying in vacuo yields N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-S-[[3-(methoxycarbonyl)phenyl]methyl]-L-cysteinamide, as a white solid.
- Oxalyl chloride (0.29 mL, 2.90 mmol) is added dropwise to DMF (20 mL), and the resulting solution is cooled to 0° C. After the solution becomes clear, pyridine (0.54 mL, 5.8 mmol) is added, followed by N-[3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanyl]-S-[[3-(methoxycarbonyl)-phenyl]-methyl]-L-cysteinamide (0.90 g,1.51 mmol), in one portion. The yellow reaction solution is stirred at 0° C. for 1.5 hours, after which time it is diluted with EtOAc (50 mL), and washed with saturated NaHCO3 (1×50 mL), saturated LiCl (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 33% EtOAc/hexane) to yield N-[2-[(3-(methoxycarbonyl)phenyl)thiomethoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide as a white solid.
- To a solution of N-[2-[(3-carboxyphenyl)thiomethoxy]-1(S)-cyanoethyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide (89 mg, 0.15 mmol) in acetone (5 mL) is added a solution of potassium peroxymonosulfate (Oxone®, 0.11 g, 0.18 mmol) in water (5 mL) at 0° C., and the solution is stirred at 0° C. for 40 minutes. 5% NaHSO4 (10 mL) is added, and the cloudy suspension is filtered. The solid is washed with water (50 mL), dried in vacuo, and then recrystalized (CH2Cl2, Et2O) to yield N-[2-[(3-carboxyphenyl)methanesulfinyl]-1(S)-cyanoethyl]-3-methyl-Nα-(2,2-diphenylacetyl-L-phenylalaninamide product, as a white solid, m.p. 170-171° C.
- To a solution of N-(t-butoxycarbonyl)-L-glutamic acid t-butyl ester (6.0 g, 19.78 mmol) and triethylamine (2.83 mL, 20.27 mmol) in THF at −10° C. is added ethyl chloroformate (1.94 mL, 20.27 mmol) dropwise, via syringe, and the solution is stirred at −10° C. for 30 minutes. The solution is filtered to remove precipitate, and the filtrate is added into a solution of NaBH4 (2.3 g, 60.86 mmol) in THF (40 mL) and water (50 mL). This solution is then stirred for 4 hours, after which time the solution is acidified with 1 N HCl to pH=5, and THF is evaporated. The aqueous residue is extracted with EtOAc (3×200 mL), and the organic layers is then washed with 114 NaOH (2×300 mL), water (300 mL) and brine (300 mL), dried over MgSO4, and evaporated. Chromatography (silica, 20% EtOAc/hexane) yields t-butyl (S)-5-hydroxy-2-(t-butoxycarbonylamino)-pentanoate as a thick oil.
- To a solution of t-butyl (S)-5-hydroxy-2-(t-butoxycarbonylamino)-pentanoate (5.79 g, 20.0 mmol), triphenylphosphine (8.13 g, 31.0 mmol) and imidazole (2.04 g, 30.0 mmol) in CH2Cl2 (200 mL) at room temperature is added iodine (6.35 g, 25.0 mmol), portionwise, over 30 minutes. The mixture is then stirred 16 hours at room temperature. Methanol (20 mL) is added to the solution, which is then stirred an additional 1 hour. Solvent is evaporated, and the residue is purified by chromatography (silica, 33% EtOAc/hexane) to yield t-butyl (S)-5-iodo-2-(t-butoxycarbonylamino)-pentanoate as a clear oil.
- A solution of 3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanine (see example 1, 10.93 g, 2.5 mmol) in dioxane (50 mL) at 0° C. is added N-hydroxysuccinimide (0.29 g, 2.5 mmol) in one portion, followed by a solution of DCC (0.52 g, 2.5 mmol) in dioxane (10 mL), which is added dropwise over 10 minutes. The cloudy mixture is warmed to room temperature overnight, after which time it is cooled back to 0° C., and filtered. The filtrate is evaporated to yield 3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalanine N-hydroxysuccinimide ester as a white solid.
- To a solution of methyl 1 H-pyrazole 3-carboxylate (Synth. Comm., 25, 1995, 761) (0.98 g, 7.74 mmol) in DMF (20 mL) at 0° C. is added NaH (60% suspension, 0.31 g, 7.74 mmol) portionwise, over 10 minutes. After stirring an additional 10 minutes, a solution of t-butyl (S)-5-iodo-2-(t-butoxy-carbonylamino)-pentanoate (2.78 g, 9.29 mmol) in DMF (20 mL) is added over 2 minutes, and the solution is warmed to room temperature over 16 hours. The solvent is evaporated (high-vac), the residue is treated with water (50 mL) and the aqueous layer is extracted with EtOAc (3×80 mL). The combined organic layers are washed with water (2×200 mL) and brine (100 mL), dried over MgSO4, and evaporated. Chromatography (silica, 25% EtOAc/hexane) yields the two regioisomeric products in a ˜2:1 ratio. The minor product, which is determined to be the desired product, t-butyl (S)-5-(3-methoxycarbonyl-1H-pyrazol-1-yl)-2-(t-butoxycarbonylamino)-pentanoate, is isolated as a thick, clear oil.
- To a solution oft-butyl (S)-5-(-3-methoxycarbonyl-1H-pyrazol-1-yl)-2-(t-butoxycarbonylamino)-pentanoate (0.84 g, 0.21 mmol) in CH2Cl2 (20 mL) at 0° C. is bubbled HCl gas for 30 minutes. Afterward, the solution is warmed to room temperature over 30 minutes. Evaporation of solvent yields (S)-5-(-3-methoxycarbonyl-1H-pyrazol-1-yl)-2-aminopentanoic acid.HCl as a gray-white solid.
- To a solution of (S)-5-(-3-methoxycarbonyl-1H-pyrazol-1-yl)-2-aminopentanoic acid.HCl (0.67 g, 2.13 mmol) in 10 mL water is added a solution of NaHCO3 (0.72 g, 8.5.3 mmol) in water (10 mL). After bubbling subsides, a solution of 3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalanine N-hydroxysuccinimide ester (0.67 g, 2.13 mmol) in 20 mL dioxane is added dropwise over 10 minutes, and the solution is stirred at room temperature for 16 hours. Solvent is then evaporated, and the residue is diluted with water (50 mL) and adjusted to pH=4 with 1 N HCl. The aqueous layer is extracted with EtOAc (3×80 mL), and the combined extracts are washed with brine (2×100 mL) dried over MgSO4, evaporated, and triturated from Et2O to yield N-[4-(3-methoxycarbonyl-1H-pyrazol-1-yl)-1(S)-carboxybutyl]-3-methyl-Na-(2,2-diphenylacetyl)-L-phenylalaninamide, which is carried on directly.
- A solution of N-[4-(3-methoxycarbonyl-1H-pyrazol-1-yl)-1(S)-carboxybutyl]-3-methyl-Na-(2,2-diphenylacetyl)-L-phenylalaninamide (0.3 g, 0.5 mmol)) and N-methylmorpholine (0.17 ML, 1.5 mmol) in CH2Cl2 (50 mL) is cooled to −10° C., and isobutyl chloroformate (0.065 mL, 0.5 mmol) is added dropwise over 10 minutes. After stirring for 15 minutes, ammonia gas is bubbled into the solution at a moderately vigorous rate for 15 minutes. The solution is then warmed to room temperature over 30 min. CH2Cl2 is evaporated, the residue is treated with water (30 mL). The suspension is adjusted to pH=7 with 1 N HCl, and filtered. The solid is washed with water (50 mL) and dried in vacuo to yield N-[4-(3-methoxycarbonyl-1H-pyrazol-1-yl)-1(S)-(aminocarbonyl)-butyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide.
- Oxalyl chloride (0.082 mL, 0.94 mmol) is added dropwise to DMF (20 mL), and the resulting solution is cooled to 0° C. After the solution becomes clear, pyridine (0.15 mL, 1.88 mmol) is added, followed by N-[4-(3-methoxycarbonyl-1H-pyrazol-1-yl)-1(S)-(aminocarbonyl)butyl]-3methyl-Nα-(2,2-diphenyl-acetyl)-L-phenylalaninamide (0.28 g, 0.47 mmol), in one portion. The yellow reaction solution is stirred at 0° C. for 1.5 hours, after which time it is diluted with EtOAc (50 mL), and washed with saturated NaHCO3 (1×50 mL), saturated LiCl (1×50 mL), dried over MgSO4, and evaporated. The residue is chromatographed (silica, 66% EtOAc/hexane) to yield N-[4-(3-methoxycarbonyl-1H-pyrazol-1-yl)-1(S)-cyanobutyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide as a white solid.
- To a solution of N-(t-butoxycarbonyl)-(S)-propargylglycine (2.44 g, 11.45 mmol) in CH2Cl2 (50 mL) is added N-methylmorpholine (3.78 mL, 34.4 mmol) in one portion. The solution is then cooled to −10° C., and isobutyl chloroformate is added dropwise over 5 minutes. After stirring for 15 minutes, ammonia gas is bubbled into the reaction mixture at a moderately vigorous rate for 15 minutes. The resulting milky suspension is then warmed to room temperature over 2 hours, and the mixture is washed with 1 N HCl (2×25 mL), aqueous NaHCO3 (25 mL) and brine (25 mL), and then dried over MgSO4. Evaporation of solvent, followed by chromatography (silica, 65% EtOAc/hexane) yields N-(t-butoxycarbonyl)-(S)-propargylglycineamide, as a clear oil.
- A solution of N-(t-butoxycarbonyl)-(S)-propargylglycineamide (1.15 g, 5.33 mmol), methyl 3-bromobenzoate (1.15 g, 5.33 mmol), and Cu(I)I(0.041 g, 0.214 mmol) in triethylamine (25 mL) is deoxygenated with bubbling N2 for 2-3 minutes. Bis(triphenylphosphine)palladium dichloride (0.075 g, 0.11 mmol) is then added in one portion, and the mixture is refluxed for 3 hours, after which time solvent is evaporated. The residue is then taken up in EtOAc (10 ml), and then washed with 1 N HCl (40 mL) and brine (30 mL), and then dried over MgSO4. The residue is chromatographed (silica, 80% EtOAc/hexane) to yield (S)-2-(t-butoxycarbonylamino)-5-(3-carbomethoxyphenyl)-4-pentynoic acid amide, as a light yellow solid.
- To a solution of (S)-2-(t-butoxycarbonylamino)-5-(3-carbomethoxyphenyl)-4-pentynoic acid amide (1.11 g, 3.22 mmol) in 1:1 ethanol/THF (50 mL) is added 10% Pd/C (0.5 g), and the mixture is hydrogenated at 1 atm. for 1.5 hours. The mixture is filtered through celite, and evaporated to yield (S)-2-butoxycarbonylamino-4-(3-carbomethoxyphenyl)-pentanamide, as a clear oil.
- To a solution of (S)-2-(t-butoxycarbonylamino)-5-(3-carbomethoxyphenyl)-pentanamide (1.22 g, 3.5 mmol) in EtOAc (75 mmol) at 0° C. is bubbled HCl gas at a moderately vigorous rate, for 5 minutes. The solution is then warmed to room temperature for 30 minutes Evaportion of solvent yields (S)-2-amino-4-(3-carbomethoxyphenyl)-pentanamide HCl salt as a light yellow solid.
- To a solution of (S)-2-amino-5-(3-carbomethoxyphenyl)-pentanamide HCl (0.30 g, 0.80 mmol), of 3-methyl-N-(2,2-diphenylacetyl)-L-phenylalanine (0.23 g, 0.80 mmol), 1-hydroxybenzotriazole hydrate (0.135 g, 0.89 mmol) and N-methylmorpholine (0.35 ml, 3.2 mmol) in CH2Cl2 (25 mL) is added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl (0.23 g, 1.2 mmol) in one portion, and the mixture is stirred at room temperature for 16 hours. The solution is then washed with 1 N HCl (100 mL, saturated aqueous NaHCO3 (1×50 mL), water (1×50 mL) and brine (1×50 mL), dried over MgSO4, and evaporated. The residual solid is triturated with ether to yield N-[4-(3-methoxycarbonyl-phenyl)-1(S)-(aminocarbonyl)-butyl]-3-methyl-Na-(2,2-diphenylacetyl)-L-phenylalaninamide as a light yellow solid.
- Oxalyl chloride (0.12 mL, 1.39 mmol) is added dropwise to DMF (10 mL), and the resulting solution is cooled to 0° C. After the solution is clear, pyridine (0.22 mL, 2.78 mmol) is added, followed by N-[4-(3-methoxycarbonylphenyl)-1(S)-(aminocarbonyl)butyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide (0.42 g, 0.70 mmol), in one portion. The yellow reaction solution is stirred at 0° C. for 1.5 hours, after which time it is diluted with EtOAc (50 mL), and washed with saturated aqueous NaHCO3 solution (1×50 mL), saturated aqueous LiCl solution (1×50 ML), dried over MgSO4, and evaporated. The residue is chromatographed to yield N-[4-(3-methoxycarbonyl-phenyl)-1(S)-cyanobutyl]-3-methyl-Nα-(2,2-diphenylacetyl)-L-phenylalaninamide, as a yellow solid.
- By repeating the procedure described above in Examples 302 to 310, using appropriate starting materials and conditions the following compounds of formula XVIII are obtained as identified below in Table 11.
TABLE 11 XVIII Exam- MS ple R30 R32 X2 Ar Z mp. (° C.) (M + 1) 311 COOH 100 dec. 312 — — — — 142-145 313 CH3CO — — — — 171-172 314 — — — — 173-175 315 — — — — 120 dec. 316 — — — — 90 dec. 317 — — — — 578 318 — — — — 139-141 319 — — — — 153-155 320 — — — — 129-131 321 — — — — 170-172 322 — — — — 522 323 — — — — 536 324 — — — — 529 325 — — — — 601 326 — — — — 572 327 — — — — 600, 602 328 — — — — 502 329 — — — — 536 330 — — — — 564 331 — — — — 540 332 — — — — 556 333 — — — — 540 334 — — — — 590 335 — — — — 564 336 — — — — 590 337 — — — — 536 338 — — — — 540 339 CH3(CH2)2C(O)— — — — 468 340 — — — — 496 341 CH3(CH2)2C(O)— — — — 439 342 — — — — 467 343 — — — 523 344 — — — 520 345 — — — — 520 346 — — — — 501 347 — — — — 500 348 CH3CH2O—C(O)— — — — — 454 349 — — — — 506 350 — — — — 476 351 — — — — 520 352 — — — — 622 353 — — — — 502 354 — — — — 460 355 CH3(CH2)2C(O)— — — — — 452 356 — — — — 531 357 — — — — 521 358 — — — — 564, 566 359 — — — — 522 360 — — — — 516 361 — — — — 586 362 — — — — 558 363 — — — — 516 364 CH3OCH2C(O)— — — — — 454 365 — — — — 572 366 — — — — 567 367 CH3(CH2)2CO — — — 477 368 — — — — 505 369 — — — — 555 370 CH3(CH2)2C(O)— — — — 442 371 — — — — 470 372 — — — — 520 373 — — — 473 374 — — — — 523 375 CH3(CH2)2C(O)— — — — — 445 376 — — — 477 377 — — — — 520 378 — — — — 528 379 — — — 469 380 — — — — 479 381 — — — — 522 382 — — — — 530 383 —(CH2)2—O— — — 169-170 384 — — —CH2—O—CH2— — 115 dec. 385 — — —CH2—S—CH2— — 145-146 386 — — —(CH2)3— — 145-146 387 — — — — 132 388 —CH2—O—CH2— — — 567 389 — — — 516 390 — — — — 577 391 — — — — 571 392 — — — — 537 393 — — — 512 394 — — — 525 395 — — — — 545 396 — — — — 579 397 — — — 508 398 — — — 544.9 399 — — — 537 400 — — — 490 401 — — — 492 402 — — — — 547.5 403 — — — 543 (M − 1) 404 — — — 582.8 405 — — — — 567.2 406 — — — — 553.1 407 — — — — 573.9 408 — — — — 609.6 409 — — — 540 410 — — — — 520.3 411 — — — — 540.1 412 — — — — 571 413 — — — — 573.9 414 — — — — 534 415 — — — 161-162 416 — — — — 145-146 590 (M+ − 1) 417 —CH2—C(O)—NH— — — 553.4 418 — — — 126-128 419 — — — 159-162 - The compounds of Examples 302 to 419 are selective inhibitors of cathepsin B, having IC50s for inhibition of cathepsin B, in the in vitro cathepsin B assay described above, which are typically in the range from about 5 nM to about 1000 nM. Illustrative of the invention, the IC50 in the in vitro cathepsin B assay is about 5 nM for the compound of example 303.
- In view of their properties as selective or broad based inhibitors of cathepsin L, S and/or B the Compounds of the Invention described above in Examples 154 to 419 may be used for treatment or prophylaxis of diseases or medical conditions mediated by cathepsin L, S or B; for instance as hereinbefore described.
- Example 420 Preparation of 1,000 capsules each containing 25 mg of a Compound of the Invention, using the following ingredients:
Compound of the Invention 25.00 g Lactose 192.00 g Modified starch 80.00 g Magnesium stearate 3.00 g - Procedure: All the powders are passed through a screen with openings of 0.6 mm. Then the drug substance is placed in a suitable mixer and mixed first with the magnesium stearate, then with the lactose and starch until homogeneous. No. 2 hard gelatin capsules are filled with 300 mg of said mixture each, using a capsule filling machine.
Claims (20)
1-20. (canceled)
21. A compound of formula (I):
wherein
R is substituted aryl selected from 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-yl-methyl)-phen-1-yl, 4-(pyrrolidin-1-yl-methyl)-phen-1-yl), 4-(4-methylpiperazin-1-yl)-phen-1-yl and 4-(piperidinyl)-phenyl;
R2 and R3 are, independently, hydrogen or lower alkyl; or
R2 and R3, together, represent lower alkylene, optionally interrupted by O, S or NR6, so as to form a ring with the carbon to which they are attached, and R6 is hydrogen, lower alkyl or aryl-lower alkyl;
R4 and R5 are, independently, hydrogen or lower alkyl; or
R4 and R5, together, represent lower alkylene, optionally interrupted by O, S or NR6, so as to form a ring with the carbon atom to which they are attached, and R6 is hydrogen, lower alkyl or aryl-lower alkyl;
X1 is —C(O)—;
Y is oxygen; and
x is zero;
or a pharmaceutically acceptable salt thereof.
22. A compound of formula (II):
wherein
R20 is substituted aryl selected from 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-yl-methyl)-phen-1-yl, 4-(pyrrolidin-1-yl-methyl)-phen-1-yl), 4-(4-methylpiperazin-1-yl)-phen-1-yl and 4-(piperidinyl)-phenyl;
R22 is hydrogen or lower alkyl and R23 is lower alkyl; or
R22 and R23, together with the carbon atom to which they are attached, form a C5-C8 cycloalkyl group or a heterocycloalkyl group of 3-10 ring atoms;
R24 and R25 are, independently, hydrogen or lower alkyl; or
R24 and R25, together with the carbon atom to which they are attached, form a C3-C7 cycloalkyl group;
X1 is —C(O)—;
Y is oxygen; and
x is zero;
or a pharmaceutically acceptable salt thereof.
23. A compound according to claim 22 , wherein R22 and R23, together with the carbon to which they are attached, represent a C6 cycloalkyl group.
24. A compound according to claim 22 , wherein R24 and R25 are both H or —CH3.
25. A compound according to claim 22 , wherein R24 is H and R25 is —CH2CH(CH3)2.
26. A method of inhibiting cathepsin activity in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound according to claim 22 .
27. A method of treating a cathepsin-dependent condition in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound according to claim 22 .
28. A method according to claim 27 , wherein the condition is selected from inflammation, osteoporosis, rheumatoid arthritis and osteoarthritis.
29. A method of treating a cathepsin-dependent condition in a mammal which comprises administering to a mammal in need thereof an effective amount of a compound according to claim 23 .
30. A method according to claim 29 , wherein the condition is selected from inflammation, osteoporosis, rheumatoid arthritis and osteoarthritis.
31. A cathepsin-inhibiting pharmaceutical composition comprising a compound according to claim 22 in combination with a pharmaceutically acceptable carrier.
32. A compound according to claim 22 , wherein
X1 is —C(O)—;
Y is oxygen;
x is zero;
R22 is H;
R23 is —CH2CH(CH3)2; and
(a) R20 is 4-(morpholin-1-ylmethyl)-phen-1-yl; and
R24 and R25 are H; or
(b) R20 is 4-(pyrrolidin-1-ylmethyl)-phen-1-yl; and
R24 and R25 are H;
or a pharmaceutically acceptable salt thereof.
33. A compound of the formula (I):
wherein
R is phenyl substituted by hetero(C3-C10)cycloalkyl(C1-C4)alkyl or hetero(C3-C10)cycloalkyl;
x is zero;
X1 is —C(O)—;
R2 is hydrogen or lower alkyl;
R3 is lower alkyl; or
R2 and R3 together represent lower alkylene optionally interrupted by O, S or NR6, wherein, so as to form a ring with the carbon atom to which they are attached, and R6 is hydrogen or lower alkyl;
Y is oxygen;
R4 and R5 are hydrogen;
or a pharmaceutically acceptable salt thereof.
34. A compound according to claim 33 , wherein R is selected from the group consisting of 4-(morpholin-1-yl)-phen-1-yl, 4-(morpholin-1-ylmethyl)-phen-1-yl, 4-(pyrrolidin-1-ylmethyl)-phen-1-yl, 4-(4-methylpiperazin-1-yl)-phen-1-yl and 4-(piperidinyl)phenyl.
35. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 33 in combination with a pharmaceutically acceptable excipient.
36. A method of treating a disease in a mammal in which cathepsin K contributes to the pathology and/or symptomatology of the disease, which method comprises administering to the mammal a therapeutically effective amount of a compound according to claim 33 .
37. A method according to claim 36 , wherein the disease is osteoporosis.
38. A method according to claim 36 , wherein the mammal is a human.
39. A method according to claim 36 , wherein the human is a post-menopausal woman.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/374,995 US20060235220A1 (en) | 1997-11-05 | 2006-03-15 | Dipeptide nitriles |
US11/835,134 US20080027060A1 (en) | 1997-11-05 | 2007-08-07 | Dipeptide nitriles |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9723407.4A GB9723407D0 (en) | 1997-11-05 | 1997-11-05 | Organic compounds |
GB9723407.4 | 1997-11-05 | ||
US10816097P | 1997-12-05 | 1997-12-05 | |
US18622398A | 1998-11-04 | 1998-11-04 | |
US09/643,639 US6353017B1 (en) | 1997-11-05 | 2000-08-22 | Dipeptide nitriles |
US5459002A | 2002-01-22 | 2002-01-22 | |
US10/342,872 US20040029814A1 (en) | 1997-11-05 | 2003-01-15 | Dipeptide nitriles |
US10/694,672 US20040110806A1 (en) | 1997-11-05 | 2003-10-28 | Dipeptide derivatives |
US11/374,995 US20060235220A1 (en) | 1997-11-05 | 2006-03-15 | Dipeptide nitriles |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/694,672 Continuation US20040110806A1 (en) | 1997-11-05 | 2003-10-28 | Dipeptide derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/835,134 Continuation US20080027060A1 (en) | 1997-11-05 | 2007-08-07 | Dipeptide nitriles |
Publications (1)
Publication Number | Publication Date |
---|---|
US20060235220A1 true US20060235220A1 (en) | 2006-10-19 |
Family
ID=10821646
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/643,639 Expired - Fee Related US6353017B1 (en) | 1997-11-05 | 2000-08-22 | Dipeptide nitriles |
US10/342,872 Abandoned US20040029814A1 (en) | 1997-11-05 | 2003-01-15 | Dipeptide nitriles |
US10/694,672 Abandoned US20040110806A1 (en) | 1997-11-05 | 2003-10-28 | Dipeptide derivatives |
US11/374,995 Abandoned US20060235220A1 (en) | 1997-11-05 | 2006-03-15 | Dipeptide nitriles |
US11/835,134 Abandoned US20080027060A1 (en) | 1997-11-05 | 2007-08-07 | Dipeptide nitriles |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/643,639 Expired - Fee Related US6353017B1 (en) | 1997-11-05 | 2000-08-22 | Dipeptide nitriles |
US10/342,872 Abandoned US20040029814A1 (en) | 1997-11-05 | 2003-01-15 | Dipeptide nitriles |
US10/694,672 Abandoned US20040110806A1 (en) | 1997-11-05 | 2003-10-28 | Dipeptide derivatives |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/835,134 Abandoned US20080027060A1 (en) | 1997-11-05 | 2007-08-07 | Dipeptide nitriles |
Country Status (3)
Country | Link |
---|---|
US (5) | US6353017B1 (en) |
GB (1) | GB9723407D0 (en) |
ZA (1) | ZA9810073B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050267129A1 (en) * | 2000-02-10 | 2005-12-01 | Norvartis Ag | Dipeptide nitrile cathepsin K inhibitors |
US10494364B2 (en) | 2015-08-29 | 2019-12-03 | Sunshin Lake Pharma Co., Ltd | Cathepsin K inhibitors and application thereof |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9723407D0 (en) * | 1997-11-05 | 1998-01-07 | Ciba Geigy Ag | Organic compounds |
WO2000055125A2 (en) * | 1999-03-15 | 2000-09-21 | Axys Pharmaceuticals, Inc. | N-cyanomethyl amides as protease inhibitors |
US6812237B2 (en) * | 2000-05-15 | 2004-11-02 | Novartis Ag | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors |
US7064123B1 (en) | 2000-12-22 | 2006-06-20 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
US7030116B2 (en) * | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
NZ528944A (en) * | 2001-06-01 | 2007-09-28 | Axys Pharm Inc | Chemical compounds and pharmaceutical compositions as cathepsin S inhibitors |
US20040147503A1 (en) * | 2002-06-04 | 2004-07-29 | Sheila Zipfeil | Novel compounds and compositions as cathepsin inhibitors |
WO2003024924A1 (en) * | 2001-09-14 | 2003-03-27 | Aventis Pharmaceuticals Inc. | Novel compounds and compositions as cathepsin inhibitors |
HUP0401906A3 (en) * | 2001-11-14 | 2008-07-28 | Aventis Pharma Inc | Novel cathepsin s inhibitors, process for their preparation and pharmaceutical compositions containing them |
US7326719B2 (en) * | 2003-03-13 | 2008-02-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cathepsin S inhibitors |
US7465745B2 (en) * | 2003-03-13 | 2008-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cathepsin S inhibitors |
WO2004084830A2 (en) * | 2003-03-21 | 2004-10-07 | Buck Institute | Method for treating alzheimer’s dementia |
US7109243B2 (en) * | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
US7384970B2 (en) * | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
US7173051B2 (en) * | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
US7256207B2 (en) * | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
WO2005044799A1 (en) | 2003-10-30 | 2005-05-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Dipeptide-analogue synthesis |
EP1686995A1 (en) * | 2003-11-19 | 2006-08-09 | Novartis AG | Use of cathepsin k inhibitors for treating of severe bone loss diseases |
JP2008513472A (en) * | 2004-09-17 | 2008-05-01 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Methods and intermediates for the preparation of cysteine protease inhibitors |
WO2006076797A1 (en) * | 2005-01-19 | 2006-07-27 | Merck Frosst Canada Ltd. | Cathepsin k inhibitors and atherosclerosis |
NZ561681A (en) | 2005-03-21 | 2011-01-28 | Virobay Inc | Alpha ketoamide compounds as cysteine protease inhibitors |
JP2008545720A (en) | 2005-06-02 | 2008-12-18 | メルク フロスト カナダ リミテツド | Fluoroalkylamine derivatives as cathepsin inhibitors |
EP2076490A4 (en) * | 2006-09-25 | 2010-07-28 | Merck Frosst Canada Ltd | Cathepsin b inhibitors |
WO2010069069A1 (en) * | 2008-12-17 | 2010-06-24 | Merck Frosst Canada Ltd. | Cathepsin b inhibitors |
WO2012151319A1 (en) | 2011-05-02 | 2012-11-08 | Virobay, Inc. | Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain |
EP3380455A1 (en) * | 2015-11-26 | 2018-10-03 | H. Hoffnabb-La Roche Ag | Trypanosomes inhibitors |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3467691A (en) * | 1964-04-22 | 1969-09-16 | Tsutomu Irikura | N-(n-acylaminoacyl)-aminoacetonitriles |
US5574064A (en) * | 1993-04-28 | 1996-11-12 | Kumiai Chemical Industry Co., Ltd. | Amino-acid amide derivatives, agricultural or horticultural fungicides, and method for producing the same |
US5780498A (en) * | 1993-11-01 | 1998-07-14 | Ciba-Geigy Japan Limited | Endothelin receptor antagonists |
US5977075A (en) * | 1995-04-21 | 1999-11-02 | Novartis Ag | N-aroylamino acid amides as endothelin inhibitors |
US5990083A (en) * | 1994-11-14 | 1999-11-23 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US6015879A (en) * | 1995-01-06 | 2000-01-18 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US6287840B1 (en) * | 1994-02-25 | 2001-09-11 | Axys Pharmaceuticals, Inc. | Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups |
US6297277B1 (en) * | 1993-12-08 | 2001-10-02 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
US6300372B1 (en) * | 1993-07-30 | 2001-10-09 | Smithkline Beecham Corporation | 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates |
US20020016207A1 (en) * | 2000-06-15 | 2002-02-07 | Matthias Geislinger | Torsionally elastic coupling |
US6353017B1 (en) * | 1997-11-05 | 2002-03-05 | Novartis Ag | Dipeptide nitriles |
US6355678B1 (en) * | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
US20020086996A1 (en) * | 1999-03-15 | 2002-07-04 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
US6451862B1 (en) * | 1999-11-05 | 2002-09-17 | Asahi Glass Company, Limited | Process for producing a spherical silica gel |
US6525052B2 (en) * | 2000-09-08 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cysteine proteases |
US6525036B2 (en) * | 2000-01-06 | 2003-02-25 | Merck & Co., Inc. | Compounds and compositions as protease inhibitors |
US6531612B2 (en) * | 1999-12-24 | 2003-03-11 | Hoffman-La Roche Inc. | Nitrile derivatives that inhibit cathepsin K |
US20030203919A1 (en) * | 2000-02-10 | 2003-10-30 | Martin Missbach | Dipeptide nitrile cathepsin K inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5206249A (en) | 1991-03-27 | 1993-04-27 | Du Pont Merck Pharmaceutical Company | Bis-naphthalimides containing amino-acid derived linkers as anticancer agents |
EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
JP3283114B2 (en) | 1992-09-07 | 2002-05-20 | クミアイ化学工業株式会社 | Condensed heterocyclic derivatives and agricultural and horticultural fungicides |
JP2848232B2 (en) | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | Aldehyde derivatives |
ES2151055T3 (en) | 1994-03-10 | 2000-12-16 | Searle & Co | DERIVATIVES OF L-N6- (1-IMINOETIL) LISINA USEFUL AS INHIBITORS OF NITRIC OXIDE SYNTHESA. |
AU1595997A (en) | 1996-01-26 | 1997-08-20 | Smithkline Beecham Plc | Thienoxazinone derivatives useful as antiviral agents |
AU3359697A (en) | 1996-07-08 | 1998-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Bone resorption inhibitors |
NZ335280A (en) | 1996-11-22 | 2001-05-25 | Lilly Co Eli | D-penicillamine derivatives for treating beta-amyloid type diseases such as Alzheimer's disease |
WO2000051998A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
-
1997
- 1997-11-05 GB GBGB9723407.4A patent/GB9723407D0/en not_active Ceased
-
1998
- 1998-11-04 ZA ZA9810073A patent/ZA9810073B/en unknown
-
2000
- 2000-08-22 US US09/643,639 patent/US6353017B1/en not_active Expired - Fee Related
-
2003
- 2003-01-15 US US10/342,872 patent/US20040029814A1/en not_active Abandoned
- 2003-10-28 US US10/694,672 patent/US20040110806A1/en not_active Abandoned
-
2006
- 2006-03-15 US US11/374,995 patent/US20060235220A1/en not_active Abandoned
-
2007
- 2007-08-07 US US11/835,134 patent/US20080027060A1/en not_active Abandoned
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3467691A (en) * | 1964-04-22 | 1969-09-16 | Tsutomu Irikura | N-(n-acylaminoacyl)-aminoacetonitriles |
US3697577A (en) * | 1964-04-22 | 1972-10-10 | Kyorin Seiyaku Kk | Derivatives of n(n-acyl amino acyl) aminoacetonitrile |
US5574064A (en) * | 1993-04-28 | 1996-11-12 | Kumiai Chemical Industry Co., Ltd. | Amino-acid amide derivatives, agricultural or horticultural fungicides, and method for producing the same |
US6300372B1 (en) * | 1993-07-30 | 2001-10-09 | Smithkline Beecham Corporation | 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates |
US5780498A (en) * | 1993-11-01 | 1998-07-14 | Ciba-Geigy Japan Limited | Endothelin receptor antagonists |
US6297277B1 (en) * | 1993-12-08 | 2001-10-02 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
US6287840B1 (en) * | 1994-02-25 | 2001-09-11 | Axys Pharmaceuticals, Inc. | Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups |
US5990083A (en) * | 1994-11-14 | 1999-11-23 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US6015879A (en) * | 1995-01-06 | 2000-01-18 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5977075A (en) * | 1995-04-21 | 1999-11-02 | Novartis Ag | N-aroylamino acid amides as endothelin inhibitors |
US20040110806A1 (en) * | 1997-11-05 | 2004-06-10 | Eva Altmann | Dipeptide derivatives |
US6353017B1 (en) * | 1997-11-05 | 2002-03-05 | Novartis Ag | Dipeptide nitriles |
US6355678B1 (en) * | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
US6593327B2 (en) * | 1999-03-15 | 2003-07-15 | Axys Pharmaceuticals, Inc. | Compounds and compositions as protease inhibitors |
US20020086996A1 (en) * | 1999-03-15 | 2002-07-04 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
US6455502B1 (en) * | 1999-03-15 | 2002-09-24 | Axys Pharmaceuticals, Inc. | Compounds and compositions as protease inhibitors |
US6476026B1 (en) * | 1999-03-15 | 2002-11-05 | Axys Pharmaceuticals, Inc. | Compounds and compositions as protease inhibitors |
US20040147745A1 (en) * | 1999-03-15 | 2004-07-29 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
US20030119788A1 (en) * | 1999-03-15 | 2003-06-26 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
US20030096796A1 (en) * | 1999-03-15 | 2003-05-22 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as protease inhibitors |
US6451862B1 (en) * | 1999-11-05 | 2002-09-17 | Asahi Glass Company, Limited | Process for producing a spherical silica gel |
US6531612B2 (en) * | 1999-12-24 | 2003-03-11 | Hoffman-La Roche Inc. | Nitrile derivatives that inhibit cathepsin K |
US6525036B2 (en) * | 2000-01-06 | 2003-02-25 | Merck & Co., Inc. | Compounds and compositions as protease inhibitors |
US20030203919A1 (en) * | 2000-02-10 | 2003-10-30 | Martin Missbach | Dipeptide nitrile cathepsin K inhibitors |
US20050267129A1 (en) * | 2000-02-10 | 2005-12-01 | Norvartis Ag | Dipeptide nitrile cathepsin K inhibitors |
US20020016207A1 (en) * | 2000-06-15 | 2002-02-07 | Matthias Geislinger | Torsionally elastic coupling |
US6525052B2 (en) * | 2000-09-08 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cysteine proteases |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050267129A1 (en) * | 2000-02-10 | 2005-12-01 | Norvartis Ag | Dipeptide nitrile cathepsin K inhibitors |
US10494364B2 (en) | 2015-08-29 | 2019-12-03 | Sunshin Lake Pharma Co., Ltd | Cathepsin K inhibitors and application thereof |
Also Published As
Publication number | Publication date |
---|---|
ZA9810073B (en) | 1999-05-05 |
US20040110806A1 (en) | 2004-06-10 |
US6353017B1 (en) | 2002-03-05 |
US20040029814A1 (en) | 2004-02-12 |
US20080027060A1 (en) | 2008-01-31 |
GB9723407D0 (en) | 1998-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060235220A1 (en) | Dipeptide nitriles | |
CA2306313C (en) | Dipeptide nitriles | |
EP0606046B1 (en) | Arylsulfonamido-substituted hydroxamic acids | |
US9133104B2 (en) | Enzyme inhibitors | |
US7183297B2 (en) | Biphenyl-derivatives as p38-kinase inhibitors | |
US6201133B1 (en) | Certain cyclic thio substituted acylaminoacid amide derivatives | |
US5817822A (en) | Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids | |
US7304094B2 (en) | Cyclohexyl sulphones | |
JPH04503057A (en) | Hydroxamic acid-based collagenase inhibitors | |
US20080234254A1 (en) | Inhibitors of Histone Deacetylase | |
AU766328B2 (en) | Arylsulfonamido-substituted hydroxamic acid derivatives | |
US6812237B2 (en) | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | |
WO2000048993A1 (en) | Arylaminoalkylamides | |
EP1283825B1 (en) | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | |
EP0318859A2 (en) | N-substituted mercaptopropanamide derivatives | |
MXPA00004375A (en) | Dipeptide nitriles | |
CZ20001610A3 (en) | Dipeptide-nitriles, process of their preparation and their use as pharmaceutical agents | |
TW527362B (en) | Dipeptide nitriles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |